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Abstract 
Acute myeloid leukaemia (AML) is a highly heterogenous haematological 
malignancy that accounts for approximately 34% of newly diagnosed leukaemia 
cases in the United Kingdom.  It is a disease that primarily affects the elderly, and 
the prognosis for AML is generally poor, with a 5-year survival rate of 25% in 
adults. Identifying factors that contribute to the pathogenesis of AML is important 
in developing new targeted treatments and improving patient outcome. The Wnt 
signalling pathway is one of the most commonly dysregulated signalling 
pathways in AML, and overexpression of its principal effector, β-catenin, is 
associated with a poor prognosis. β-catenin is a transcription factor that regulates 
key cellular processes, including proliferation and cell survival, by binding in 
complex with T-cell factor/lymphoid enhancer-binding factor (TCF/LEF) proteins 
to Wnt target gene promoters. Nuclear localization of β-catenin is fundamental 
for its role as a transcription factor. Despite this, little is known about the 
mechanisms regulating this process in AML; previous work has shown AML 
blasts and cell lines are highly variable in their ability to translocate β-catenin from 
the cytosol to the nucleus. This study used a mass spectrometric approach to 
identify candidate β-catenin nuclear localization factors in AML. This approach 
was based on comparisons of β-catenin binding partners in the nucleus and 
cytoplasm of leukaemia cell lines that i) freely translocate β-catenin to the nucleus 
(K562 and HEL), or ii) resist the nuclear localization of β-catenin (THP-1, U937 
and NOMO-1). Cytoplasmic/nuclear fractionation and immunoprecipitation of β-
catenin were optimized in K562 cells, before being used to prepare samples of 
each cell line for mass spectrometry. Following mass spectrometric analysis, 
eight candidate β-catenin nuclear localization factors were identified, of which two 
proteins, RUNX1 and LEF-1, were verified by western blotting. Since LEF1 has 
been previously implicated as a β-catenin nuclear import factor in other contexts 
and because of its known role in AML, LEF-1 was chosen for further analysis. To 
determine the relevance of LEF-1 mediated β-catenin nuclear localization in AML 
pathogenesis, knockdown and overexpression studies were conducted. 
Knockdown of LEF-1 was successful in leukaemia lines. In cells stimulated with 
the Wnt agonists (Wnt3a and BIO), LEF-1 knockdown decreased the nuclear 
translocation of β-catenin and impacted β-catenin mediated transcription. 
Additionally, knockdown of LEF-1 appeared to reduce proliferation of leukaemia 
cells, but did not impact their migration or survival. Ectopic nuclear 
overexpression of LEF1 proved difficult to achieve in myeloid cells due to protein 
instability; making reciprocal demonstration of the role of LEF1 difficult to 
demonstrate. Overall this study has identified candidate β-catenin nuclear 
localization factors and has validated the role of one of these proteins (LEF1).  
This work provides insight into the potential mechanisms governing β-catenin 
nuclear localization in AML, and in the longer term, may lead to novel approaches 
for the treatment of AML. 
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1 Introduction 
 
 
Haematopoiesis is the process by which blood cells are made. It involves the self-
renewal and differentiation of the haematopoietic stem cell (HSC) into a variety 
of cell types, which are classified into two groups; the myeloid and lymphoid 
lineages. Classically haematopoietic cells are organised in a hierarchy, in which 
there is an ordered progression from HSCs into haematopoietic progenitor cells 
(HPCs) and then finally into terminally differentiated haematopoietic cells which 
have distinct roles (Figure 1.1). Briefly, the cells of the lymphoid lineage mediate 
the immune response, whereas the cells of the myeloid lineage are involved in a 
wider range of processes, including blood clotting (platelets) and oxygen 
transport (erythrocytes). This section will focus on HSCs and cells of the myeloid 
lineage only, which is the focus of this study. 
HSCs are a rare population of cells that retain the ability to differentiate into all 
other blood cell types (Spangrude et al, 1988). They are split into two groups; 
long-term haematopoietic stem cells (LT-HSCs) and short-term haematopoietic 
stem cells (ST-HSCs). ST-HSCs have a reduced self-renewal capacity compared 
to LT-HSCs, however, this view may be oversimplified, with HSCs representing 
a more fluid and heterogenous population of cells (Liu et al, 2012). A delicate 
balance between self-renewal and differentiation is important in maintaining the 
pool of HSCs, ensuring that blood cells can be replenished throughout an 
individual’s lifetime.  
There are two main models of HSC division; asymmetric and symmetric. 
According to the asymmetric theory, a single stem cell always give rise to one 
daughter stem cell and one differentiated daughter cell. In contrast, in the 
symmetric theory (or “stochastic” model) a single stem cell can either give rise to 
two stem daughter cells or two differentiated daughter cells. The symmetric 
division of stem cells may play an important role, for example, when responding 
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to increasing demand for differentiated blood cells following infection or injury 
(Morrison & Kimble, 2006). 
 
Figure 1.1 A diagram of the haematopoietic hierarchy.  
The cells of the haematopoietic system are split into two lineages; the myeloid lineage (left) and 
the lymphoid lineage (right). The main cells in each lineage are outlined above, but other 
progenitor cells exist that have not been included in this diagram, for example, the MEP 
(megakaryocyte erythroid progenitor), which gives rise to erythroid and megakaryocyte cells. 
Terminally differentiated blood cells have distinct roles. Megakaryocytes produce thrombocytes 
(platelets), which are involved in blood clotting. Erythrocytes transport oxygen to the cells of the 
body. Mast cells are involved in wound healing and the immune response. Basophils are 
involved in the inflammatory response. Neutrophils are phagocytes that are involved in the 
innate immune response. Eosinophils have varied roles, including in the inflammatory response. 
Monocytes are involved in phagocytosis, cytokine production and antigen presentation. 
Macrophages are phagocytes that perform many roles, including in the immune response and 
inflammation. Abbreviations; CMP (common myeloid progenitor) and CLP (common lymphoid 
progenitor). 
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In the classical model of haematopoiesis, as HSCs differentiate, each branch (or 
bifurcation) in lineage progression is associated with a decreased capacity of the 
cell type to respond to external factors governing the development to the other 
lineage, or differentiation path. This is a gradual process, that involves the 
differentiation of early progenitors into pools of different progenitor cell types, 
such as the megakaryocyte-erythroid progenitor cell (MEP), that subsequently 
differentiate into the different blood cell types.  
More recent data, from studies looking at HSCs and early haematopoiesis using 
single cell analysis, is incompatible with this classical model. It suggests that 
HSCs do not need to go through the defined stages of differentiation. Instead, 
lineage commitment can occur much earlier than expected and bypass the stages 
of early progenitor differentiation outlined in the classical model (Velten et al, 
2017). 
 
Haematopoiesis is regulated by a combination of extrinsic and intrinsic factors. 
Extrinsic factors include cytokines, growth factors and other environmental cues 
that can trigger changes in haematopoietic cells by activating cell signalling 
pathways. Many of these factors are expressed on the cell surface of (or secreted 
by) cells of the haematopoietic stem cell niche (Figure 1.2). Intrinsic factors 
include signalling pathway components and transcription factors that drive key 
haematopoietic processes, including self-renewal, differentiation, survival and 
cell growth.  
 
Cytokines and growth factors control haematopoiesis by regulating downstream 
signalling pathway components. These pathways are transmitted from 
membrane receptors at the cell surface and activate haematopoietic transcription 
factors. Examples of cytokines and growth factors that regulate haematopoiesis 
are outlined in Table 1.1. Knockdown studies suggest that there is a high degree 
of redundancy between these factors, and that the loss of one factor generally 
does not lead to a failure in haematopoiesis. One exception is the cytokine 
erythropoietin (EPO), which is essential to produce erythrocytes in response to 
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haematopoietic stress. Following haematopoietic injury, EPO is produced in the 
kidney and its increased presence in the bone marrow acts to i) bias the 
differentiation of HSCs into erythroid progenitors and ii) rapidly induce erythroid 
progenitors to proliferate and differentiate into erythroid cells (de Haan et al, 1996; 
De Maria et al, 1999). 
Cytokines and downstream effector proteins converge on haematopoietic 
transcription factors, such as members of the C/EBP family and PU.1 (Table 1.2). 
These transcription factors regulate target gene expression to drive changes in 
progenitor cells that regulate their differentiation down the haematopoietic 
hierarchy.  
Many of the cytokines, growth factors, signalling components and transcription 
factors that regulate normal haematopoiesis are dysregulated in leukaemia (1.2). 
The role of Wnt signalling pathway components in the regulation of 
haematopoiesis and leukaemia are discussed in 1.3.  
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Table 1.1. Cytokines and growth factors that regulate myeloid development. 
Cytokines that regulate HSCs and cells of the myeloid lineage. Many of these factors are 
expressed by cells in the bone marrow niche, and work in combination to regulate myeloid 
development by activating downstream signalling pathways and transcription factors in HSCs 
and myeloid progenitor cells.  
Cytokine/growth factor Example of role 
Interleukin-1 (IL-1) Emergency response following injury. Regulates 
proliferation of HSCs/early progenitors and promotes 
commitment to a myeloid fate (Pietras et al, 2016). 
Interleukin-6 (IL-6) Works in synergy with other factors such as SCF, to 
promote survival and self-renewal of HSCs and early 
progenitors. Promotes commitment of early 
progenitors to a myeloid fate (Bernad et al, 1994; 
Schürch et al, 2014). 
Granulocyte-macrophage colony-
stimulating factor (GM-CSF) 
Stimulates the differentiation of progenitors into 
granulocytes and macrophages (Ushach & Zlotnik, 
2016). 
Stem cell factor (SCF) Works in synergy with other growth factors to regulate 
the self-renewal and differentiation of HSCs and early 
progenitors (Broudy, 1997). 
Erythropoietin (EPO) Promotes the survival, proliferation and differentiation 
of erythroid progenitors (de Haan et al, 1996; De 
Maria et al, 1999). 
Thrombopoietin (TPO) Stimulates the differentiation of progenitors into 
megakaryocytes and regulates HSC quiescence 
(Kaushansky et al, 1995; Qian et al, 2007) 
Interleukin-5 (IL-5) Promotes the maturation, differentiation and survival 
of eosinophils (Sanderson, 1992; Yamaguchi et al, 
1988) 
Granulocyte colony stimulating factor 
(G-CSF) 
Stimulates the differentiation of progenitors into 
neutrophils (Demetri & Griffin, 1991). 
Jagged-1 (JAG1) Supports the self-renewal and expansion of HSCs 
(Poulos et al, 2013; Weber & Calvi, 2010). 
Wnt ligands Promote the homing of HSCs to the bone marrow 
niche and self-renewal of HSCs. This is discussed 
further in 1.3.2. 
Angiopoentin-1 Regulates HSC quiescence (Arai et al, 2004). 
 C-X-C motif chemokine 12 (CXCL12) Involved in maintaining the HSC pool (Sugiyama et al, 
2006). 
Transforming growth factor beta 
(TGFβ) 
Promotes HSC quiescence (Vaidya & Kale, 2015).  
Osteopontin Promotes HSC quiescence (Nilsson et al, 2005). 
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Table 1.2. Haematopoietic transcription factors 
Haematopoietic transcription factors that regulate HSCs and cells of the myeloid lineage. 
Transcription factor Example of role 
PU.1 Many; for example, HSC commitment to 
both lymphoid and myeloid lineages 
(regulates HSC differentiation into GMP 
and GLP), biases monocytic commitment 
of the GMP etc  (Iwasaki et al, 2005). 
CCAAT-enhancer-binding protein alpha 
(C/EBPα) 
Promotes granulocyte differentiation. 
Activates other haematopoietic 
transcription factors, e.g. PU.1 (Friedman 
et al, 2003). 
Growth factor independent 1 transcriptional 
repressor (GFI1) 
Granulocyte differentiation (de la Luz 
Sierra et al, 2010). 
GATA-1/GATA-2 Erythropoiesis (Suzuki et al, 2013; Weiss 
et al, 1997). 
Runt-related transcription factor 1 (RUNX1) Homeostasis of HSC/early haematopoietic 
progenitor cell numbers (Burns et al, 2005; 
Ichikawa et al, 2013). 
JunB Represses proliferation and differentiation 
of HSCs (Passegué et al, 2004; 
Santaguida et al, 2009). 
Myc Regulates the balance between self-
renewal, differentiation and survival of 
HSCs (Laurenti et al, 2008; Wilson et al, 
2004). 
Homeobox protein B4 (Hox-B4) HSC proliferation/expansion (Antonchuk et 
al, 2002; Björnsson et al, 2003). 
Nuclear factor erythroid derived-2 (NF-E2) Formation of megakaryocytes/platelets 
(Lecine et al, 1998; Shivdasani et al, 
1995). 
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The bone marrow is the primary site of haematopoiesis in adults, and classically 
it is thought to contain two niches in which HSCs reside; the osteoblastic niche 
and vascular niche. These niches are composed of different cell types, including 
osteoclasts, osteoblasts, stromal cells, extracellular matrix components and a 
vascular network (Figure 1.2). The niche cells play a vital role in haematopoiesis, 
by regulating key processes in HSCs and progenitor cells, including adhesion, 
self-renewal, survival and differentiation. This is achieved through direct cell-cell 
contact with HSCs/progenitors and niche cells, as well as secretion of regulatory 
factors into the microenvironment. 
The importance of the osteoblastic niche in regulating HSCs remains unclear. In 
vivo studies that increase osteoblast numbers lead to an increase in HSCs (Calvi 
et al, 2003; Zhang et al, 2003) and in the reverse experiment, involving the 
conditional removal of osteoblasts from the niche, decreased HSC numbers and 
abnormal haematopoiesis are observed (Visnjic et al, 2004). Although this 
suggests that the osteoblastic niche is important in regulating HSCs, in the study 
by Visnjic et al, the effect of depleted osteoblasts on HSCs was only observed 
after a decrease in differentiated blood cells. This suggests that osteoblasts 
regulate other cell types and that the observed decrease in HSC number may be 
a result of changes in other cell types. Additionally, more recent in vivo studies, 
using HSC markers to visualize HSC localization in murine bone marrow, found 
that most HSCs do not reside in the osteoblastic niche and are primarily 
localized around sinusoids (Acar et al, 2015; Morrison & Scadden, 2014). 
Furthermore, deletion of the key niche cytokines Scf and Cxcl12 from murine 
osteoblasts did not affect HSC number or function in vivo (Ding & Morrison, 
2013; Ding et al, 2012b). In contrast, conditional knockout of Scf and Cxcl12 in 
perivascular/vascular niche stromal cells led to HSC depletion. Together, these 
studies suggest that the perivascular/vascular niche surrounding sinusoids 
may play a more prominent role in regulating HSCs than the osteoblastic niche. 
Given the importance of the regulation of HSCs by niche cells, it is not surprising 
that factors controlling adhesion of HSCs and niche components are also 
important in regulating haematopoiesis. These include vascular cell adhesion 
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molecule-1 (VCAM-1), integrin, N-cadherin(N-cad), β-catenin (1.3.5) and 
osteopontin (OPN) (Yin & Li, 2006).  
 
 
  
Figure 1.2. The bone marrow niche. 
The bone marrow contains two niches where HSCs reside (osteoblastic and vascular niches). 
Some of the cell types found in these niches are highlighted. 
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In addition to niche cells, HSCs are also regulated by other factors in the bone 
marrow, such as oxygen tension. The bone marrow niche has low levels of 
oxygen (is hypoxic), which promotes HSC quiescence, maintaining them in an 
undifferentiated state. This implicates the osteoblastic niche as the site for 
maintenance of quiescent HSCs, and the vascular niche (next to blood vessels 
that provide higher oxygen levels) as the site of HSC proliferation and 
differentiation. The low level of oxygen in the bone marrow niche may provide 
protection from harmful reactive oxygen species (ROS) that can cause mutations 
and impact the ability of HSCs to promote normal haematopoiesis. (Ludin et al, 
2014; Mohyeldin et al, 2010; Zhou et al, 2013).  
 
 
Leukaemia is a term used to describe haematological malignancies that usually 
develop in the bone marrow. It is generally associated with a high level of 
abnormal white blood cells and reduced levels of other blood cell types such as 
erythrocytes and platelets. This leads to a multitude of symptoms including 
anaemia, fatigue, bruising and immunodeficiency.  
Acute myeloid leukaemia (AML) is a highly heterogenous disease and is 
characterized by a block in normal myeloid development and accumulation of 
abnormal immature blast cells (Figure 1.3). In the UK, 3.4 people per 100,000 
are diagnosed with AML per annum and it is most common in the elderly, with a 
median age of diagnosis of approximately 72 years old1. The prognosis for AML 
is generally poor and varies depending on different prognostic risk factors 
(1.2.5.1). Current treatment for AML usually involves the use of combinations of 
chemotherapeutic agents, and to a lesser extent growth factor therapy and 
radiotherapy (1.2.5.2). Although around 40-80% of patients go into remission 
following these treatments (Tallman, 2005), the rate of relapse is high, particularly 
in the elderly, with ~85% of AML patients over the age of 60 relapsing within two 
years (Burnett, 2012). In addition, the toxicity of these treatments is a major 
                                            
1 https://www.hmrn.org (accessed on 25/03/2018) 
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disadvantage. As such, developing more effective treatments for AML is 
important for improving patient outcome and quality of life. 
 
 
 
Figure 1.3. Differentiation bock in AML. 
The mutations leading to a differentiation block and accumulation of blasts in AML can occur in 
cells at different stages of the haematopoietic hierarchy (some examples are marked by an X 
above). This leads to individuals with AML blasts of different differentiation stages, which can be 
used to classify AML (Table 1.4). Abbreviations; CMP = common myeloid progenitor, HSC= 
haematopoietic stem cell. 
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Mutations involved in AML have historically been split into two different classes 
based on the ‘two hit hypothesis’ of AML progression: class I involved mutations 
that increase proliferation, whereas class II inhibited differentiation and apoptosis 
(Kelly & Gilliland, 2002). More recently a third mutation class has been added to 
this classification system, class III, which involves epigenetic regulators  
(Dombret, 2011; Kao et al, 2014).  Studies have highlighted a wide array of 
mutation types in AML that do not fit into the class system described above and 
the combination of mutations in each patient are thought to collectively regulate 
increased proliferation and impaired differentiation and apoptosis required for 
AML pathogenesis. 
A recent study using whole genome sequencing, exome sequencing, 
RNA/miRNA sequencing and DNA methylation analysis of AML patients provides 
an overview of the common molecular abnormalities in AML (Table 1.3). Briefly, 
the two most commonly mutated genes in AML are the cytoplasmic-nuclear 
shuttling protein nucleophosmin (NPM1) and the tyrosine kinase FLT3. NPM1 
mutations are observed in 27% of AML patients, the FLT3-internal tandem 
duplication (FLT3-ITD) mutation occurs in 24% of AML patients, and mutations 
of the FLT3 tyrosine kinase domain (FLT3-TKD) are observed in 4.8% of AML 
patients (Bacher et al, 2008; Lee et al, 2007). These mutations have different 
prognostic values; NPM1 mutations are associated with a favourable prognosis 
and FLT3-ITD is associated with a poor prognosis (De Kouchkovsky & Abdul-
Hay, 2016).  There are also common chromosomal abnormalities in AML, 
including the t(8;21) translocation and the inversion inv(16) which result in the 
abnormal proteins RUNX1-ETO and MHY11-CBFβ respectively. MLL-fusions are 
also commonly observed in AML (Table 1.3) (most commonly MLL-AF9) (Meyer 
et al, 2013). Signalling genes and transcription factors also have a high mutation 
rate in AML, for example, RUNX1 and CEBPA (Ley et al, 2013). RUNX1 
mutations are observed in ~ 33% of patients with cytogenetically normal AML, 
and mutations in CEBPA are present in ~10% of AML patients (Fasan et al, 2014; 
Schnittger et al, 2011).  
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Table 1.3. Common molecular abnormalities in AML 
Information in this table was taken from (Ley et al, 2013). 
Type of mutation % AML 
patients 
Example(s) 
Activated signalling 59% FLT3, KIT, KRAS, NRAS, 
PTPs, Ser/Thr kinases and 
other Tyr kinases 
DNA methylation 46% TET1, TET2, IDH1, IDH2, 
DNMT3B, DNMT1, DNMT3A. 
Chromatin modifiers 30.5% MLL fusions, MLL PTD, NUP-
98-NSD1, ASXL1, EZ112, 
KDM6A. 
NPM1 27% 
 
Myeloid transcription factors 22% RUNX1, CEBPA and others. 
Transcription factor fusions 18% PML-RARA, MYH11-CBFB, 
RUNX1-RUNX1T1, PICALM-
MLLT10. 
Tumour suppressors 16.5% TP53, WT1, PHF6 
Spliceosome 13.5% 
 
Cohesin complex 13% 
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It is unlikely that novel high frequency abnormalities will be found in AML because 
extensive genomic classification/whole genome sequencing has been conducted 
on large AML patient cohorts (Ilyas et al, 2015; Ley et al, 2013; Papaemmanuil 
et al, 2016) with similar high frequency mutations being characterised across 
studies, but interestingly AML occurs in patients without DNA mutations. In one 
study, gene profiling of 1540 AML patients found that 4% of the cohort carried no 
mutations in any of the currently recognised driver genes associated with the 
pathogenesis of AML (Papaemmanuil et al, 2016). This indicates that other 
factors can cause disease pathogenesis. These factors include abnormal protein 
expression levels and epigenetic factors such as methylation of genes and non-
coding RNA (e.g. miRNA). Abnormal expression levels of the Wnt pathway 
component β-catenin will be discussed in 1.3.3. 
 
In the past, individuals were diagnosed with AML if their bone marrow presented 
a blast count of 30% or more, and following diagnosis, French-American-British 
(FAB) typing was used to classify the AML (Table 1.4), based on their 
morphology and cytochemistry (Bennett et al, 1976). Although this system could 
account for some of the heterogeneity observed in AML, it had limitations for 
distinguishing AML based on the wide array of genetic and clinical features it can 
present (Vardiman et al, 2002) and was generally poor at predicting outcome. 
As a result, FAB typing has been replaced with a newer classification system, 
outlined by the World Health Organization (WHO) and updated in 2016 (Arber et 
al, 2016). This system was developed to more accurately reflect the 
heterogeneity observed in AML. It considers the morphological, cytochemistical, 
immunophenotypic, genotypic and clinical features of the disease. AML is now 
diagnosed if a patient presents with a bone marrow blast count of 20% and the 
blasts have a myeloid origin or contain at least one of the genetic abnormalities 
outlined by the WHO classification system (Table 1.5). This classification of AML 
into subtypes is important in assigning prognosis and best treatment options for 
patients. In academic research it also enables comparison of different subtypes 
of AML to establish the relevance of any findings to a clinical setting e.g. if a 
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protein or drug being studied will benefit all AML patients, or just a specific 
subtype. 
 
 
Table 1.4. The French-American-British classification system for AML 
Information in this table is from (Bennett et al, 1976). 
Subtype Feature 
M0 Undifferentiated 
M1 Myeloblastic without maturation 
M2 Myeloblastic with maturation 
M3 Promyelocytic 
M4 Myelomonocytic 
M4 EO Myelomonocytic with bone marrow eosinophilia 
M5 Monocytic 
M6 Erythroleukemic 
M7 Megakaryocytic 
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Table 1.5. The World Health Organisation classification system for AML 
Information in this table is taken from (Arber et al, 2016). 
Category Features 
Acute myeloid leukaemia with recurrent genetic 
abnormalities 
AML with t(8;21) (q22;q22), (AML1/ETO) 
AML with inv(16) (p13q22) or t(16;16) 
(p13;q22), (CBFβ/MYH11) 
APL with t(15;17) (q22;q12), (PML/RARα) 
and variants 
AML with t(9;11) (p21.3;q23.3);MLLT3-
KMT2A 
AML with t(9;11) (p22;q23); MLLT3-MLL  
AML with t(6;9) (p23;q34.1);DEK-NUP214 
AML with inv(3) (q21.3q26.2) or t(3;3) 
(q21.3;q26.2); GATA2, MECOM 
AML (megakaryoblastic) with t(1;22) 
(p13.3;q13.3);RBM15-MKL1 
AML with mutated NPM1 
AML with biallelic mutations of CEBPA 
AML with myelodysplasia-related changes 
 
Therapy-related myeloid neoplasms 
 
AML, not otherwise specified AML with minimal differentiation 
AML without maturation  
AML with maturation  
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Pure erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
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There are different theories of AML propagation and this section will briefly 
summarise each.  
 
The clonal evolution theory is based on the observation that in AML there is a 
heterogenous population of leukaemia cells that contain different molecular 
abnormalities (1.2.2). These are subject to selection pressures, favouring 
subtypes of cells that have an advantage over others (Figure 1.4A), for example, 
increased survival or proliferation. This results in the ‘evolution’ of AML blasts and 
a population of cells that is different than the one present at the beginning of 
disease pathogenesis (Ding et al, 2012a).  
 
The hierarchical model (leukaemia stem cell model) theorises that the 
heterogenous clones in AML are organised in a structure like the normal 
haematopoietic hierarchy (Figure 1.1). According to the model, all AML blasts 
arise from leukemic stem cells (LSCs) which can establish and maintain disease 
(Figure 1.4B). Early xenograft mouse models suggested that LSCs were derived 
from normal HSCs or early HPCs. This was based on the observation that only 
CD34+ CD38- AML cells engrafted into mice and led to the establishment of 
leukaemia blasts (Bonnet & Dick, 1997; Lapidot et al, 1994). Subsequently it was 
discovered that antibody labelling of CD38+ cells resulted in immune clearing in 
these initial experiments and later experiments have shown that CD38+ cells are 
in fact able to engraft and cause disease, though at a lower frequency (Taussig 
et al, 2008). Studies focusing on the immunophenotype of AML LSCs have 
identified cell surface markers that are more strongly expressed on LSCs. These 
include CD96 (Hosen et al, 2007), CD123 (Du et al, 2011; Jordan et al, 2000) 
and CD47 (Majeti et al, 2009b).  
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Figure 1.4. Theories of AML leukaemogenesis. 
(A) The clonal evolution theory. In this model selection pressures act on AML clones, which 
causes clones with certain characteristics to survive. Over time this changes the population of 
the AML blasts, so the disease is constantly changing due to environmental factors. This can 
be used to explain relapse in patients following treatment, as the treatment acts as a selection 
pressure. (B) The hierarchical model. In this model all of the AML blasts arise from an LSC.  
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There are different factors that influence the prognosis of AML patients, including 
age, initial treatment, white blood cell count, cytogenetic status and secondary 
disease (Estey & Döhner, 2006). Age is an important predictor of prognosis in 
patients with AML. Survival of patients enrolled in MRC clinical trials between 
1970 and 2009, highlight the significant progress that has been made in the 
treatment of patients below the age of 60, with a five-year survival rate of >50%. 
This decreases to 25% survival in patients aged 60-69 and 10% in patients 70+ 
years old (Burnett, 2012).  
Cytogenetics is also a reliable predictor of AML prognosis, and recurring 
abnormalities are classified as favourable, intermediate or adverse according to 
their influence on prognosis (Table 1.6). For example, FLT3-ITD is associated 
with an adverse patient outcome prognosis, whereas NPM1 is associated with a 
favourable patient outcome (De Kouchkovsky & Abdul-Hay, 2016). Karyotypic 
abnormalities are common in AML, occurring in around 60% of AML patients 
before treatment (Mrózek et al, 2001) and these abnormalities have a profound 
clinical relevance. For example, patients with deletion of chromosomes 5 or 7 
have a poor prognosis and are unlikely to respond to treatment, whereas patients 
with CBF abnormalities such as inv(16) or t(8;21) have a favourable prognosis 
and are more likely to respond to treatment (Grimwade et al, 1998).  
In AML, the largest cytogenetic group is a normal karyotype, which confers an 
intermediate risk. In these patients, the presence of other molecular abnormalities 
(1.2.2) are more useful for predicting prognosis. For example, NPM1 mutations 
predict a favourable outcome (Döhner et al, 2005) with such accuracy that they 
have been included in the updated WHO classification system of AML (Table 1.5) 
The presence of multiple mutations complicates the prognosis of AML. For 
example, although NPM1 mutations predict a favourable outcome in AML 
patients, this is not the case when they are found in combination with FLT3-ITD 
mutations (Döhner et al, 2005; Thiede et al, 2006). 
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Table 1.6. Risk groups based on cytogenetics and other molecular abnormalities 
The information in this table was taken from (De Kouchkovsky & Abdul-Hay, 2016). 
Risk Group Abnormality 
Favourable t(8;21) without c-KIT mutation 
t(15;17) 
inv(16) 
NPM1 without FLT3-ITD mutation (normal karyotype) 
Biallelic CEBPA mutation (normal karyotype) 
Intermediate Normal karyotype (unless included in the other risk groups) 
t(8;21) with c-KIT mutation 
t(9;11)  
Other cytogenetic abnormalities not included in the other risk 
groups 
Adverse TP53 mutation  
FLT3-ITD (normal karyotype) 
DNMT3A (normal karyotype) 
KMT2A-PTD (normal karyotype) 
inv (3) 
t(6;9) 
11q abnormalities (except t(9;11)) 
-5 
del(5q) 
-7 
Complex karyotype (greater than or equal to three or four 
chromosomal abnormalities in the absence of any recurrent 
genetic abnormalities outlined by the WHO classification system 
(Mrózek, 2008; Stölzel et al, 2016)).  
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Currently, the treatment of AML involves the use of chemotherapy to reduce the 
bulk blast population and induce long term complete remission (<5% bone 
marrow blasts and differentiation/maturation of other lineages) (Gale et al, 2005). 
Chemotherapy drugs are generally non-specific and target processes that are 
important for both AML blasts and normal cells (e.g. DNA replication). As such, 
there are a multitude of side effects including nausea, infertility, hair loss, 
immune-suppression and vomiting. 
The therapeutic approach used for most patients is the 3+7 approach, involving 
treatment of patients with daunorubicin for 3 days and cytarabine (AraC) for 7 
days (Appelbaum et al, 2001). These agents work by targeting DNA replication 
and cell metabolism, and this approach induces complete remission in 65-75% 
of adults (18-60 years old) (Tallman, 2005). If patients do not achieve complete 
remission or shortly relapse after treatment, bone marrow transplants are 
considered as a next step in treatment. Owing to common complications, high 
rates of relapse and toxicity of bone marrow transplants, however, they are only 
suitable for the fittest of patients.  
Owing to the poor prognosis and lack of increased survival in elderly AML 
patients, new therapeutic options are necessary. This is likely to involve agents 
that target specific molecular abnormalities that are present in AML (1.2.2). This 
paradigm has been used successfully in the treatment of other haematological 
malignancies, for example chronic myeloid leukaemia (CML), in which targeting 
the Bcr-Abl fusion protein using tyrosine kinase inhibitors, such as Imatinib, has 
increased eight-year survival rate of CML patients from ~65% to ~87% 
(Kantarjian et al, 2012).  Components of the Wnt signalling pathway could provide 
a target for such therapeutics in AML patients, as members of the Wnt pathway 
are frequently dysregulated in AML (1.3.3). 
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The Wnt pathway is an evolutionarily conserved signalling pathway that mediates 
embryonic development and tissue homeostasis. Wnt proteins are encoded by 
19 genes in humans and belong to a family of secreted glycoproteins (Clevers, 
2006; Nusse & Clevers, 2017) that bind to specific cell membrane receptors. 
Three known mechanisms of Wnt signalling have been characterized which fit 
into two groups; canonical Wnt signalling and non-canonical Wnt signalling. The 
canonical and non-canonical pathways are regulated by different ligands, 
receptors and downstream components (Table 1.7). Non-canonical Wnt 
signalling is transduced (1) by small G proteins, for example Rho (in the planar 
cell polarity (PCP) pathway)) or (2) via regulation of intracellular calcium levels 
(Kim & Kahn, 2014). Canonical Wnt signalling is transduced through the 
transcription factor β-catenin (Figure 1.5). This section will focus on the canonical 
Wnt pathway because its central mediator, β-catenin, is the focus of this study. 
 
In the absence of a Wnt ligand, β-catenin is constitutively degraded by a 
destruction complex comprising glycogen synthase kinase 3β (GSK3β), casein 
kinase 1 (CK-1), Axin-1/2, adenomatous polyposis coli (APC) and the E3 ligase, 
β- transducing repeat containing-protein (β-TrCP). Phosphorylation of β-catenin 
is important in regulating its degradation by this complex; CK-1 phosphorylates 
β-catenin on Serine 45 (Ser45) and GSK3β phosphorylates β-catenin on Ser33, 
Ser 37 and Threonine 41 (Thr41). These phosphorylation events generate 
recognition sites for β-TrCP which ubiquitinates β-catenin, targeting it for 
proteasomal degradation (Aberle et al, 1997; Orford et al, 1997; Polakis et al, 
1999; Salomon et al, 1997). In the nucleus, β-catenin target genes (1.3.1.2) are 
repressed by a complex comprising TCF, Groucho, histone deacetylases 
(HDACs) and C-terminal binding protein (CtBP) (Billin et al, 2000; Roose et al, 
1998; Willert & Jones, 2006). 
  
Chapter 1: Introduction 
 
Page | 22  
 
Table 1.7. Components of the canonical and non-canonical (PCP) pathways. 
Information in this table is taken from (Komiya & Habas, 2008; Siar et al, 2012). Abbreviations; 
Wnt= wingless, LRP= low-density lipoprotein receptor-related protein, Ryk= receptor-like 
tyrosine kinase, ROR= receptor tyrosine kinase-like orphan receptor, PTK= protein tyrosine 
kinase, Dvl= dishevelled, CK= casein kinase, GSK= glycogen synthase kinase, TCF= T-cell 
factor, LEF= lymphoid enhancer-binding factor, BCL= B cell/CLL lymphoma, DAAM= 
dishevelled associated activator of morphogenesis, Rac= Ras-related C3 botulinum toxin 
substrate, JNK= c-Jun N-terminal kinase. 
 
Canonical Non-canonical (PCP) pathway 
Ligands Wnt 1, Wnt2, Wnt3, Wnt8a, 
Wnt8, Wnt10a and Wnt10b  
Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, 
Wnt7b and Wnt 11  
Receptors Frizzled receptors + LRP5/6 co-
receptors 
Frizzled receptors + proposed co-
receptors (e.g. Ryk, ROR2, and 
PTK7) 
Downstream 
signalling 
molecules 
Dvl, CK1γ and GSK3β, β-
catenin, TCF/LEF, pygopus, 
BCL-9 
Dvl, DAAM1, Rho, Rac, JNK,Jun. 
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Figure 1.5. Canonical Wnt signalling. 
Left; In inactive Wnt signalling, Wnt target gene expression is repressed (X). Right; In active 
Wnt signalling Wnt target genes are expressed. Abbreviations; PM= plasma membrane, P= 
phosphorylation, Ub= ubiquitin. Adapted from (Shi et al, 2016). 
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Canonical Wnt signalling is activated by binding of Wnt ligands (e.g. Wnt3a) to 
Frizzled receptors and their co-receptors, low-density lipoprotein receptor-related 
proteins 5/6 (LRP5/6). Dishevelled (Dvl) is recruited to the receptor complex and 
assists CK-1 and GSK3β mediated phosphorylation of LRP5/6 (Zeng et al, 2008; 
Zeng et al, 2005). The phosphorylated sites on LRP5/6 act as docking sites for 
Axin-1/2, which detaches from the catenin destruction complex and relocates to 
the plasma membrane. This leads to the dissociation of the destruction complex, 
and CK-1 and GSKβ can no longer phosphorylate β-catenin. Without these 
phosphorylation events, the E3 ubiquitin ligase, β-TrCP, no longer targets β-
catenin for proteasomal degradation and β-catenin accumulates in the cytoplasm 
before translocating to the nucleus (1.3.6). In the nucleus, β-catenin displaces 
Groucho, leading to the dissociation of the transcriptional repressor complex. β-
catenin binds the TCF/LEF family of transcription factors in a transcriptional 
activation complex with pygopus, B-cell CLL/lymphoma-9 protein (BCL-9) and 
histone acetyl transferases (e.g. CBP/p300) (Evans et al, 2010; Kramps et al, 
2002; Sun et al, 2000; Townsley et al, 2004). Well characterized β-catenin/TCF 
target genes include cyclinD1, c-myc, TCF-1, survivin and CD44 (He et al, 1998; 
Roose et al, 1999; Shtutman et al, 1999; Wielenga et al, 1999; Zhang et al, 2001). 
These genes regulate processes such as proliferation and cell survival. 
 
The canonical Wnt pathway is negatively regulated at different levels of the 
pathway. For example, at the ligand-receptor level, proteins can act as Wnt 
decoys by binding to the Wnt receptor complex without transducing the signal to 
intracellular Wnt pathway components. Characterized Wnt decoy proteins include 
Wnt inhibitory factor (WIF), Dickkopf-related protein 1 (DKK1) and soluble frizzled 
related proteins (sFRPs). In the nucleus, β-catenin can be sequestered by the β-
catenin-interacting protein (ICAT), reducing the levels of TCF/LEF bound β-
catenin available for activation of Wnt target genes (Daniels & Weis, 2002). 
Alternative splicing of TCF proteins (including TCF-1 and LEF-1) can also 
negatively regulate β-catenin mediated transcription. Whilst the longer TCF 
isoforms can bind to β-catenin, the shorter isoforms lack the β-catenin binding 
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site and instead bind to target gene promoters and act as transcriptional 
repressors (Molenaar et al, 1996; Roose et al, 1999)  
 
There is growing evidence to suggest that canonical and non-canonical Wnt 
signalling is active in normal haematopoiesis, however, this remains a 
contentious issue due to conflicting experimental results. Early studies observed 
the haematopoietic expression of various Wnt pathway components in murine 
models, including Wnt5A, Wnt10B and Frizzled receptors. In vitro, culturing HSCs 
in conditioned media containing Wnt1, Wnt3a and Wnt10B led to HSC expansion, 
suggesting that the Wnt pathway promotes the survival and proliferation of HSCs 
(Austin et al, 1997). Other studies characterizing the expression of Wnt genes in 
human haematopoiesis found that Wnt2B, Wnt5A and Wnt10B were expressed 
in bone marrow stromal cells, and to varying degrees in haematopoietic cells of 
the lymphoid and myeloid lineages. In the Lin-CD34+ cell population, only Wnt5a 
was expressed and this cell population expanded in response to Wnt secreting 
stromal cells (Van Den Berg et al, 1998).  
Since these early observations, other studies have focused on the role that Wnt 
signalling plays in the regulation of HSCs and haematopoiesis. In vivo studies, in 
which the Wnt antagonist DKK-1 was overexpressed in the bone marrow niche, 
led to increased HSC proliferation and a reduction in post-transplant regeneration 
capacity, suggesting that Wnt signalling regulates the quiescence and 
reconstitution of HSCs (Fleming et al, 2008). In contrast, depleting Wnt3a led to 
a decrease in HSC numbers, reduced their long-term repopulation capacity in 
secondary recipient lethally irradiated mice, and reduced the number of myeloid 
progenitors (Luis et al, 2009). This suggested that Wnt signalling regulates the 
proliferation and long-term survival of HSCs. This was supported by another in 
vivo study, in which inhibition of the catenin destruction complex component 
GSK3β led to increased β-catenin levels and an increase in self-renewal and 
reconstitution of HSCs (Trowbridge et al, 2006). Additionally, repression of the β-
catenin co-activator LEF-1 in CD34+ progenitor cells inhibited proliferation and led 
their apoptosis (Skokowa et al, 2006). Wnt signalling also has a proposed role in 
the homing of HSCs to the stem cell niche. Inhibition of Wnt signalling using DKK-
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1 interfered with homing of HSCs to the osteoblastic niche in vivo (Lane et al, 
2011). 
In vitro studies overexpressing ICAT (Wnt inhibitor) in murine haematopoietic 
progenitor cells, interfered with T-cell development (Pongracz et al, 2006) 
suggesting that Wnt signalling is important for normal T-cell development. 
Conversely, in vitro studies overexpressing Wnt3a in human bone marrow 
progenitor cells had an anti-proliferative effect on B cells, suggesting that Wnt 
signalling negatively regulates the expansion of this cell type (Døsen et al, 2006). 
The role of the primary canonical Wnt pathway effector β-catenin in 
haematopoiesis remains a contentious issue. Some in vitro and in vivo studies 
using β-catenin overexpression and knockout mouse models suggest that β-
catenin plays an essential role in HSC self-renewal and survival (Nemeth et al, 
2009; Reya et al, 2003; Zhao et al, 2007), whereas other studies suggest that 
activation of β-catenin leads to exhaustion of the HSC pool and a block in 
multilineage differentiation (Kirstetter et al, 2006; Scheller et al, 2006). Studies 
deleting β-catenin and/or γ-catenin (a close homologue of β-catenin) in HSCs did 
not inhibit normal haematopoiesis upon transplantation of these cells into 
irradiated mice, however, in these cells TCF/LEF1 expression was still active, 
suggesting that there are other redundant factors that can regulate their 
expression in the absence of β-catenin and γ-catenin (Cobas et al, 2004; Jeannet 
et al, 2008). In another study, overexpression of β-catenin in bone marrow 
stromal cells led to proliferation of HSCs, but when β-catenin was overexpressed 
in HSCs this led to exhaustion of the HSC pool (Kim et al, 2009). Stromal cells 
overexpressing β-catenin also exhibited an enrichment of Notch ligands and 
downstream Notch signalling. Notch signalling can regulate the self-renewal of 
HSCs and repress their differentiation (Weber & Calvi, 2010). This suggests that 
crosstalk between the Wnt and Notch pathways may be important in regulating 
HSC self-renewal and maintaining them in an undifferentiated state. Studies 
overexpressing β-catenin in myeloid and lymphoid progenitor cells led to their 
increased self-renewal and a differentiation block. This suggests that β-catenin’s 
role in haematopoiesis could primarily be to regulate cell ‘’stemness’’ (Baba et al, 
2005). β-catenin may also play a role in regulating the adhesion of HSCs to stem 
cell niche cells (1.1.2.2). In one study, in vitro imaging of HSCs and MSCs 
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identified colocalization of N-Cadherin and β-catenin at the point of contact 
between HSCs and MSCs, suggesting that these components could be involved 
in regulating their adherence (Wein et al, 2010).  
The contrasting observations regarding the role Wnt/β-catenin in haematopoiesis 
in these studies could be due to the different experimental approaches used. An 
in vivo study examining the effect of different APC mutations (leading to a 
gradient of Wnt signalling), suggested that Wnt signalling regulates 
haematopoiesis in a dosage dependent manner, which could explain the 
contrasting observations in previous studies (Luis et al, 2011). Whether β-catenin 
is essential for haematopoiesis or not, tight regulation of Wnt signalling seems to 
be important in haematopoiesis, and Wnt pathway components including β-
catenin, are dysregulated in leukaemia (1.3.3). 
 
Gene expression analysis of HSCs and LSCs and microarray analysis of AML 
blasts suggest that the Wnt pathway is one of the most commonly dysregulated 
pathways in AML (Daud, 2014; Majeti et al, 2009a). 
In AML, canonical and non-canonical Wnt pathway components are dysregulated 
at different levels of the signalling pathway. Starting at the cell membrane, 
aberrant expression of Wnt ligands and receptors have been identified in AML. 
For example, the Wnt ligands Wnt1 and Wnt2B are expressed in AML blasts but 
are undetectable in CD34+ progenitor cells (Simon et al, 2005). Aberrant 
expression of Wnt receptors is also observed in AML. For example, 
overexpression of Frizzled-4 protein is seen in AML blasts and when these cells 
are induced with Wnt3a, this leads to stabilisation of β-catenin (Tickenbrock et al, 
2008). Components of the catenin destruction complex are also dysregulated in 
AML. For example, overexpression of GSK3β is associated with resistance of 
AML to chemotherapy and missplicing of GSK3β can lead to elevated levels of 
β-catenin, contributing to leukaemogenesis (Abrahamsson et al, 2009; De Toni 
et al, 2006)  
Different studies have focused on the central canonical Wnt pathway effector β-
catenin and its role in AML. Studies using Western blotting and 
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immunohistochemistry have shown that β-catenin is expressed in AML blasts. 
Aberrant β-catenin mRNA expression is observed in approximately 20% of AML 
patients and β-catenin overexpression is associated with poor prognosis and 
enhanced proliferation of colony forming units in vitro. (Chen et al, 2009; Simon 
et al, 2005; Xu et al, 2008; Ysebaert et al, 2006).  In the study by Xu et. al the 
level of β-catenin nuclear localization was investigated. The presence of 
unphosphorylated (active β-catenin) was detected by immunohistochemistry in 
the nucleus of almost 50% of the AML samples. In the study by Simon et. al, β-
catenin mediated transcription was evaluated in AML blasts using a TOPFLASH 
reporter (which measures intracellular TCF/LEF activity). They found that 
TOPFLASH reporter expression was higher in AML blasts than in normal 
progenitors. However, they did not correlate this to increased levels of β-catenin. 
Knockdown of β-catenin in AML cell lines and AML blasts decreases their 
proliferation in vitro (Siapati et al, 2011) and impacts the engraftment of AML cell 
lines to the bone marrow niche in vivo (following xenotransplantation in mice) 
(Gandillet et al, 2011). Other in vivo studies suggest that β-catenin is required for 
self-renewal of mouse leukaemia initiating cells (LICs) co-expressing the 
oncogenes (homeobox A9 (HoxA9) or Meis homeobox 1a (Meis1a) (Wang et al, 
2010). In vivo studies looking at preleukaemic stem cell (pre-LSC) and LSC 
enriched cell populations in AML with MLL fusion proteins have suggested that 
β-catenin is critical for development of MLL LSCs. Knockdown of β-catenin in 
MLL LSCs led to delayed disease latency and reduced in vitro cloning capacity. 
Knockout of β-catenin in pre-LSCs led to a failure of these cells to induce 
leukaemia. This suggests that β-catenin plays a vital role in the establishment of 
LSCs in MLL AML (Yeung et al, 2010). Recently, in vivo studies of murine lin-
Sca1+kit+ (LSK) derived MLL cancer stem cells have demonstrated that HoxA9 
suppression sensitises the cells to β-catenin inhibition which leads to the 
abolishment of the cancer stem cell transcriptional signature and interferes with 
their transformation capacity (Siriboonpiputtana et al, 2017). This suggests that 
this could be a potential axis for treatment of these aggressive MLL LSCs. 
Focusing on another Wnt transcription factor, γ-catenin, studies have observed 
γ-catenin mRNA and protein overexpression in the presence of AML fusion 
proteins e.g. RUNX1/ETO. This led to downstream activation of Wnt target gene 
promoters including c-myc and cyclin D1 (Müller-Tidow et al, 2004; Zheng et al, 
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2004). Overexpression and aberrant nuclear localization of γ-catenin occurs 
frequently in AML, and γ-catenin overexpression is associated with the 
stabilization and nuclear localization of β-catenin (Morgan et al, 2013). 
In the nucleus, β-catenin binding partners that regulate Wnt target genes have 
also been implicated in AML. For example, aberrant LEF-1 expression is 
observed in AML and transplantation of bone marrow cells overexpressing LEF-
1 into mice leads to the development of AML and B lymphoblastic leukaemia 
(Petropoulos et al, 2008). LEF-1 was also identified as one of the Wnt pathway 
components regulating AML by AML associated fusion proteins (Müller-Tidow et 
al, 2004). Microarray analysis of AML patient blasts and normal progenitor cells 
identified another TCF family member, TCF7L2 (TCF-4) as aberrantly expressed 
in 78% of patients. In the same study, knockdown of TCF7L2 in leukaemia lines 
led to a decrease in β-catenin/TCF mediated transcription and an inability of these 
cells to respond to the Wnt agonists Wnt3a and 6-bromoindirubin-3′-oxime (BIO) 
(Daud, 2014).   
Wnt pathway components are regulated by common AML molecular 
abnormalities, including FLT3-ITD and fusion proteins (1.2.2). For example, the 
t(8;21) fusion product can bind the promoter of the Wnt antagonist SFRP and 
repress its function (Cheng et al, 2011). In a study examining the promoter 
methylation status of Wnt antagonist promoters in 269 AML patients, including 
WIF-1, SFRPs and DKK-1, 62% of patients had methylation of at least one of 
these factors. WIF-1 hypermethylation was associated with CEBPA mutations 
and the t(15;17) translocation product, and SFRP-1/SFRP-2 hypermethylation 
was associated with the t(8;21) translocation product (Hou et al, 2011). FLT3-ITD 
has also been associated with the nuclear localization of the Wnt pathway 
component β-catenin into the nucleus of AML cells (Kajiguchi et al, 2007). 
Despite this common dysregulation of Wnt signalling in AML, there is no 
published evidence of recurrent mutations of canonical Wnt pathway genes in 
AML.  
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Owing to the high relapse rate and poor prognosis in AML (particularly in the 
elderly) (1.2.5), targeted therapies are becoming a major focus for new 
treatments. Since Wnt signalling is one of the most commonly dysregulated 
pathways in AML (Daud, 2014; Majeti et al, 2009a), it presents a potential target 
for future therapies. Current research is focusing on the use of novel drugs to 
target different Wnt pathway components (Table 1.8).  
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Table 1.8. Targeting Wnt signalling in cancer. 
Small molecules, antibodies and natural products that can target the Wnt signalling pathway 
and may be useful for treatment of cancer. Adapted from (Shang et al, 2017).  
 
Agent Details 
LGK974 I A small molecule that inhibits lipid 
modification of Wnt by targeting protein-
serine O-palmitoleoyltransferase porcupine 
(PORCN). 
OMP-54F28 An antibody that inhibits Wnt ligands. 
OMP-18R5 An antibody that inhibits multiple Frizzled 
receptors. 
OTSA101 An antibody that inhibits Frizzled 10. 
Celecoxib A small molecule that promotes GSK3β 
activation and subsequent targeting of β-
catenin for degradation. 
DIF1/3  A natural product that activates GSK3β 
leading to subsequent targeting of β-
catenin for degradation.  
Genistein A natural product that activates GSK3β 
leading to subsequent targeting of β-
catenin for degradation.  
G007-LK A small molecule that stabilizes Axin-2 and 
promotes subsequent targeting of β-
catenin for degradation.  
XAV939  A small molecule that stabilizes Axin-2 and 
promotes subsequent targeting of β-
catenin for degradation.  
JW55  A small molecule that stabilizes Axin-2 and 
promotes subsequent targeting of β-
catenin for degradation.  
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Agent Details 
WGA A small molecule that supresses the 
nuclear pore complex and inhibits β-
catenin nuclear translocation. 
PRI 724 A small molecule that interrupts β-
catenin/CBP interactions. A phase I clinical 
trial has been completed in AML, but the 
results are yet to be published2. 
PKF115-584 A small molecule that interrupts β-
catenin/TCF interactions. In vitro studies 
treating AML cell lines and AML blasts 
suggest this molecule could potentially be 
used in the treatment of AML (Minke et al, 
2009). 
CGP9049090 A small molecule that interrupts β-
catenin/TCF interactions. In vitro studies 
treating AML cell lines and AML blasts 
suggest this molecule could potentially be 
used in the treatment of AML (Minke et al, 
2009). 
Vitamin D A natural product that competes with 
TCF/LEF-1 for β-catenin interaction. 
Retinoid acid  A natural product that competes with 
TCF/LEF-1 for β-catenin interaction. 
SAH-BCL-9 A peptide that interrupts β-catenin BCL9 
interaction.  
CWP232291 Identified as a β-catenin inhibitor. A phase 
I clinical trial has been completed in AML, 
but the results are yet to be published3.  
 
                                            
2 https://clinicaltrials.gov/ct2/show/NCT01606579 (accessed 04/01/2018) 
3 https://clinicaltrials.gov/ct2/show/study/NCT01398462 (accessed 04/01/2018) 
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β-catenin is a member of the Armadillo repeat family of proteins and a product of 
the CTNNB1 gene located at 3p224.  This gene gives rise to 15 different 
transcripts which are mostly protein coding5. Four of these transcripts encode full 
length β-catenin (781 amino acids). Although this project focuses on the role of 
β-catenin as a transcription factor and component of the Wnt pathway, it is 
important to note that β-catenin performs other roles, including its regulation of 
adhesion as a component of adherens junctions. There is some evidence to 
suggest that β-catenin is involved in regulating the adhesion of HSCs to niche 
cells (Wein et al, 2010)(1.3.2). 
The structure of β-catenin is key to its functionality; it features a stretch of 12 
armadillo repeats (R1-R12) in addition to distinct C and N terminal domains 
(Figure 1.6). Each armadillo repeat is approximately 42 amino acids long and 
contains three α-helices (H1, H2 and H3) (Huber et al, 1997). These armadillo 
repeats are the most evolutionarily conserved area of the protein, which is 
unsurprising given that most of β-catenin’s characterized binding partners interact 
with them (Table 1.9). These interactions are vital in regulating β-catenin stability, 
nuclear localization and β-catenin mediated transcription. 
  
                                            
4 https://www.ncbi.nlm.nih.gov/gene/1499 (accessed on 04/01/2018) 
5 
http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168036;r=3:41194837-
41260096 (accessed on 04/01/2018 
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Figure 1.6. Structure of β-catenin and its binding to Wnt pathway components. 
The arrows represent areas in the β-catenin structure to which interaction partners bind. More 
specific information about the most important residues for binding of some of these partners is 
outlined in Table 1.9. The numbers 1-12 represent the 12 armadillo repeats. Abbreviations; NT= 
N-terminus, CT= C-terminus. 
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Table 1.9. Binding of interaction partners to β-catenin.  
β-catenin binding 
partner 
Binding details 
Axin-1 The β-catenin armadillo repeats are vital for its binding to Axin-1. 
Mutation of histidine
260
 and lysine
292 
completely blocks its binding 
to Axin-1 (Nakamura et al, 1998; von Kries et al, 2000).  
APC Armadillo repeats 5 & 6 of β-catenin seem to be the most 
important in regulating its interaction with APC. There is a strong 
reduction in binding when arginine
386
, lysine
345
 and tryptophan
383
 
are mutated (von Kries et al, 2000). 
GSK3β GSK3β is thought to interact indirectly with β-catenin via its binding 
to Axin-1 (Wu & Pan, 2010). 
PP2A PP2A is thought to interact indirectly with β-catenin via its binding 
to other catenin destruction complex components, e.g. Axin-1 
(Stamos & Weis, 2013). 
CK-1 CK-1 is thought to interact indirectly with β-catenin via its binding 
to Axin-1 (Stamos & Weis, 2013) 
LEF-1 β-catenin armadillo repeats 8 & 9 are important for its binding to 
LEF-1. Studies mutating residues in this area (specifically residues 
that flank a hydrophobic area near leucine
427
) abolished LEF-1 
binding. Mutations in other areas did not significantly affect its 
binding to LEF-1 (von Kries et al, 2000). 
TCF-4 Residues of β-catenin that are thought to regulate its interaction 
with TCF-4 are; asparagine
426
, lysine
435
, arginine
469
, histidine
470
, 
lysine
508
 and lysine
312  (Fasolini et al, 2003). 
BCL9 β-catenin binds to BCL9 via armadillo repeat 1. Leucine156, 
leucine159, and leucine178 form part of the domain that interacts 
with BCL9 (Sampietro et al, 2006). 
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Localization of β-catenin to the nucleus is necessary for its role as a transcription 
factor as part of the canonical Wnt pathway. Studies correlating the cytoplasmic 
and nuclear levels of β-catenin protein expression have highlighted that 
stabilization of cytoplasmic β-catenin does not necessarily lead to nuclear 
localization of β-catenin in AML. Some AML blasts present with a low cytoplasmic 
level but high nuclear level of β-catenin, and vice versa (Morgan et al, 2014). AML 
cell lines also exhibit variable levels of nuclear β-catenin. Previous analysis of 
AML cell lines in our laboratory has identified some cell lines that freely 
translocate β-catenin to the nucleus (termed translocators), and others that resist 
the nuclear localization of β-catenin (termed non-translocators) (Figure 1.7) 
(Morgan et al, 2014). In agreement with the observations made in AML blasts, 
the level of nuclear β-catenin in these cell lines does not correlate with 
cytoplasmic levels, suggesting that these cell lines could present a good model 
system to study the regulation of β-catenin nuclear localization in AML. Identifying 
factors that regulate β-catenin nuclear localization in AML is important in 
understanding the mechanism of Wnt signalling in leukaemogenesis and could 
provide novel therapeutic targets for AML.  
Translocators and non-translocators 
“Translocation” is a global term used to describe the movement of proteins from 
one cellular location or compartment to another, and the term “nuclear 
translocation” is commonly used to describe the movement of β-catenin from the 
cytoplasm to the nucleus of cells (Chen et al, 2005; Griffin et al, 2018; Herencia 
et al, 2012; Jian et al, 2006). The derivative terms “translocator” and “non-
translocator” are not commonly used in the literature to describe cells, but in this 
study they provide a way of classifying the cell lines according to whether they 
freely translocate β-catenin to the nucleus or resist nuclear accumulation of β-
catenin. The reason for characterizing these cells was so they could be used as 
a model system to identify potential candidate nuclear localization factors (1.4) 
and so the results could be easily analysed and discussed. This characterization, 
however, does not consider all the complexity observed in these cell lines, with 
some “non-translocator” cell lines in fact translocating β-catenin to the nucleus, 
albeit at a much lower level than “translocator” cell lines (Appendix 1).  
Chapter 1: Introduction 
 
Page | 37  
 
 
 
Figure 1.7 Translocator and non-translocator cell lines.  
Classification of myeloid cell lines into cell lines that (A) resist the nuclear localization of β-catenin 
(non-translocators) and (B) translocate β-catenin to the nucleus (translocators). (C) Comparison 
of cytoplasmic and nuclear levels of β-catenin in AML blasts.  This data was generated by Dr. 
Rhys Morgan (Morgan et al, 2014). 
 
β-catenin nuclear import has been studied in various contexts, and different 
mechanisms governing its localization to the nucleus have been implicated. 
Some of these mechanisms were reviewed in our paper (Morgan et al, 2014). 
Briefly, β-catenin nuclear localization can be mediated by direct interaction of β-
catenin with nuclear membrane components (such as nucleoporins and emerin), 
CRM1 dependent import, nuclear retention, CRM1 dependent export, 
cytoplasmic/membrane retention and CRM1 independent export. Different 
factors have been implicated in the regulation of β-catenin nuclear localization in 
different contexts (Table 1.10). Most studies looking at the regulation of β-catenin 
localization in cancer have been conducted in solid tumours, but some of these 
factors could also be relevant to haematological malignancies. Interestingly, 
some of the factors that mediate β-catenin stability (e.g. Axin and APC) and β-
catenin mediated transcription (e.g. LEF-1 and TCF-4) also appear to regulate β-
catenin localization to the cytoplasm or nucleus. 
  
A
B
 
C
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Table 1.10. β-catenin nuclear localization factors. 
Name of 
factor(s) 
Mode of action Relevance to 
cancer 
Reference 
Nucleoporins β-catenin binds directly to 
nucleoporins via its 
central armadillo repeats 
(R10-12 and R3-8) and 
enters the nucleus. 
β-catenin is aberrantly 
expressed and 
localized in different 
cancers e.g. 
leukaemia, colon 
cancer, breast cancer 
and ovarian cancer. 
(Fagotto et al, 
1998; Funayama et 
al, 1995; Kau et al, 
2004; Mikesch et 
al, 2007; Wiechens 
& Fagotto, 2001; 
Wiechens et al, 
2004; Yokoya et al, 
1999) 
Emerin  Binds directly to β-
catenin. Limits β-catenin 
nuclear entry. 
Unknown  (Markiewicz et al, 
2006) 
FoxM1 Can directly bind to β-
catenin and shuttle it into 
the nucleus.  
FoxM1 
overexpression is 
observed in solid 
tumours including 
gliomas and gastric 
cancer. FoxM1 
mediated β-catenin 
nuclear translocation 
has been observed in 
glioma cells. 
(Pilarsky et al, 
2004; Zhang et al, 
2011) 
IRS-1 IRS-1 can shuttle β-catenin 
into the nucleus. 
Overexpression of 
IRS-1 has been 
observed in solid 
tumours and been 
correlated to β-
catenin signalling in 
ovarian cancer. 
(Chen et al, 2005) 
MUC-1 Binds to β-catenin and 
promotes nuclear 
translocation. 
MUC-1 has been 
implicated in cancer 
and MUC-1 CT 
expression 
correlates with β-
catenin expression 
in colorectal and 
gastric cancers. 
(Baldus et al, 2004; 
Kufe, 2009; Li et al, 
2011; 
Udhayakumar et al, 
2007)  
BCL-9 Can promote β-catenin 
nuclear localization and 
retention. 
BCL-9 has been 
implicated in the 
pathogenesis of 
solid tumours and 
haematological 
malignancies. 
(Townsley et al, 
2004) 
Androgen 
receptor 
Promotes β-catenin nuclear 
translocation. 
Increased androgen 
receptor signalling is 
a linked to human 
(Mulholland et al, 
2002) 
Chapter 1: Introduction 
 
Page | 39  
 
Name of 
factor(s) 
Mode of action Relevance to 
cancer 
Reference 
cancer e.g. breast 
cancer. 
γ-catenin Promotes β-catenin 
stabilization and nuclear 
translocation. 
γ-catenin and β-
catenin are frequently 
dysregulated in 
cancer. γ-catenin has 
been shown to 
promote β-catenin 
nuclear localization in 
AML. 
(Morgan et al, 
2013) 
LEF-1 LEF-1 can bind to β-
catenin and promotes 
nuclear β-catenin 
localization and retention. 
LEF-1 is 
dysregulated in 
colon cancer and 
leukaemia.  
(Behrens et al, 
1996; Fu et al, 
2014; Huber et al, 
1996; Jamieson et 
al, 2011; 
Petropoulos et al, 
2008; Prieve & 
Waterman, 1999; 
Tandon et al, 2011) 
TCF XTCF-3 (Xenopus TCF-1 
homologue) binds 
directly to β-catenin and 
promotes its nuclear 
translocation. 
TCF-4 overexpression 
shifts β-catenin 
localization to the 
nucleus. In addition, 
TCF-4 may act by 
retaining β-catenin in the 
nucleus. 
TCF-4 can regulate 
nuclear retention of 
β-catenin in 
leukaemia patients 
and may contribute 
to oncogenesis in 
colorectal cancer. 
 (Korinek et al, 
1997; Krieghoff et 
al, 2006; Molenaar 
et al, 1996; Morin 
et al, 1997) 
 
Axin Axin can shuttle β-catenin 
out of the nucleus. 
Mutations in Axin 
have been identified 
in colorectal cancer. 
(Cong & Varmus, 
2004; Krieghoff et al, 
2006; Wiechens et 
al, 2004) 
 
α-Catenin α-Catenin can export β-
catenin from the nucleus 
and can retain β-catenin 
at the cell membrane. 
A reduction in α-
catenin expression 
has been implicated 
in solid tumour 
progression and 
metastasis. This 
may also be the 
case in myeloid 
leukaemia. 
(Giannini et al, 
2004; Harris & 
Peifer, 2005; 
Nelson & Nusse, 
2004) 
Ran BP-3 Shuttles active β-catenin 
from the nucleus to the 
cytoplasm in an APC and 
Unknown  (Hendriksen et al, 
2005) 
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Name of 
factor(s) 
Mode of action Relevance to 
cancer 
Reference 
CRM1 independent 
manner. 
Pin1 Mediates nuclear β-
catenin nuclear 
localization following 
Wnt3a induction. 
Pin1 mediates 
numerous cancer 
driving signalling 
pathways. 
(Shin et al, 2016; 
Zhou & Lu, 2016) 
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The overall aim of this study is to identify factors that regulate β-catenin nuclear 
localization in AML. To do so, a mass spectrometric (MS) approach (2.6) will be 
used to identify candidate β-catenin interaction partners that regulate nuclear 
localization of β-catenin in AML cell lines, by comparing β-catenin interaction 
partners in the cytoplasm and nucleus of cell lines that i) freely translocate β-
catenin to the nucleus (translocator cell lines) and ii) resist the nuclear localization 
of β-catenin (non-translocator cell lines) (Figure 1.7). The reason for using this 
approach, rather than focusing on previously identified β-catenin nuclear 
localization factors (Table 1.10) was to ensure that important factors regulating 
the nuclear localization of β-catenin in AML were not overlooked. Analysing all 
the known β-catenin nuclear localization factors would be time and labour 
intensive and would not necessarily lead to the identification of β-catenin nuclear 
localization factors in AML. This is because proteins are expressed and regulated 
differently depending on their context, so proteins that regulate β-catenin nuclear 
localization in other contexts will not necessarily regulate this process in AML. An 
MS approach allows many candidate proteins to be identified, increasing the 
likelihood that key nuclear localization factors in AML will be discovered. Using 
an MS approach, the identification of candidate nuclear localization factors in 
AML will be achieved through the subsequent aims: 
1) Optimisation of the nuclear/cytoplasmic fractionation of leukaemia lines and 
co-immunoprecipitation of β-catenin and its binding partners. 
Before MS analysis of β-catenin interaction partners in the cytoplasm and nucleus 
of AML cell lines can be made, the cell lines need to be fractionated and a co-
immunoprecipitation approach needs to be optimized to capture β-catenin 
interaction complexes. 
2) MS analysis of co-immunoprecipitated lysates to identify candidate β-catenin 
nuclear localization factors. 
Identification of interaction partners from β-catenin co-immunoprecipitations will 
be done using MS. Comparison of nuclear and cytoplasmic interaction partners 
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will be conducted to identify candidate β-catenin nuclear localization factors. 
Western blotting will then be used to validate the MS findings. 
3) Functional analysis of putative factors regulating β-catenin localization.  
Knockdown and overexpression studies will be used to confirm the role of 
candidate factors in mediating β-catenin nuclear localization and to establish the 
functional consequences of modulating their expression in AML cell lines in terms 
of:  β-catenin-mediated transcription, cell proliferation, cell migration and cell 
survival.  
Chapter 2: Materials and Methods 
 
Page | 43  
 
2 Materials and Methods 
 
 
Cell culture was conducted in a Microflow Class II biological safety cabinet 
(Bioquell, Andover, UK), and prior to cell culture work all surfaces were sterilised 
with 70% ethanol. Cells were incubated at 37°C in 5% CO2/air in a Hera Cell 
humidified incubator (DJB Labcare).  
Roswell Park Memorial Institute - 1640 (RPMI-1640), Dulbecco’s Modified Eagles 
Medium (DMEM) and Iscove’s Modified Dulbecco’s Medium (IMDM) were 
purchased from Sigma-Aldrich and supplemented with L-Glutamine (Thermo 
Fisher), FBS (Biowest, Nuaillé, France) and gentamycin (University Hospital of 
Wales Pharmacy) (Table 2.1). All plasticware was purchased pre-sterilised.  
Contaminated waste was soaked in Haz-Tabs (Guest Medical, Kent, UK) at 2500 
parts per million (ppm) overnight prior to disposal, and if appropriate, discarded 
into autoclave bins. If retrovirus or lentivirus was used in the cell culture work, the 
strength of the Haz-Tab solution was doubled. 
The cell lines used in this project are summarized in Table 2.1.  All cultures were 
maintained at a cell density between 1x105 and 8x105/mL, by passage every 48-
72 hours.  
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Table 2.1. Cell lines used in this project 
Cell line Derivation AML subgroup/ 
associations 
Culture 
conditions 
Source 
K562 Erythroleukemia 
cell type derived 
from a 53 year 
old female CML 
patient6. 
FAB M1 
BCR/ABL1 - 
t(9;22)(q34;q11) 
(Andersson et al, 2005) 
c-KIT+ (Hu et al, 1994) 
TP53 mutation7 
HOXA9  mutation7 
ASXL1 mutation7 
KDM3B mutation7 
RPMI-1640, 
10% FBS, 
2mM L-
Glutamine, 
20μg/mL 
Gentamicin 
European 
Collection of 
Cell Cultures 
(ECACC) 
HEL Erythroleukemia 
cell type derived 
from a 30 year 
old male 
erythroleukemia 
patient6. 
FAB M6  
JAK2 mutation 
c-KIT+ (Heo et al, 2017) 
TP53 mutation7 
RPMI-1640, 
10% FBS, 
2mM L-
Glutamine, 
20μg/mL 
Gentamicin 
European 
Collection of 
Cell Cultures 
(ECACC) 
THP-1 Monocytic cell 
type derived 
from a 1 year 
old male AML 
patient6. 
FAB M5  
MLL translocation: 
t(9;11)(p22;q23)(Andersson 
et al, 2005) 
N-RAS mutation7 
TP53 mutation (Sugimoto 
et al, 1992) 
RPMI-1640, 
10% FBS, 
2mM L-
Glutamine, 
20μg/mL 
Gentamicin 
European 
Collection of 
Cell Cultures 
(ECACC) 
U937 Monocytic cell 
type derived 
from a 37 year 
old male 
histiocytic 
FAB M5  
MLL translocation : 
t(10;11)(p12;q14) 
(Andersson et al, 2005) 
RPMI-1640, 
10% FBS, 
2mM L-
Glutamine, 
American Type 
Culture 
Collection 
(ATCC)  
                                            
6 https://www.lgcstandards-atcc.org (accessed on 26/03/2018) 
7 https://cancer.sanger.ac.uk/cosmic (accessed on 13/05/2018) 
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Cell line Derivation AML subgroup/ 
associations 
Culture 
conditions 
Source 
lymphoma 
patient6. 
TP53 mutation (Sugimoto 
et al, 1992) 
20μg/mL 
Gentamicin 
 
NOMO-1 Derived from a 
31 year old 
female AML 
patient8. 
FAB M5a  
MLL translocation: 
t(9;11)(p22;q23)8 
K-RAS mutation (Weisberg 
et al, 2014) 
ASXL1 mutation (Abdel-
Wahab et al, 2012) 
RPMI-1640, 
10% FBS, 
2mM L-
Glutamine, 
20μg/mL 
Gentamicin 
DSMZ 
(Braunschweig, 
Germany) 
HEK293T Embryonic 
kidney cells 
(derived from a 
fetus)6. 
 DMEM, 
10% FBS, 
2mM L-
Glutamine, 
20μg/mL 
Gentamicin 
European 
Collection of 
Cell Cultures 
(ECACC) 
LS174T Colon cancer 
cell line derived 
from a 58 year 
old female 
colorectal 
adenocarcinoma 
patient6. 
 DMEM, 
10% FBS, 
2mM L-
Glutamine, 
20μg/mL 
Gentamicin 
These were a 
kind gift from 
Dr. Kenneth 
Ewan (Cardiff 
University, 
UK). 
Phoenix Embryonic 
kidney cell 
type6. 
 DMEM, 
10% FBS, 
2mM L-
Glutamine, 
20μg/mL 
Gentamicin 
These were a 
kind gift from 
Prof. Garry 
Nolan 
(Stanford 
University, 
California, 
USA).  
                                            
8 https://www.dsmz.de (accessed on 26/03/2018) 
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For cryopreservation, 1x106-1x108 cells were centrifuged at 280 x g for 5 minutes, 
resuspended in the recommended growth medium (Table 2.1) and added drop-
wise to freezing medium (v/v 50% IMDM, 30% FBS, 20%, dimethylsulphoxide 
(DMSO)) of equal volume. Cells were transferred to 1.8mL cryopreservation vials, 
placed into a Mr. Frosty cryopreservation chamber (Thermo Fisher) with 100% 
isopropanol, and stored at -80°C overnight. The tubes were then transferred to 
liquid nitrogen for long-term storage.  
When recovering cryopreserved cells, vials were removed from liquid nitrogen 
storage and thawed rapidly in a 37°C water bath. Freezing medium was diluted 
slowly (drop-wise) by adding 5mL of growth medium, to all cells to adapt to the 
changing osmolarity of the solution. The cells were centrifuged at 280 x g for 10 
minutes, resuspended in 5mL of the recommended growth medium (Table 2.1), 
seeded in F25 culture flasks and incubated overnight for recovery. 
 
Cells were counted using a haemocytometer (Hawksley, Brighton, UK) and an 
Eclipse TS100 light transmission microscope (Nikon, Surrey, UK).  8μL cell 
aliquots were aseptically removed from culture and pipetted under the 
haematocytometer cover slip. Cell density per mL was calculated by counting the 
cells in each of the four counting square sections, calculating an average and 
multiplying by 1x104. 
 
To isolate mononuclear cells, heparinised human cord blood (obtained with 
ethical permission from University Hospital of Wales) was diluted 1:1 in Hanks 
balanced salt solution (HBSS) containing 100μg/mL gentamicin, 25mM 4-
(2hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES) and 1U/mL heparin. 
This mixture was carefully layered on top of Ficoll ®-Paque (GE Healthcare, 
Hemel Hempstead, UK) in a 50mL falcon tube. This was done at a ratio of 8:5 
(blood:Ficoll). The tube was then centrifuged for 40 min at 400 x g with the brake 
disengaged and slow acceleration. Whilst the cells were being centrifuged, 15 mL 
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of wash medium (RPMI-1640, 10% FBS, 1U/mL heparin and 20μg/mL 
Gentamicin) was added to a UC. After centrifugation, the mononuclear cells 
formed a visible layer between the Ficoll and plasma and were aspirated into the 
UC containing wash medium. The UC was centrifuged for 10 min at 200 x g and 
the cells were washed again as described above, until there was no longer any 
visible platelet contamination in the supernatant. The mononuclear cells were 
counted as described in 2.1.3 and resuspended in RPMI-1640 +10% FBS. The 
cells were cryopreserved (2.1.2). 
CD34+ cells were purified from these mononuclear cells using a magnetic-
activated cell separation (miniMACS™) kit (Miltenyi Biotec, UK). Mononuclear 
cells were recovered from liquid nitrogen storage (2.1.2) and 1x108 cells were 
resuspended in 150μL magnetic-antibody cell sorting (MACS) buffer (v/v 1 x 
phosphate-buffered saline (PBS), 0.5% BSA, 5mM MgCl2). The cells were 
centrifuged for 15 min at 4° C with 50μL hapten-conjugated monoclonal CD34 
antibody (clone QBEND/10) in the presence of FcR blocking agent. To stop the 
reaction, 5 mL of MACS buffer was added and the cells were centrifuged for 5 
min at 200 x g. The cell pellet was washed and resuspended in MACS buffer 
before incubation at 4° C for 15 min in the presence of 50μL anti-hapten 
microbeads. The cells were washed again, resuspended in MACS buffer and 
applied to a magnetised column. The column was removed from the magnet and 
1 mL MACS buffer was used to elute the magnetically labelled CD34+ cells. To 
maximise purity, this fraction was passed through a second column.  
To assess the purity of the eluted CD34+ cells, 1x104 cells were resuspended in 
staining buffer (1 x PBS, 0.5% BSA, 0.02% Sodium Azide) and 2.5μg/mL R-PE-
conjugated anti-human monoclonal CD34 antibody (Clone 8G12, BD) was 
added. The cells were incubated at 4° C for 30 min and analysed by flow 
cytometry (2.4).   
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To stabilize β-catenin, (2'Z,3'E)-6-Bromoindirubin-3'-oxime (BIO) (Tocris 
Bioscience) and Wnt3a (R&D systems) were used. BIO stabilizes β-catenin by 
competing with ATP binding to the catenin destruction complex component 
GSK3β. This inhibits the kinase activity of GSK3β and subsequent 
phosphorylation of β-catenin and β-catenin degradation. To induce cells, 2.5µM 
BIO or 1µg/mL Wnt3a was added to 2x105/mL cells in 500µl, and the cells were 
incubated overnight.  
 
 
Reaction buffers, enzymes, DNA ladders, dNTP mix and BSA used for subcloning 
were purchased from New England Biolabs (Hitchin, UK) and molecular grade 
water was purchased from Sigma-Aldrich. Digestions and ligation conditions 
used in this study are outlined in Table 2.2.  
 
Table 2.2. List of enzymes used in this study and their reaction conditions 
Enzyme Buffer Incubation 
Kpn1 NEB1 buffer + BSA 37°C for 1 hour 
Xba1 NEB2 buffer + BSA 37°C for 1 hour 
Hpa1 NEB2 buffer + BSA 37°C for 1 hour 
BamH1 NEB4 buffer + BSA 37°C for 1 hour 
Klenow NEB1 buffer + dNTP mix   25°C for 15 min 
T4 ligase Ligase buffer 16°C for at least 4 hours 
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Restriction digested DNA was electrophoresed on a 1% SeaKem GTG agarose 
gel, prepared in Tris-Acetate-EDTA (TAE) buffer. The DNA was diluted in loading 
buffer (v/v 30% Glycerol, 0.25%, 0.25% Xylene Cyanol, Bromophenol Blue) and 
compared to a 1 kilobase (kb) New England Biolabs DNA ladder. The gel was 
submerged in TAE buffer and electrophoresed at 40V for 1-2 hours. The gel was 
then stained in PeqGREEN (VWR, UK) diluted 1:10 in TAE buffer for 15 mins, 
followed by destaining for 15 mins in water. To visualise and isolate DNA 
fragments for purification, the gel was placed on saran wrap and a long UV 
wavelength box was used on high power. A clean scalpel was used to excise the 
required DNA fragment(s) in low melting point agarose.   
A QIAquick™ Gel Extraction kit (Qiagen, Sussex, UK) was used for purification 
of DNA, according to the manufacturer’s instructions. 
 
To make growth agar and broth for competent E.coli culture, Luria Bertani (LB) 
agar or LB broth (Sigma-Aldrich) was dissolved in 1L of sterile water and 
autoclaved to ensure sterility (using standard laboratory practice). Before use, 
agar was melted in a microwave, cooled to approximately 45-50oC and ampicillin 
(University Hospital of Wales Pharmacy) was added to the concentration of 
100μg/mL. 30 mL of agar was poured into each 90 mm Petri dish plate and the 
plates were cooled before being stored at 4°C overnight.  
To amplify vector DNA, competent E.coli cells were transformed. Retroviral 
plasmids contain components required for plasmid replication by bacterial cells, 
including a component for ampicillin resistance. This allows ampicillin to be used 
to select for colonies containing the retroviral plasmid, and vector of interest.  
Vectors for amplification and One Shot® TOP10 or Stbl3 Chemically Competent 
E.coli (Invitrogen) were thawed on ice. For each vector, 20ng of DNA was 
aseptically transferred into a vial of competent cells. The vials were gently mixed 
by tapping and incubated on ice for 30 min. The cells were then placed in a 42˚C 
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water bath for 30-45 seconds and placed on ice for 2 min. 250μL of pre-warmed 
S.O.C medium (Invitrogen) was added to each vial and the vials were shaken at 
37oC for 1 hour at 225 revolutions per minute (rpm) in a shaking incubator. 
Bacteria from each vial was spread on a separate pre-warmed selective LB-agar 
plate and incubated overnight at 37° C. Colonies were selected for test digests, 
grown in LB broth overnight at 37° C in a shaking incubator and plasmid DNA 
was purified using QIAprep® Mini and Maxi-prep kits (Qiagen, Sussex, UK) and 
the manufacturer’s protocol.  
DNA quantification was performed using a NanoDrop® ND-1000 
spectrophotometer (NanoDrop Technologies, Delaware, USA) and stored at -20° 
C. DNA purity was assessed using the 260/280 absorbance ratio, with a value of 
greater than or equal to 1.8 indicating a ‘pure’ sample. The 260/230 absorbance 
ratio was measured as a secondary assessment of DNA purity, with a value of 
~2 or above indicating a ‘pure’ sample.  
If required, samples were sent for sequencing using Eurofins Genomic’s 
SmartSeq kit sequencing service. 50-100ng/µL of DNA was diluted in 15µL of 
DNA elution buffer (supplied with Qiagen’s QIAprep® Mini and Maxi-prep, or Gel 
Extraction kits). The relevant primer was added at a concentration of 10pmol/µL 
(10 µM). The premixed samples were sent for sequencing to Eurofins Genomics, 
Germany. 
 
 
Retroviruses are RNA viruses that belong to the Retroviridae viral family. They 
are duplicated in host cells and use the enzyme, reverse transcriptase, to produce 
DNA. The DNA incorporates into the host’s genome using an integrase enzyme 
and then replicates with the host’s DNA. Lentiviruses are the only retroviral family 
member that can integrate in non-dividing cells, making them one of the most 
efficient gene delivery systems. The constructs used in the project are outlined in 
Table 2.3 and Figure 2.1. Each of the viruses used in this study are replication 
defective. 
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Table 2.3. Vectors/constructs used to transduce cell lines 
Vector Description Source 
pcDNA3-β-catenin-FLAG Nonviral vector. Contains a 
neomycin selectable marker. 
Addgene 
pHIV-EGFP/pHIV-EGFP-β-catenin-
FLAG 
Lentiviral vector. Contains an 
EGFP selectable marker 
(expressed from an IRES in 
the same message as the 
insert). 
pHIV-EGFP was 
purchased from 
Addgene 
pHIV-EGFP-β-
catenin-FLAG was 
created using 
subcloning as 
outlined in 3.3.1.1. 
polyPOZ/ β-catenin-polyPOZ Retroviral vector. Contains a 
LacZ selectable marker. 
These were a kind 
gift from Prof. Trevor 
Dale (Cardiff 
University, UK). 
pcDNA3-PKC-FLAG Nonviral vector. Contains a 
neomycin selectable marker. 
Addgene 
pLV-EGFP:T2A:Puro-EF1A>hLEF1 Lentiviral LEF-1 
overexpression vector. 
Contains puromycin and 
EGFP selectable markers. 
VectorBuilder 
(Cyagen) 
PLKO.1-puro shRNA control Lentiviral knockdown control 
vector. Contains a puromycin 
selectable marker. 
Sigma 
LEF-1 shRNATRCN0000020163 
PLKO.1-puro 
Lentiviral LEF-1 knockdown 
vector. Contains a puromycin 
selectable marker. 
Sigma 
LEF-1 shRNATRCN0000413476 
PLKO.1-puro 
Lentiviral LEF-1 knockdown 
vector. Contains a puromycin 
selectable marker. 
Sigma 
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Vector Description Source 
LEF-1 shRNATRCN0000418104 
PLKO.1-puro 
Lentiviral LEF-1 knockdown 
vector. Contains a puromycin 
selectable marker. 
Sigma 
LEF-1 shRNATRCN0000428178 
PLKO.1-puro 
Lentiviral LEF-1 knockdown 
vector. Contains a puromycin 
selectable marker. 
Sigma 
LEF-1 shRNATRCN0000428355 
PLKO.1-puro 
Lentiviral LEF-1 knockdown 
vector. Contains a puromycin 
selectable marker. 
Sigma 
pBARVUbR Lentiviral TCF/LEF mediated 
transcription reporter 
construct. Contains a Venus 
(variant of EYFP) reporter 
and a DsRed selectable 
marker (Figure 2.1). 
This was a kind gift 
from Prof. Randall 
Moon (University of 
Washington, Seattle, 
WA, USA) 
 
 
 
 
 
Figure 2.1. Structure and components of the pBARV construct. 
The construct contains a concatemer of 12 TCF response elements that have been separated 
by unique linkers that minimize recombination which would lead to loss of TCF binding sites. 
The functional promoter driving transcription of Venus (variant of EYFP) is Prol11cga’s minP 
minimal promoter. The Ubi (Ubiquitin) promoter drives DsRed as a selectable marker and the 
reporters are inserted between the long terminal repeats (LTRs) of a lentivirus transducing 
plasmid. 
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In this study, Phoenix amphotropic or HEK293T packaging cell lines (designed to 
yield high titre retrovirus or lentivirus respectively) were seeded at 7.0  106 in an 
F75 tissue culture flask in 10mL appropriate medium (Table 2.1). The next day, 
the medium was replaced with 15mL of fresh medium and transfection of plasmid 
DNA was performed. To do this, 20μg of the relevant plasmid DNA was added to 
125mM Calcium Chloride (CaCl2) and made up to 450μL in sterile water. This 
was then added to 450μL HEPES-buffered saline dropwise using gentle 
‘bubbling’. The mixture was vortexed briefly and incubated at room temperature 
for 20 min to allow a precipitate of calcium-phosphate-DNA complexes to 
develop. 5 minutes before the end of the incubation, 25μM chloroquine was 
added to the cultures to be transformed to promote the uptake of DNA. At the end 
of the 20min incubation, the 900μL of precipitated DNA was pipetted onto the 
cells, and the flask was gassed with 5% CO2 and incubated at 37˚C overnight. 
The next morning, the medium was replaced with 8mL of fresh medium and the 
flask was gassed with 5% CO2 and incubated again at 37˚C overnight. The next 
day harvesting of the virus was conducted, by centrifuging the medium at 200 x 
g for 10 minutes. The supernatant containing the retrovirus was then aliquoted 
into 1mL cryovials, snap frozen in liquid nitrogen and stored at -80˚C.   
 
Cell lines were transduced using a Retronectin based spin infection protocol. 
Retronectin is a recombinant human fibronectin peptide fragment that binds cell 
surface proteins and viruses. It significantly enhances retroviral/lentiviral 
transduction of mammalian cells when coated on the surface of cell culture plates 
(Tonks et al, 2005). Cells were transduced in a sterile untreated 24 multi-well 
plate using a spin infection procedure. Wells were coated with 250μL of 
Retronectin (Takara Bio, Europe) and incubated for 2 hours at room temperature, 
or overnight at 4°C. The Retronectin was then replaced with 200μL of PBS (+1% 
BSA) and incubated for 30 min at room temperature. A few minutes before the 
end of the incubation, the relevant viruses were rapidly thawed at 37˚C and 
placed in the culture cabinet.  After blocking with 1% BSA was complete, it was 
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aspirated from each well and immediately replaced with 1mL of retrovirus. The 
plate was then centrifuged at 4°C for 120 min at 930 x g.   
During the centrifugation, cells were prepared at a density of 1x105/mL in the 
relevant culture medium (Table 2.1). Once the centrifugation was complete, the 
supernatant in the wells was replaced with 1mL of cells and the plate was 
incubated at 37˚C overnight. The next day, a second spin infection was carried 
out. Cells that had been transduced with vectors containing puromycin resistance 
markers were selected for. To do this, 2 x 105 cells in fresh medium were placed 
in a new 24-well plate incubated with 1 µg/mL puromycin at 37° C overnight in 
5% CO2. Selection was continued in the presence of puromycin until all control 
uninfected cells were killed.  
 
 
Flow cytometry is a technique that can be used to measure the light scattering 
properties and fluorescence emission of single cells in a heterogenous mixture. 
During flow cytometry, single cell suspension samples are taken into the 
instrument and surrounded by sheath fluid which acts as a buffer. Hydrodynamic 
focusing organises the cell suspension into a stream of single cells that travel to 
an interrogation point. Here a laser light beam illuminates the cell, and some of 
the light scatters and is measured by the flow cytometer as forward (FSC) or side 
(SSC) scatter. This can be used to determine the relative cell size and give an 
indication of its cellular structure, respectively. The laser also excites fluorophores 
in the cell, which produce a fluorescence emission. These emissions pass 
through a set of filters and dichromic mirrors that isolate light of specific 
wavelengths. This light is then converted into a digital signal that is displayed on 
the flow cytometer’s computer software9. When using a flow cytometer to 
measure the presence of fluorophores, a knowledge of its excitation/emission 
peaks is necessary so that the correct laser is used for excitation and the correct 
                                            
9 http://www.thermofisher.com/uk/en/home/life-science/cell-analysis/cell-analysis-learning-
center/molecular-probes-school-of-fluorescence/flow-cytometry-basics/flow-cytometry-
fundamentals/how-flow-cytometer-works.html (accessed on 04/01/2018) 
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filters are used to collect the emitted light.  If more than one fluorophore is used 
a knowledge of their excitation and emission points also allows for correct 
“compensation”. Table 2.4 outlines the filter settings that were used for the 
fluorophores in this study, and unless otherwise stated, an Accuri C6 benchtop 
Flow Cytometer™ (Accuri Cytometers, Ann Arbor, MI, USA) was used for 
analysis. 15,000 events were measured per sample, and backflushing was 
performed between each acquisition to reduce cell transfer between samples. 
Flow cytometric data analysis was conducted using FCS Express 6 (De Novo 
Software, California, USA). Forward and side scatter characteristics were used 
to exclude debris from the analysis and 7-AAD was added to the samples to allow 
gating out of dead cells (Table 2.4).  
 
Table 2.4. Fluorophores used in flow cytometric analysis  
Fluorophore Excitation/emission 
wavelength (nm) 
Filter set (Accuri C6) 
7-AAD 546/647 FL2 
To-PRO3 624/661 FL3 
Venus  515/528 FL1 
Fluorescein 490/525 FL1 
EGFP/GFP 489/509 FL1 
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Fluorodeoxyglucose (FDG) can be used for cell sorting. In the presence of β-
galactosidase (the LacZ gene product) it is converted into fluorescein (Plovins et 
al, 1994) which can be measured by flow cytometry (Table 2.4). For FDG sorting, 
cells were counted (2.1.3) and 500K cells were diluted in 250μL of PBS+1% BSA 
in 5mL BD FACS tubes. Hypotonic shock was conducted by warming the tubes 
for 2 min in a 37° C water bath. 250μL of prewarmed FDG was added to the cells 
and mixed by pipetting up and down twice. The tubes were returned to the water 
bath and incubated for 60s. 2500μL of ice cold stop solution (PBS+1% BSA + 
1μg/mL 7-AAD) was added, and the tubes were mixed and immediately placed 
on ice. The tubes were incubated on ice for 2 hours. The cells were transferred 
to a UC and centrifuged at 280 x g for 5 min. The cells were resuspended in 
500μL of stop solution and passed through a 70µM cell strainer (Miltenyi Biotec) 
into clean 5mL FACS tubes.  These samples were sent for fluorescence activated 
cell sorting (FACS) at the Flow Cytometry Facility, Cardiff University. A small 
sample of the cells were analysed on the Accuri flow cytometer prior to FACS to 
determine the percentage of cells emitting fluorescein. Dead cells were removed 
by gating out cells with a high uptake of 7-AAD. This was repeated after the sort 
to determine how successful the sorting process had been. 
 
To measure proliferation and survival of cells a proliferation/viability assay was 
conducted. Cells in log phase growth (4-8 x105 cells/mL) were pelleted in a 
universal container (UC) and washed in 10 mL of serum free medium. The 
medium was discarded, and the pellet was again washed in 10mL of fresh serum 
free medium. 90μL of cells were distributed into each required well of a 96 well 
dish using a multichannel pipette. 10μL serum dilutions were added to the cells 
(to yield 0%, 1%, 3% and 10% v/v serum), the lid was put on the plate and it was 
vortexed to mix. The plate was boxed up and incubated overnight (2.1.1). Three 
replicate plates were set up for analysis over the next three days. The residual 
cells (in the UC) were recounted using the flow cytometer to give starting 
densities for the assay: cell suspension (99μL) was added to a 1mL tube 
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containing 1μL of 100μg/mL 7-AAD, viable cell density was calculated from a 
calibrated uptake of 10μL  of cell suspension. 
The next day 1μL of 100μg/mL 7-AAD was added to a 1mL tube for each sample. 
The cells were mixed using a multichannel pipette and 99μL of cells were 
transferred to each minitube. The Accuri flow cytometer was used to count the 
cells (as above) and the % viability was calculated for each sample. This was 
repeated for the plate replicates over the next two days.  
 
To measure the migration of cells, 24-well chemotaxis chambers (pore size 
5.0uM) (Corning Costar) were used. The inserts were placed into the wells and 
rinsed with PBS to remove any debris. 600μL of chemotaxis medium (IMDM + 
1% BSA) was added to wells in a receiver plate. 100μL of chemotaxis medium 
was added to the inserts which were placed in medium containing-wells. These 
were incubated (2.1.1) whilst the cells were prepared. Cells were counted (2.1.3) 
and 100K cells were aspirated into a UC which was topped up with 10mL of 
prewarmed chemotaxis medium. The cells were centrifuged for 10min at 350 x g 
and the supernatant was aspirated and discarded. The cells were resuspended 
in 590μL prewarmed chemotaxis medium, giving a density of 1.7 x105 cells/mL. 
The inserts were transferred to empty wells and their contents were aspirated 
and replaced with 100μL of cells. 5μL SDF-1 (PBS+1% BSA) was added to the 
wells giving final concentrations of 100ng/mL, 30ng/mL, 10ng/mL and 3ng/mL. 
The inserts were returned to the wells and incubated (2.1.1) for four hours. After 
the incubation, the inserts were lifted from the wells and the contents of the inserts 
were transferred to 1mL tubes. The inserts were rinsed with 100μL of chemotaxis 
medium which was combined in the 1mL tubes. This process was repeated for 
each well and 1μg/mL 7-AAD was added to each tube. Cells were counted using 
the Accuri flow cytometer (2.4.1), which was set to acquire 50μL of each sample. 
The number of events in this volume was measured for each sample.  
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Statistical analyses of the proliferation and migration assay results were 
conducted using a two sample T test and evaluating p values. Values of p <0.01 
and <0.05 were considered significant differences.  
 
 
For cytoplasmic/nuclear fractionation prior to western blotting, a modified version 
of the protocol provided with the BioVision fractionation (Biovision, California, 
USA) kit was used. Cells (2x106) were pelleted and washed twice with 20mL Tris-
buffered saline (TBS), followed by centrifugation for 10 min at 280 x g. Next, cells 
were resuspended in 200μL cytosol extraction buffer A (CEB-A) containing 1x 
protease inhibitor cocktail (PIC)(Sigma) and 1mM dithiothreitol (DTT), vortexed 
for 15 seconds and incubated on ice for 10 min. Eleven μL of cytosol extraction 
buffer B (CEB-B) was then added to the cells followed by a quick vortex and 
incubation on ice for 1 min. Cells were vortexed quickly before being centrifuged 
at 3,000 x g for 8 minutes in a 4˚C microcentrifuge. The supernatant (cytoplasmic 
extract) was removed to a clean mini Eppendorf tube and stored at -80°C. The 
pellet was washed with 500μL of pellet wash buffer (1 x PBS + 5mM MgCl2) and 
centrifuged at 3000 x g for 3 minutes. The supernatant was removed, and the 
nuclear pellet was snap frozen in liquid nitrogen.  The pellets were then freeze 
thawed three times, and 1μL of Benzonase (Sigma) was added directly to the 
pellet. The tube was tapped to mix and incubated on ice for 30-60 min. During 
this incubation, the tube was tapped regularly. Fifty μL of TEAB buffer (0.5M 
TEAB, 0.05% SDS, PIC) was added and the tube was incubated on ice for 30 
min, with vortexing every 10 minutes. The tubes were centrifuged at 10,000 x g 
for 10 min and the supernatant (nuclear extract) was transferred to a clean tube 
and stored at -80° C.  
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The protein concentration of cytoplasmic/nuclear fractions was calculated using 
the Bradford’s protein assay (Bradford, 1976). Protein standards (0, 10, 40, 70 
and 100 g/mL BSA) were diluted in fractionation buffer. Ten μL of protein 
standards were loaded onto wells of a 96-well plate, using 2 duplicates of each. 
Next, 10μL of each cell fraction was loaded into wells in duplicate. 190μL of 
Bradford’s reagent was added to the samples and incubated for 10 min. 
Absorbances for each sample were read at 590nm using an ASYS Hitech Expert 
plus spectrophotometer (Biochrom, Cambridge, UK). Protein concentrations 
were calculated by interpolation from the standard curve. 
 
Lithium-dodecyl sulphate polyacrylamide gel electrophoresis (LDS-PAGE) 
separates proteins in a gel matrix with an applied electric field. Addition of LDS 
to protein samples results in them having a negative charge. During 
electrophoresis the proteins travel through the gel towards the cathode, and are 
separated based on their size, with smaller proteins migrating more quickly 
through the gel matrix. Following gel electrophoresis, the proteins are transferred 
to a membrane for western blotting.  
Gel electrophoresis and western blotting was conducted using the NuPAGE® 
PreCast Gel System (Invitrogen), and unless otherwise stated all reagents were 
purchased from Invitrogen (Thermo Fisher).  
Protein lysates were thawed on ice, and equivalent amounts of total protein were 
prepared for each sample. To do this, samples were diluted in NuPAGE® 1xLDS, 
50nM NuPAGE® reducing agent and dH20, well mixed and incubated at 70˚C for 
10 minutes to denature the proteins.  The samples were then placed back on ice.  
Pre-cast NuPAGE® Novex 4-12% bis-Tris gels were washed with water and the 
wells were rinsed with running buffer (1 x NuPAGE® MOPS-sodium dodecyl 
sulphate (MOPS-SDS)) twice.  The gels were placed into an XCell SureLock™ 
Mini Cell gel electrophoresis tank and the inner chamber was filled with 200mL 
of running buffer (+ 500μL NuPAGE® anti-oxidant). The samples were loaded 
into the wells, and a MagicMark™ XP Western Protein Standard ladder was 
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included. The outer chamber was filled with running buffer, and gel 
electrophoresis was conducted at 200V for 50 minutes.  
The gel was removed from the tank and one surface of the gel was dampened 
with transfer buffer (1 X NuPAGE® Transfer Buffer, 10% MeOH, dH20, 1mL 
antioxidant). A piece of pre-soaked Whatman 3M filter paper was layered on the 
gel and the other side of the gel was moistened with transfer buffer. A pre-soaked 
nitrocellulose membrane was placed on the gel surface and another piece of pre-
soaked filter paper was layered on top. The gel and membrane were placed 
between pre-soaked blotting pads (Figure 2.2).  
 
 
Figure 2.2. Diagram of the blot module set up. 
 
This was placed into an XCell II™ Blot Module, which was filled with transfer 
buffer. The tank was filled with distilled water and the transfer was conducted at 
30V for 1 hour.   
Once the electroblotting was complete, the gel and membrane were removed 
from the blot module and the membrane was rinsed twice with ultra-pure water. 
The membrane was then washed twice for 5 min with ultra-pure water on a rotary 
shaker. The membranes were incubated in 30mL of Ponceau S solution for 30 
seconds with agitation, to check for efficient protein transfer. Two more washes 
of the membrane for 5 minutes in ultra-pure water were conducted.  
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Proteins on the membrane were visualized using the Amersham ECL™ Prime 
Western Blotting Detection Kit (GE Healthcare). The membrane was placed in 
10mL of blocking solution (2.5% marvel milk in TBST (TBS +1% Tween20)) and 
incubated at room temperature for 1h on a shaker. The membrane was washed 
in TBST once for 15 mins and three times for 5 mins on a shaker.  Primary 
antibody was prepared to the appropriate concentration (Table 2.5) in 10mL of 
blocking solution. The membrane was incubated in this primary antibody solution 
overnight at 4˚C with gentle rotation. The next day, the membrane was washed 
as outlined above and HRP-conjugated anti-rabbit or anti-mouse secondary 
antibodies (GE Healthcare) were prepared in 1% marvel milk solution.  The 
secondary antibody solution was added to the membrane and the membrane was 
incubated at room temperature for 1h with gentle shaking. The membrane was 
washed as outlined above.  
Detection was performed according to the manufacturer’s protocol. Briefly, equal 
volumes of solution A and solution B (5 mL in total per membrane) were combined 
at room temperature and protected from light. The membrane surface was blotted 
using filter paper to dry it and 4mL of the chemiluminescent substrate (combined 
solution A and B) was added. The membrane was incubated with the substrate 
for 5 min in the dark and excess substrate was blotted away. A piece of clean 
acetate was placed on top of the membrane and a digital image was captured 
using a LAS3000 digital scanner (FUJIFILM UK Ltd, Bedfordshire, UK). 
Exposures between 30 sec-30 min were included. 
Table 2.5.  Antibodies used for western blotting 
Antibody Western blotting dilution Supplier (catalogue 
number) 
β-catenin (14/Beta-
Catenin) mouse 
monoclonal IgG1 
1/1K BD Biosciences 
LEF-1 (C12A5) rabbit 
monoclonal 
1/5K Cell Signalling Technology 
(#2230) 
Chapter 2: Materials and Methods 
 
Page | 62  
 
Antibody Western blotting dilution Supplier (catalogue 
number) 
Flag (m2) mouse 
monoclonal 
1/2K Sigma (F1804) 
GAPDH (D16H11) rabbit 
monoclonal IgG 
1/10K Cell Signalling Technology 
(#5174) 
Histone H1 (AE-4) 
mouse monoclonal 
1/5K BioRad (4974-7808) 
RUNX1 rabbit polyclonal 1/1K Sigma (HPA004176) 
TCF7 (C46C7) rabbit 
monoclonal 
1/1K Cell Signalling Technology 
(#2206) 
HRP-conjugated anti-
rabbit (NA934) 
1/5K Amersham (GE Health Care) 
HRP-conjugated anti-
mouse (NXA931) 
1/5K Amersham (GE Health Care) 
 
 
The digital images were analysed using Advanced Image Data Analyzer (AIDA) 
software v4.2.0 (Raytek Scientific, UK) and a pixel-based densitometry approach, 
in which the intensity of pixels were used to quantitate the protein on the blot. A 
region of interest was generated around the band(s), which produced a peak 
intensity histogram. This was used to measure background pixel intensity 
(calculated using the area surrounding the protein band). The area under the 
curve was used to calculate an intensity value for the band(s), which allowed 
estimates of percentage overexpression or underexpression/knockdown to be 
calculated.  
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In this project a mass spectrometric (MS) approach was used to identify 
candidate nuclear localization factors (Figure 2.3). In this approach, AML cell 
lines were fractionated to isolate/enrich cytoplasmic and nuclear proteins, and β-
catenin immunoprecipitation was conducted prior to MS analysis of β-catenin 
interaction partners. β-catenin interaction partners present in the cytoplasm and 
nucleus of AML cell lines that i) freely translocate β-catenin to the nucleus and ii) 
resist the nuclear accumulation of β-catenin were compared. Based on the 
localization of β-catenin interaction partners in these cell lines, candidate factors 
regulating the nuclear localization of β-catenin were identified (Chapter 4).  
 
Figure 2.3. Diagram of the MS approach used in this project 
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CHAPS buffer (0.8% CHAPS, 150mM NaCl, 30mM Tris-HCl, 1mM DTT, PIC) 
was used to fractionate AML cell lines prior to β-catenin immunoprecipitation. To 
isolate cytoplasmic fractions, 1x107 cells were pelleted and washed twice with 
20mL TBS, followed by centrifugation for 10 min at 280 x g. Next, cells were 
resuspended in 1mL CHAPS buffer, vortexed for 15 seconds and incubated on 
ice for 20 min followed by a quick vortex and centrifugation at 3000 x g for 8 
minutes in a 4˚C microcentrifuge. The supernatant (cytoplasmic extract) was 
removed to a clean mini Eppendorf tube and stored at -80°C. To isolate nuclear 
fractions, a nuclear pellet was generated following the steps outlined in 2.5.1, but 
scaled up for 1x107 cells and the pellet was washed with 500μL of pellet wash 
buffer (1 x PBS + 5mM MgCl2) followed by centrifugation at 3000 x g for 3 
minutes. The supernatant was removed, and the nuclear pellet was snap frozen 
in liquid nitrogen.  The pellet was then freeze thawed three times, and 1μL of 
Benzonase was added directly to the pellet. The tube was tapped to mix and 
incubated on ice for 30-60 min. During this incubation, the tube was tapped 
regularly. 250μL of CHAPS buffer was added and the tube was incubated on ice 
for 30 min, with vortexing every 10 minutes. The tube was centrifuged at 10,000xg 
for 10 mins and the supernatant (nuclear extract) was transferred to a clean tube 
and stored at -80°C.  
 
Immunoprecipitations were first attempted using protein G agarose beads (Santa 
Cruz). First a preclearing step was conducted by combining 300μg of protein, 
10μL of agarose G beads and 0.5μg of mouse IgG1 antibody (Table 2.6) in 2mL 
of CHAPS buffer and incubating on ice for 30 min. The sample was centrifuged 
at 580 x g for 5 min at 4°C and the supernatant (precleared lysate) was 
transferred into two clean 1.5mL protein LoBind Eppendorf tubes (Sigma). 2μg of 
β-catenin antibody (14/Beta-Catenin) or mouse (G3A1) control antibody (Table 
2.6) was added and the tubes were incubated on ice for 1h. 20μL of agarose 
beads was added and the tubes were incubated overnight at 4°C with 
inversion/rotation. The next day the tubes were centrifuged at 580 x g for 5 min 
at 4°C and the supernatant was transferred to a new Eppendorf tube and stored 
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at -80°C. The beads (with immunoprecipitated β-catenin) were washed four times 
with 1mL CHAPS buffer and centrifuged at 580 x g for 5 min at 4°C. 40μL of LDS 
buffer (NuPAGE® 1xLDS, 50nM NuPAGE® reducing agent) was added to the 
beads, well mixed and the tubes were incubated at 70˚C for 10 minutes to elute 
the proteins from the beads. 
 
Following unsuccessful immunoprecipitation using protein agarose G beads, a 
different protocol using protein G Dynabeads was used prior to MS. All steps 
unless otherwise specified were performed on ice. Firstly, β-catenin or 
IgG1control antibodies were crosslinked to the beads. To do this, the protein G 
Dynabeads were vortexed to mix them and 165μL of beads (enough for 5 
immunoprecipitations) were placed into a 1.5mL protein LoBind Eppendorf tube, 
a magnet was applied and the supernatant (storage buffer) was removed. The 
beads were then resuspended in 165μL of PBST (v/v PBS + 0.02% Tween-20), 
40μg of antibody was added and then the mixture was made up to 1mL in PBST. 
The tube was incubated at room temperature for 2h with rotation. Following 
incubation, a magnet was applied to the tube and the supernatant was discarded. 
The antibody-bound beads were washed three times in PBST with inverting. The 
beads were then washed three times in coupling buffer (PBST + 0.2M 
triethanolamine pH 9) before incubation with 1mL freshly prepared dimethyl 
phthalate (DMP) solution (coupling buffer + 2mM DMP) for 30 min at room 
temperature with rotation. A magnet was applied, and the supernatant was 
discarded before repeating the incubation with fresh DMP solution. The DMP 
solution was discarded and the beads were incubated for 30 min at room 
temperature with 1mL of quenching buffer (PBST + 50mM ethanolamine). The 
beads were washed three times in elution buffer (0.2M glycine pH2.5, 0.01% 
Tween-20 pH.2.5 dh20) and then resuspended in 165μL of TBST and stored at 
4° C. 
Following crosslinking of antibodies to beads, immunoprecipitation of β-catenin 
and its binding partners was conducted. First a preclearing step was conducted. 
33μL of IgG1 control antibody-bound beads were placed in an Eppendorf tube 
and the supernatant was removed and replaced with 33μL of CHAPS buffer. One 
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thousand μg of protein lysate was added and made up to 500μL in CHAPS buffer. 
The tube was incubated for 6 hours in a cold room with rotation.  A magnet was 
applied and the supernatant (precleared lysate) was transferred to a clean tube. 
Thirty-three μL of antibody-bound beads was added to the lysate and the tube 
was incubated overnight in the cold room with rotation. The next day, a magnet 
was applied to the tube and the supernatant was transferred to a clean tube and 
stored at -80° C for use in western blotting analysis of immunoprecipitation 
efficiency. The beads were washed 6 times with 500μL of CHAPS buffer with 
inverting and incubation on ice for 5 min. To elute β-catenin and its binding 
partners from the beads, they were boiled in 2x LDS buffer (NuPAGE® 2xLDS, 
50nM NuPAGE® reducing agent and dH20) at 95°C for 5 min. The eluted protein 
was stored at -20° C. 
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Table 2.6. Antibodies used in immunoprecipitation 
Antibody (clone) Supplier (catalogue number) 
β-catenin (14/Beta-Catenin) mouse 
monoclonal IgG1. Binds β-catenin amino 
acids 571-781. 
BD Biosciences (610154) 
β-catenin (L87A12) mouse monoclonal 
IgG1. Binds residues surrounding Asp56 of 
β-catenin. 
Cell Signalling Technology (#2698) 
β-catenin rabbit polyclonal. 
Binds residues surrounding Asp56 of β-
catenin. 
Cell signalling technology (#9581) 
β-catenin (6B3) rabbit monoclonal IgG. 
Binds C-terminus of β-catenin. 
Cell Signalling technology (#9582) 
β-catenin (H-102) rabbit polyclonal. Binds β-
catenin amino acids 680-781. 
Santa Cruz (sc-7199) 
Mouse monoclonal IgG1 (G3A1) Cell Signalling Technology (#5415) 
Rabbit monoclonal IgG (DA1E) Cell Signalling Technology (#3900) 
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Mass spectrometers measure the mass-to-charge ratio (m/z) of ionized 
molecules, and can be used to identify proteins in a complex mixture. For protein 
identification, the proteins are cleaved into smaller peptides, their absolute mass 
is measured by a mass spectrometer and compared to a protein sequence 
database for peptide/protein identification (Henzel et al, 1993; James et al, 1993; 
Mann et al, 1993; Pappin, 2003). In this project, a tandem MS (MS/MS) approach, 
outlined in Figure 2.4 was used to identify peptides. Briefly, the AML cell line 
nuclear and cytoplasmic fractions were run on an SDS-PAGE gel, each gel lane 
was cut into slices and in-gel tryptic digestion was performed. The peptides were 
then fractionated, and ionized prior to mass spectra acquisition by tandem MS. 
These spectra were processed and quantified before database searching.  
 
 
Figure 2.4. Overview of MS procedure. 
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The samples were sent to Bristol Proteomics Facility (Bristol University, UK) for 
MS to be performed. There, the samples were run on a 10% SDS-PAGE gel until 
the dye front moved ~3 cm into the separating gel. Each lane was cut into 3 equal 
slices, followed by in-gel tryptic digestion of each slice using a DigestPro 
automated digestion unit (Intavis Ltd.)  The peptides were fractionated using an 
Ultimate 3000 nanoHPLC system in conjunction with an LTQ-Orbitrap Velos 
mass spectrometer (Thermo Scientific).  Briefly, peptides in 1% formic acid were 
injected onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific). The 
peptides were washed with 0.5% acetonitrile and 0.1% formic acid peptides were 
resolved on a 250 mm × 75 μM Acclaim PepMap C18 reverse phase analytical 
column (Thermo Scientific). This was done over a 150min organic gradient, using 
7 gradient segments of aqueous 80% acetonitrile in 0.1% formic acid (1-6%, 6-
15%,15-32%, 32-40%, 40-90%, 90% and then reduced to 1%) with a flow rate of 
300 nL min−1.  
Peptides were ionized at 2.1 kV using a stainless-steel emitter with an internal 
diameter of 30 μM (Thermo Scientific) and a capillary temperature of 250°C. 
Tandem mass spectra were measured using an LTQ- Orbitrap Velos mass 
spectrometer and Xcalibur 2.1 software (Thermo Scientific) in data-dependent 
acquisition mode.  The Orbitrap was configured to analyse survey scans at 
60,000 resolution (at m/z 400) in the mass range m/z 300 to 2000. The top twenty 
multiply charged ions in each duty cycle were selected for MS/MS in the LTQ 
linear ion trap.  Charge state filtering (where unassigned precursor ions were not 
selected for fragmentation) and dynamic exclusion (repeat count, 1; repeat 
duration, 30s; exclusion list size, 500) were used.  The LTQ fragmentation 
conditions were set to normalized collision energy, 40%; activation q, 0.25; 
activation time 10ms; and minimum ion selection intensity, 500 counts. 
The raw data files were processed/quantified using Proteome Discoverer 
software v1.4 (Thermo Scientific) and the UniProt Human database (131351 
entries) was searched using the SEQUEST algorithm.  MS/MS tolerance was set 
to 0.8Da and peptide precursor mass tolerance was set at 10ppm. MS/MS.  
searches were performed with full tryptic digestion and a maximum of 1 missed 
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cleavage was allowed.  The reverse database search option was enabled, and 
all peptide data was filtered to satisfy false discovery rate (FDR) of 1% or 5%. 
The output of this analysis was 2 Excel Spreadsheets, one for FDR 1% and one 
for FDR 5%. These contained a list of proteins that were identified by MS, which 
samples they were present in, and metadata about each of the peptides, including 
a peptide score, molecular weight and number of amino acids. The spreadsheets 
containing the raw data are included in Appendix 4 (see the attached CD disk).  
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3 Development of fractionation and 
immunoprecipitation techniques for 
analysis of leukaemia cell lines by MS 
 
β-catenin is dysregulated in AML and its overexpression is associated with a poor 
prognosis (Chen et al, 2009; Simon et al, 2005; Xu et al, 2008; Ysebaert et al, 
2006). Key to its role as a transcription factor is its localization to the nucleus, and 
nuclear unphosphorylated β-catenin is observed in ~50% of AML blasts (Xu et al, 
2008). In AML blasts and cell lines, nuclear β-catenin levels do not correlate with 
cytoplasmic β-catenin levels (Morgan et al, 2014), suggesting that cytoplasmic 
accumulation of β-catenin does not necessarily lead to its nuclear localization and 
there are additional factors regulating this process. Factors that regulate β-
catenin nuclear localization in other contexts have been identified (1.3.6), but little 
is known about the nuclear localization of β-catenin in AML. In this project, an MS 
approach was used to identify factors that regulate the nuclear localization of β-
catenin in AML (Figure 3.1). In this approach, cytoplasmic and nuclear 
fractionation of cell lines was conducted, followed by β-catenin 
immunoprecipitation and MS identification of β-catenin binding partners. 
Comparisons of binding partners in translocator and non-translocator cell lines 
were made to identify candidate β-catenin nuclear localization factors, and 
functional analysis of identified candidates was conducted. This approach was 
taken rather than focusing on previously identified β-catenin nuclear localization 
factors (Table 1.10) to ensure that important factors regulating the nuclear 
localization of β-catenin in AML were not overlooked. Analysing known β-catenin 
nuclear localization factors would be time and labour intensive and may not lead 
to the identification of β-catenin nuclear localization factors in AML. This is 
because proteins are expressed and regulated differently depending on their 
context, so proteins that regulate β-catenin nuclear localization in other contexts 
will not necessarily regulate it in AML. An MS approach allows multiple 
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candidates to be identified, increasing the likelihood of finding key β-catenin 
nuclear localization factors in AML.  This chapter outlines the optimization steps 
taken to efficiently extract β-catenin in leukaemia cell line fractions and 
immunoprecipitate β-catenin ready for MS analysis. This involved i) expression 
of epitope tagged β-catenin for use in pull down experiments (to decrease the 
likelihood of background binding which would interfere with identification of 
candidate localization factors by MS analysis) or expression of wild type β-catenin 
(to increase the amount of β-catenin available for analysis) ii) cytoplasmic/nuclear 
fractionation with CHAPS buffer (to maintain protein-protein interactions that are 
important in the identification of interaction partners by MS) and iii) 
immunoprecipitation of β-catenin and its binding partners.    
 
• To express FLAG-β-catenin in leukaemia cells lines for use in 
immunoprecipitation. 
• Develop a fractionation technique for leukaemia cell lines using a 
detergent that maintains protein-protein interactions. 
• To optimize immunoprecipitation of β-catenin. 
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Figure 3.1. Schematic of the experimental approach to identify candidate β-catenin 
nuclear localization factors in leukaemia lines. 
This diagram summarizes the steps taken to identify candidate β-catenin nuclear 
localization factors in leukaemia lines. 
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To isolate β-catenin binding partners in leukaemia cell lines, epitope tagged β-
catenin was chosen for use in pulldown experiments, because antibodies raised 
against epitope tags have a low reactivity with other cellular proteins compared 
to those raised against endogenous proteins. This was an important 
consideration because using samples with the lowest possible background 
binding was key to the success of my MS approach, outlined in (Figure 3.1).  
Initially I adopted a FLAG-tagged β-catenin overexpression system.  FLAG is an 
artificial antigen (DYKDDDDK) to which high affinity monoclonal antibodies are 
available (this study employed clone M2 (Table 2.5). The FLAG tag is relatively 
small at 1kDa, decreasing the risk of it interfering with β-catenin protein function. 
Out of the leukaemia cell lines used in the experimental approach, K562 cells 
were chosen to test the methodology and reagents before transduction of other 
lines. This was because they are a rapidly growing cell line and are easy to 
transduce. 
 
A FLAG-β-catenin pcDNA3 construct was purchased from Addgene. In this 
construct the FLAG tag is attached to the C-terminal end of β-catenin. This was 
subcloned into the lentiviral vector (pHIV-EGFP) (Table 2.3). This was done 
because the lentiviral vector is more efficient at stably transducing cells than the 
original pcDNA3 vector. 
Briefly, the original vector (pcDNA3-β-catenin-FLAG) was digested with 
restriction enzymes to provide some evidence that the construct was correct. To 
do this, PDRAW32 (AcaClone) was used to identify restriction sites on the vector 
that could be used as a strategy to help validate the construct. Figure 3.2A shows 
a diagrammatic representation of the vector and the two enzymes that  
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Figure 3.2. Test digest of FLAG-β-catenin pcDNA3 vector (Addgene). 
(A) A diagram of the FLAG-β-catenin pcDNA3 vector purchased from Addgene. Restriction sites 
for Kpn1 and XbaI are highlighted. This diagram was generated using PDRAW32 (Acaclone). 
(B) Expected banding pattern following digestion of the vector with KpnI and XbaI enzymes. (C) 
Banding pattern observed following digestion of the vector with these enzymes. Abbreviations; 
MW= molecular weight, kb= kilobases. Marker=NEB 1kb DNA ladder. 
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were chosen for use in the digestion (KpnI and XbaI). Each of these enzymes 
was a ‘single cut’ vector, with restriction sites in the multiple cloning sites, in-
between which the FLAG-β-catenin construct was located.  Figure 3.2B shows 
the predicted banding pattern observed when agarose gel electrophoresis (2.2.2) 
was used to analyse the digest. This included a band at 5.3kb corresponding to 
the digested vector backbone and a band at 2.4kb corresponding to the excised 
FLAG-β-catenin. Figure 3.2C shows the result of the digestion of the pcDNA3 
vector with KpnI and XbaI. As predicted in Figure 3.2B, bands were visible at 
~5.3kb and ~2.4kb. This verified that the construct was likely correct and could 
be used in sub-cloning to transfer FLAG-β-catenin to the lentiviral pHIV-EGFP 
vector.  
For subcloning, KpnI was used to digest the FLAG- β-catenin-pcDNA3 vector, 
and Klenow fragment was used to selectively blunt this end. Next, XbaI was used 
to excise the FLAG-β-catenin from the pcDNA3 vector, for use in the subcloning 
procedure. Correspondingly, the destination vector, pHIV-EGFP, was prepared 
by digestion at the multiple cloning site with XbaI and the blunt cutter, HpaI, 
allowing directional subcloning of the FLAG-β-catenin into the vector under the 
control of the EF1A promoter. The pHIV-EGFP vector and FLAG-β-catenin insert 
were ligated (2.2.1) and Stbl-3 cells were transformed with the ligated vector to 
amplify the DNA. Three transformed colonies were selected, and the DNA was 
purified (2.2.3).  
Test digests were performed on the DNA from three different colonies to check 
that the pHIV-EGFP-β-catenin-FLAG vector had been successfully created. 
Figure 3.3A shows a diagrammatic representation of the EGFP-β-catenin-FLAG 
vector and the restriction for BamHI (the enzyme chosen to be used in the test 
digest). The restriction sites (G’GATC) for this enzyme occurred twice in the 
constructed vector, at the multiple cloning site of the lentiviral vector and in the 5’ 
sequence of the insert. Figure 3.3B shows the banding pattern expected when 
the samples were electrophoresed on an agarose gel if the subcloning was 
successful. This included a band at 7.6kb corresponding to the cut vector 
backbone and a band at 2.4kb corresponding to the excised FLAG-β-catenin. 
Figure 3.3C shows the results of the test digest, following digestion of the vector 
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with the BamHI enzyme. The vector isolated from colony 1 had visible bands at 
~7.7kb and ~2.4kb, as predicted in Figure 3.3B.  
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Figure 3.3. Test digest of FLAG-β-catenin pHIV-EGFP vector. 
(A) A diagram of the β-catenin-FLAG pHIV-EGFP vector. Expression of the inserted gene is 
driven by the EF1A promoter, which generates an mRNA which also contains an internal 
ribosome entry site (IRES) and an EGFP sequence. (B) The predicted banding pattern following 
digestion of the vector with the BamHI enzyme. (C) The banding pattern observed following 
digestion of the vector from transformed E.coli colonies (Stbl3) with BamHI. Abbreviations; 
MCS= multiple cloning site, MW= molecular weight, kb= kilobases. Marker= NEB 1kb DNA 
ladder. 
Chapter 3: Development of fractionation and immunoprecipitation techniques for 
analysis of leukaemia cell lines by MS 
 
Page | 79  
 
The other colonies analysed did not contain insert. This suggested that the 
construct in colony 1 was the successfully ligated pHIV-EGFP-β-catenin-FLAG 
that could be used in subsequent experiments to transduce leukaemia cell lines 
with FLAG-β-catenin. To verify this was the case, samples of the construct were 
sent for sequencing (Eurofins). The results (Appendix 5) verified that the 
construct was correct. 
 
After successful generation of the FLAG-β-catenin construct, K562 cells were 
lentivirally transduced with the pHIV-EGFP-β-catenin-FLAG or pHIV-EGFP 
control vector (2.3). Briefly, K562 cells were transduced, BIO induced (2.1.5), 
fractionated into cytoplasmic and nuclear lysates and western blotted using the 
FLAG M2 antibody (2.5). K562 cells transduced with the empty pHIV-EGFP 
vector were included as a control. Cells were also blotted with β-catenin antibody 
(BD) in addition to the FLAG M2 antibody. 
Figure 3.4A shows the results of this test transduction in the K562 cells. When 
cells were immunoblotted with β-catenin antibody (BD) there was only a faint 
signal in the cytoplasmic or nuclear fractions of uninduced K562 cells. In contrast, 
in induced cells (+BIO), bands were visible in the cytoplasmic and nuclear 
fractions at ~90kDa, corresponding to full length β-catenin; however, there was 
no difference in overall β-catenin expression between the control and the FLAG-
β-catenin transduced cells. 
When cells were blotted with FLAG antibody (Sigma) there was no visible signal 
in the cytoplasmic or nuclear fractions of uninduced K562 cells. This was the 
same in both control and FLAG-β-catenin transduced cells. In addition, no signal 
was detected in induced cells. This suggested that the FLAG-β-catenin construct 
was either not being expressed, or the FLAG antibody was not successfully 
binding to FLAG.  
To verify that the K562 cells had been successfully transduced with the FLAG-β-
catenin construct, flow cytometry was used (2.4) to measure GFP expression 
(expressed from an IRES in the same mRNA as FLAG-β-catenin). Figure 
3.4B&C shows the results of this flow cytometric analysis.  
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Figure 3.4. Transduction of K562 cells with flag-tagged β-catenin. 
(A) Western blotting of K562 cytoplasmic and nuclear fractions following transduction with 
control and  FLAG-β-catenin vectors. BIO was used to stabilize β-catenin. Abbreviations; C= 
cytoplasmic fraction, N= nuclear fraction, IB= immunoblot, β-cat= β-catenin, Ab= antibody, MW= 
molecular weight, kDa= kilodalton. Marker = MagicMark XP (Thermo Fisher). (B) Measurement 
of auto fluorescence in control transduced K562 cells by flow cytometry.  Region defines 
threshold (c1%) for GFP expression in C. (C) Measurement of GFP expression in K562 cells 
transduced with pHIV-EGFP-β-catenin-FLAG by flow cytometry. GFP= green fluorescent 
protein. To gate out dead cells, a viable gate was applied which excluded cells permeable to the 
DNA-intercalating fluorescent compound, 7-AAD (data not shown). 
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Background auto fluorescence was established using untransduced K562 cells. 
In FLAG-β-catenin transduced cells, the FL-1 (GFP emission detection channel) 
signal was 52%. This suggested that the FLAG-β-catenin construct was 
transduced into ~50% of the cells and that mRNA for FLAG-β-catenin is being 
expressed in these cells suggesting there must be another reason for the lack of 
protein expression in K562 cells observed in Figure 3.4A. These and later data 
(discussed below) suggested that there may be an issue of protein stability with 
the FLAG-β-catenin construct. To rule out the possibility that the FLAG epitope 
was responsible for this, I assessed whether overexpression could be achieved 
in K562 cells using wildtype β-catenin. Despite the robust increase in β-catenin 
following BIO induction, I wanted to also overexpress β-catenin to further 
increase the amount available for immunoprecipitation. This was an important 
consideration because the more β-catenin that was immunoprecipitated, the 
more likely β-catenin interaction partners would be identified by mass 
spectrometry, particularly low abundance or transiently binding partners.   
 
To assess whether wildtype β-catenin could be overexpressed, K562 cells were 
transduced with a β-catenin polyPOZ retroviral vector which co-expresses lacZ 
as a selectable marker (Table 2.3). Transduced K562 cells were incubated with 
the lacZ fluorogenic substrate, FDG, and FACS sorted (based on the presence 
of lacZ in the vector) (2.4.2). Figure 3.5 shows the effectiveness of this FDG 
sorting. Prior to FDG sorting only 21% of cells were lacZ positive (Figure 3.5A), 
suggesting that the β-catenin polyPOZ vector was only expressed in ~20% of 
cells. After FDG sorting the percentage of cells that were lacZ positive increased 
to 74% (Figure 3.5B), suggesting that the β-catenin polyPOZ vector was 
enriched to ~70% of cells. These cells were fractionated and immunoblotted with 
β-catenin antibody (2.5). Figure 3.5C shows the results of this western blot. 
Despite the successful transduction of cells with the β-catenin polyPOZ vector, 
the bands observed at ~90kDa (corresponding to full length β-catenin) were at a 
similar intensity for both control and β-catenin transduced cells. This suggested 
that there was no overexpression of β-catenin in the transduced cells. Owing to 
the similar results observed for the FLAG-β-catenin construct, this suggested that 
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a mechanism may be present in these cells to prevent the stable overexpression 
of β-catenin (3.4.1). 
 
 
 
 
Figure 3.5. Transduction of cells with β-catenin polyPOZ and flag-tagged β-catenin. 
(A) Percentage of K562 cells with fluorescein following transduction with β-catenin polyPOZ. (B) 
Percentage of K562 cells with fluorescein following sorting. 7-AAD was included to check the 
viability of the cells and debris was excluded using forward vs. side scatter (data not shown). (C) 
Western blotting of K562 whole cell lysates from sorted cultures of K562 cells transduced with 
control and β-catenin polyPOZ vectors. (D) Western blotting of HEK293T whole cell lysates 
following transfection with β-catenin vectors. The western blot marker was not visible at the 
relevant MW, but the relative migration was consistent with the signal being due to β-catenin. 
Abbreviations; IB= immunoblot, Ab = antibody, kDa= kilodalton, MW= molecular weight.  
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To determine if the lack of β-catenin construct overexpression was specific to 
K562 cells, the β-catenin and FLAG-β-catenin constructs were overexpressed in 
a different context (HEK293T cells). HEK293T cells were transfected with both β-
catenin vectors, lysed and western blotted with β-catenin and FLAG M2 
antibodies (Chapter 0). A FLAG-PKC construct was included as a positive control 
to verify the FLAG antibody. The FLAG-β-catenin pcDNA3 vector was also 
included as another comparison, to determine if the sub-cloning of FLAG-β-
catenin into the pHIV-EGFP vector (3.3.1.1) had led to issues with 
overexpressing the protein. 
Figure 3.5D shows the results of these western blots. Upon blotting with β-
catenin antibody, a band was visible at ~90kDa in all lysates (corresponding to 
full length β-catenin). The intensity of this band did not increase upon transfection 
of HEK293T cells with β-catenin polyPOZ. This suggested that the β-catenin 
polyPOZ vector was not overexpressed in this line and could indicate a problem 
with this vector. In contrast, the intensity of the banding pattern increased in cells 
transfected with the FLAG-β-catenin vectors. This suggested that FLAG-β-
catenin was expressed in the transfected HEK293T cells. 
Upon blotting with FLAG M2 antibody, as expected no bands were visible in the 
untransfected cells nor in cells transfected with β-catenin polyPOZ; however, a 
band was visible at ~90kDa in the lysates of cells transfected with the positive 
control PKC-FLAG (which has a similar molecular weight to β-catenin) and both 
vectors containing FLAG-β-catenin.  
To conclude, the β-catenin polyPOZ vector was not expressed in HEK293T cells, 
suggesting that there could be a problem with this construct. In contrast, FLAG-
β-catenin vectors were expressed in HEK293T cells. This suggested that the lack 
of expression in K562 cells observed in 3.3.1.2 was context specific and did not 
arise from problems with vector design or performance. 
Owing to the general issues of overexpression of β-catenin and the time 
constraints of the project, the decision was made to rely on endogenous β-catenin 
in subsequent experiments, and use cell lines treated with BIO to increase the 
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levels of β-catenin in both the cytosolic and nuclear compartments sufficiently for 
immunoprecipitation and MS analysis.  
 
The next step in optimizing the methodology for the MS approach was to optimize 
a different cytoplasmic-nuclear fractionation method to the one used so far 
(2.6.2). The reason for optimizing a new technique was because of the proprietary 
formulation of the Biovision C/N fractionation kit used in our standard laboratory 
method (incorporating buffer CEB-A) and the fact that common lysis buffer 
components are incompatible with MS. The new cytoplasmic-nuclear 
fractionation method was optimized in K562 cells prior to its use in other cell lines. 
First, the extraction of β-catenin from the cytosol and nucleus of K562 cells using 
the detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS) was tested. CHAPs was chosen as a potential detergent for the 
fractionation buffer, because it had been shown to maintain protein-protein 
interactions in other contexts (Kim et al, 2002; Rosner & Hengstschläger, 2012). 
Maintaining protein-protein interactions was important in my experimental 
approach, which relied on identifying β-catenin binding partners. A range of 
CHAPS concentrations (0.5%, 0.6%, 0.8%, 1%) were tested and compared to 
our standard protocol buffers (CEB-A and TEAB extraction buffer (2.5.1)) to 
identify the most effective conditions for β-catenin extraction. In our standard 
protocol, CEB-A is used to isolate cytoplasmic protein and TEAB extraction buffer 
is used to isolate nuclear protein. Samples were immunoblotted and probed with 
β-catenin antibody (2.5) 
Figure 3.6A shows the relative extraction of β-catenin following fractionation with 
buffers containing different CHAPS concentrations. In the cytoplasmic fractions, 
bands were visible at ~90kDa in cells fractionated with CEB-A buffer and cells 
fractionated with the range of CHAPS concentrations. This corresponded to the 
molecular weight of full length β-catenin, suggesting that β-catenin was 
successfully extracted from the cytoplasmic fraction of K562 cells using all the 
buffers. The intensity of the band was higher in the cytoplasmic extracts 
fractionated with CHAPS, compared to using our standard CEB-A buffer. This 
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suggested that using the CHAPS buffer would be a more efficient way of 
extracting β-catenin from the cytoplasm of leukaemia lines. The percent increase 
in cytoplasmic β-catenin extraction for each CHAPS concentration compared to 
extraction with CEB-A was calculated. These were 837% for 0.5% CHAPS, 837% 
for 0.6% CHAPS, 679% for 0.8% CHAPS and 815% for 1% CHAPS. 
The results for the nuclear fractions were similar. Bands were visible at ~90kDa 
in cells fractionated with TEAB buffer and cells fractionated with the range of 
CHAPS concentrations. This corresponded to the molecular weight of full length 
β-catenin, suggesting that β-catenin was successfully extracted from the nuclear 
fraction of K562 cells, with each buffer. The intensity of the band was higher in 
the nuclear extracts fractionated with CHAPS, compared to using our standard 
TEAB buffer. This suggested that using the CHAPS buffer would be a more 
efficient way of extracting β-catenin from the nucleus of leukaemia cells. 
For nuclear extracts, the percent difference in β-catenin nuclear extraction for 
each CHAPS concentration was compared to extraction with TEAB was 
calculated. These were a 42% increase for 0.5% CHAPS, a 65% increase for 
0.6% CHAPS, a 79% increase for 0.8% CHAPS and a 42% increase for 1% 
CHAPS. 0.8% CHAPS was chosen for use in subsequent fractionations because 
it gave a higher amount of β-catenin isolation than using TEAB buffer. It was 
chosen in preference over 1% CHAPS because lower detergent levels were less 
likely to interfere with downstream applications (immunoprecipitation and MS).  
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Figure 3.6. Fractionation of K562 cells with CHAPS and immunoprecipitation of β-catenin. 
(A) Western blotting of K562 fractions following fractionation with buffers containing different 
levels of CHAPS. CEB-A and TEAB were included as controls. (B) β-catenin 
immunoprecipitation in K562 cytoplasmic fractions using agarose G beads. The marker was not 
visible at the relevant MW, but the relative migration was consistent with the signal being due to 
β-catenin. (C) β-catenin immunoprecipitation in K562 cytoplasmic fractions using different 
antibody concentrations. (D) β-catenin immunoprecipitation of K562 cytoplasmic fractions using 
different antibodies. The marker was not visible at the relevant MW, but the relative migration 
was consistent with the signal being due to β-catenin. See Table 2.6 for information about the 
antibodies used. Abbreviations; IB= immunoblot, MW= molecular weight, Ab= antibody, kDa = 
kilodalton, SN= supernatant (immunodepleted lysate following the IP reaction), IP= 
Immunoprecipitation. Marker = MagicMark XP (Thermo Fisher).  
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Next, immunoprecipitation of β-catenin and its binding partners was optimized in 
K562 cell fractions. Protein G agarose beads were used in these 
immunoprecipitations due to their wide usage and low cost. The 
immunoprecipitation protocol provided with the beads (from Santa Cruz10) was 
used. K562 cells were BIO induced and fractionated (using CHAPS). The 
cytoplasmic fraction was then immunoprecipitated using β-catenin antibody (BD) 
and western blotted (Chapter 0). 
Figure 3.6B shows the results following blotting with β-catenin antibody.  A band 
was visible in the input, supernatant and immunoprecipitation at ~90kDa, 
corresponding to the expected molecular weight of full length β-catenin. The 
intensity of this banding was similar in the input and supernatant lanes, 
suggesting that only a very small amount of β-catenin had left the supernatant by 
binding to the beads. The very low intensity of the band observed in the 
immunoprecipitation verified that only a small amount of β-catenin had bound to 
the beads. This showed that the immunoprecipitation efficiency was very low, and 
improving this efficiency became the aim of subsequent optimization steps.  
 
One factor that could have caused the low immunoprecipitation efficiency was an 
insufficient concentration of antibody in the reaction. This is because if the 
antibody concentration is too low, not enough antibody binds to the agarose 
beads and there are less antibody-bead complexes for β-catenin to bind to.  A 
range of different antibody concentrations (0.2µg, 0.6µg and 2µg) were tested in 
K562 cells, following the same procedure as described previously (3.3.3.). Figure 
3.6C shows the results following western blotting of the immunoprecipitations. A 
band was visible at ~90kDa in the inputs, supernatant and immunoprecipitations 
at each antibody concentration. This corresponded to the expected molecular 
weight of full length β-catenin. Though the yield of immunoprecipitated protein 
                                            
10 http://datasheets.scbt.com/sc-2002.pdf 
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improved with increasing antibody the efficiency of immunoprecipitation remained 
well below 50%.  
Another factor that could have led to the low immunoprecipitation efficiency was 
the antibody used. This is because different antibodies have different binding 
affinities and the low efficiency of β-catenin binding could be due to a low binding 
efficiency under the conditions of the extraction. Additionally, β-catenin binding 
partners could be masking the antibody epitope and preventing the binding of the 
antibody to β-catenin. As such, different antibodies, which bound to different β-
catenin domains (Table 2.6), were tested using both CHAPS and CEB-A buffers. 
Figure 3.6D shows the results of blotting of these immunoprecipitations. Banding 
was observed at ~90kDa in each of the immunoprecipitations. The intensity of 
the banding remained low in all the immunoprecipitations when comparing them 
to the input, for both CHAPS and CEB-A buffers.  
In addition, Figure 3.7A shows the results of combining two antibodies (with C 
and N terminal epitopes) into one immunoprecipitation. The banding observed 
was also very low. These results suggest that the antibody being used in the 
immunoprecipitation is not responsible for the low immunoprecipitation efficiency. 
As a result, the original β-catenin antibody (BD) was used for subsequent 
immunoprecipitations. 
 
Another factor that may have led to a low immunoprecipitation efficiency was the 
concentration of CHAPS in the buffer. Detergents can alter the structure and 
function of proteins and therefore interfere with immunoprecipitation by reducing 
antibody-target binding and/or antibody-bead binding. To determine if the level of 
CHAPS in the buffers was interfering with the immunoprecipitation, K562 cells 
were BIO induced, fractionated with 0.4% or 0.8% CHAPS, immunoprecipitated 
with β-catenin antibody and western blotted (Chapter 0). Figure 3.7A shows the 
results of these immunoprecipitations following blotting of K562 cytoplasmic 
fractions with β-catenin antibody. Banding was observed at ~90kDa, which 
corresponded to the expected molecular weight of full length β-catenin. The 
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intensity of the banding was the same (very low) for the immunoprecipitations 
with 0.4% and 0.8% CHAPS. In addition, the intensity of the banding in the 
supernatants of both immunoprecipitations was similar to the input lane. This 
suggested that very little β-catenin had left the supernatant and bound to the 
agarose beads and that the level of CHAPS in the buffer was not responsible for 
the low immunoprecipitation efficiency. 
 
Another factor that could have led to the low immunoprecipitation efficiency was 
the volume of beads in the reaction. It was theorized that increasing the volume 
of beads in the immunoprecipitation reaction would increase the surface area for 
β-catenin-antibody complex binding, thereby increasing immunoprecipitation 
efficiency. To test this, K562 fractions were immunoprecipitated as before, but 
using a range of bead volumes (20-80µL). Figure 3.7B shows the results of 
western blotting of these immunoprecipitations with β-catenin antibody. Bands 
were visible at ~90kDa in the input and the immunoprecipitations for each bead 
volume (20µL, 40µL and 80µL). This corresponded to the expected banding 
pattern for full length β-catenin. The intensity of the band was similar for all the 
bead volumes, and very low compared to the input. This suggested that the 
immunoprecipitation efficiency was low, regardless of the volume of beads in the 
reaction.  
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Figure 3.7 β-catenin immunoprecipitation efficiency under different buffer conditions. 
(A) β-catenin immunoprecipitation in K562 cytoplasmic fractions using buffers containing 0.4% 
CHAPS, 0.8% CHAPS and containing 2 different β-catenin antibodies with N and C terminal 
epitopes (CST #9581 and CST #9582) (Table 2.6). (B) β-catenin immunoprecipitation in K562 
cytoplasmic fractions using different amounts of beads. The marker was not visible at the 
relevant MW, but the relative migration was consistent with the signal being due to β-catenin. 
(C) β-catenin immunoprecipitation in K562 cytoplasmic fractions in the presence of DTT (+DTT) 
and in the absence of DTT (-DTT). The marker was not visible at the relevant MW, but the 
relative migration was consistent with the signal being due to β-catenin.  (D) β-catenin 
immunoprecipitation in K562 cytoplasmic fractions in buffers containing different salt 
concentrations. Abbreviations; IB= immunoblot, Ab= antibody, MW= molecular weight, kDa= 
kilodalton, IP= Immunoprecipitation, SN= supernatant (immunodepleted lysate following the IP 
reaction). Marker = MagicMark XP (Thermo Fisher).  
Chapter 3: Development of fractionation and immunoprecipitation techniques for 
analysis of leukaemia cell lines by MS 
 
Page | 91  
 
 
Other components in the buffer could have caused the low efficiency of 
immunoprecipitation. Firstly, DTT (Dithiothreitol) can damage the structure of 
proteins, therefore reducing the amount of target-antibody-bead complexes 
formed. To determine if DTT was causing the low immunoprecipitation efficiency 
observed in my experiments, K562 cells were BIO induced and fractionated with 
and without DTT. Cytoplasmic fractions were then immunoprecipitated and 
western blotted with β-catenin antibody. Figure 3.7C shows the results of this 
western blot. Banding was observed at ~90kDa in both inputs and supernatants 
(-/+ DTT). In contrast, only very faint banding was observed in the 
immunoprecipitation in the presence of DTT, and no band could be seen in the 
immunoprecipitation without DTT in the buffer. This suggested that only a very 
small amount of β-catenin was immunoprecipitated both in the presence and 
absence of DTT, suggesting that DTT was not responsible for the low β-catenin 
immunoprecipitation efficiency.  
Another component in the buffer that could be leading to low immunoprecipitation 
efficiency was the salt level. Too much salt can interfere with protein binding and 
thereby affect binding of antibody to beads or target protein. To test if the salt 
(NaCl) concentration in the CHAPS buffer used for fractionation was impacting 
the efficiency of immunoprecipitation, a range of salt concentrations were 
compared. K562 cells were BIO induced and fractionated with buffers containing 
a range of NaCl concentrations (37.5mM, 75mM, 150mM and 300mM). 
Cytoplasmic fractions were immunoprecipitated and western blotted with β-
catenin antibody. Figure 3.7D shows the results of this western blot. Banding 
was observed at ~90kDa in all the supernatants and immunoprecipitations. This 
corresponded to full length β-catenin. The intensity of the banding was similar for 
all the immunoprecipitations (very faint). This suggested that the 
immunoprecipitation efficiencies were not impacted by the salt level in the buffer. 
Taken together, the results of this section suggest that individual components of 
the fractionation buffer were not responsible for the low β-catenin 
immunoprecipitation efficiency and that there was a major limiting factor in the 
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protocol, either because of the reagents or the method used. Subsequently, a 
collaboration was established with Dr. Alex Greenhough (Bristol, UK). In their 
laboratory, they had successfully immunoprecipitated β-catenin and its binding 
partners in colon cancer cell lines.  
 
Upon comparing my protocol with the one used by Dr. Greenhough’s laboratory, 
a few key differences were observed which could be leading to the low β-catenin 
immunoprecipitation efficiency in my experiments. Firstly, in Dr. Greenhough’s 
protocol, there was a step which cross-linked the antibody and beads prior to 
immunoprecipitation. This is an important difference because cross-linking 
strengthens the binding of antibodies to the beads and reduces the likelihood that 
antibody/protein complexes are lost during the washing steps, which could lead 
to a low immunoprecipitation efficiency. They were also using different buffers 
and different beads. Each of these factors was tested to determine if I could 
increase immunoprecipitation efficiency.  
Firstly, to test if cross-linking would increase the immunoprecipitation efficiency, 
cells were BIO induced and cytoplasmic fractions were immunoprecipitated as 
before (2.6.3). However, β-catenin antibody was cross-linked to the agarose 
beads prior to immunoprecipitation. K562 and the colon adenocarcinoma cell line 
LS174T (positive control) cells were included in the experiment and the 
immunoprecipitations were western blotted using β-catenin antibody. Figure 
3.8A shows the results of this western blot. A band was visible at ~90kDa in the 
input and supernatant of both K562 and LS174T cells. This corresponded to the 
expected weight of full length β-catenin. A band was not visible in the 
immunoprecipitations without cross-linking. This suggested that in both K562 and 
LS174T cells, only a very small amount (if any) of β-catenin was 
immunoprecipitated. A very faint band was observed in the immunoprecipitations 
with cross-linking. This suggested that there was an increase in 
immunoprecipitation efficiency in both K562 and LS174T cells after cross-linking 
of β-catenin to the agarose beads. This increase in efficiency was only modest, 
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however, suggesting that the lack of cross-linking was not responsible for the low 
immunoprecipitation efficiencies observed so far. 
 
Figure 3.8 Immunoprecipitation of β-catenin using two methods in K562 and LS174T cell 
lines. 
(A) Immunoprecipitation of β-catenin in K562 and LS174T cells using 0.8% CHAPS buffer and 
protein G agarose beads with and without cross-linking. The western blot marker was not visible 
at the relevant MW, but the relative migration was consistent with the signal being due to β-
catenin. (B) β-catenin immunoprecipitation in K562 whole cell lysates (-/+ BIO) using Triton 
buffer (Appendix 3). The higher than expected banding pattern observed in the K562 
Dynabeads β-catenin IP is due to slower sample migration on one side of the gel.  (C) Repeat of 
the immunoprecipitation in K562 lysates prepared using Triton and CHAPS buffers. 
Abbreviations; IB= immunoblot, Ab= antibody, MW= molecular weight, SN=supernatant 
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(immunodepleted lysate following the IP reaction), IP= immunoprecipitated protein sample. 
Marker = MagicMark XP (Thermo Fisher). 
 
 
Due to the failure to increase β-catenin immunoprecipitation using agarose 
beads, the decision was made to abandon this method in favour of the method 
from Dr.Greenhough’s laboratory (2.6.4). To test this method in my cell line, K562 
cells were BIO induced, lysed with Triton buffer and immunoprecipitated using 
protein G Dynabeads. Immunoprecipitations were then western blotted using β-
catenin antibody. Figure 3.8B shows the results of this western blot. A band was 
visible at ~90kDa in the supernatant of K562 cells following induction with BIO, 
corresponding to full length β-catenin. The intensity of this band was lower in the 
immunoprecipitation supernatant, compared to IgG control. There was also 
intense banding visible in the immunoprecipitation of BIO induced K562 cells. 
Taken with the reduction of banding in the supernatant this suggested that β-
catenin was efficiently immunoprecipitated using this new method in K562 whole 
cell lysates. This indicated that β-catenin could be immunoprecipitated in K562 
cells and that BIO did not interfere with the reaction. Next, this method needed 
testing in K562 fractions (using CHAPS buffer). 
K562 cells were BIO induced, fractionated using 0.8% CHAPS and cytoplasmic 
fractions were immunoprecipitated using β-catenin antibody. K562 whole cell 
lysate (lysed with Triton buffer) was also included as a positive control.  Figure 
3.8C shows the results of these immunoprecipitations following blotting with β-
catenin antibody. A band was visible at ~90kDa in the supernatants of the K562 
cytoplasmic fraction and whole cell lysate. This corresponded to full length β-
catenin. The intensity of the band was lower in the immunoprecipitation 
supernatants compared to IgG control. An intense band was also visible in the 
immunoprecipitations from the cytoplasmic fraction and whole cell lysate. This 
band was absent in the IgG controls. This suggested that β-catenin was 
successfully immunoprecipitated at high efficiency using both buffers.   
To conclude, attempts to overexpress β-catenin constructs in leukaemia cell lines 
were unsuccessful. C/N fractionation was successfully achieved using CHAPS 
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buffer in K562 cells, and a 0.8% CHAPS buffer was chosen for use in subsequent 
fractionations. Immunoprecipitation of β-catenin was unsuccessful using protein 
G agarose beads, despite attempts to increase immunoprecipitation efficiency by 
using different antibodies, different antibody concentrations, different CHAPs 
levels and different bead amounts, as well as altering the levels of DTT and salt 
in the buffer and cross-linking antibodies to the beads prior to 
immunoprecipitation. Immunoprecipitation was successful using an alternative 
method and protein G Dynabeads. This method will be used for subsequent 
immunoprecipitations (Chapter 4). 
 
The aim of the experiments presented in this chapter was to optimize 
cytoplasmic/nuclear fractionation and immunoprecipitation techniques for use in 
the MS analysis approach summarized in (Figure 3.1). This section discusses 
the approach taken to optimize these techniques as well as some of the issues 
that were encountered throughout this process. 
 
To isolate β-catenin binding partners in leukaemia cell lines, I attempted to 
overexpress β-catenin, this was done to increase the total amount of β-catenin 
available for immunoprecipitation. A FLAG-tagged β-catenin construct was 
chosen for use in pulldown experiments. The reason for this is that, firstly, 
antibodies raised against epitope tags have a low reactivity with other cellular 
proteins compared to those raised against endogenous proteins, and can be 
eluted from IP beads gently using short peptides rather than harsh methods such 
as boiling in SDS. This should result in less background binding proteins in MS 
analysis (Gingras et al, 2005). Additionally, an anti-FLAG antibody was readily 
available (clone M2, Sigma), and the small size of the FLAG protein decreased 
the risk of it interfering with β-catenin protein function. Test digests were 
performed to verify that the construct bought from Addgene (PCDNA3-β-catenin-
FLAG) contained the correct construct. Sequencing could have been used to 
verify that the base level sequence was correct, however, this was done for the 
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subcloned pHIV-EGFP-β-catenin-FLAG vector, which verified that the β-catenin-
FLAG construct was the correct sequence. When overexpression of this construct 
was unsuccessful in K562 cells, attempts to overexpress wild type β-catenin were 
made instead in case the addition of FLAG was destabilising the expression of β-
catenin. Again, this was unsuccessful in K562 cells. 
Despite lack of protein expression, β-catenin-FLAG mRNA appeared to be 
successfully expressed, as highlighted by the detection of GFP in transduced 
cells (which was expressed from an internal ribosome entry site (IRES) in the 
same message as β-catenin-FLAG mRNA). An IRES initiates ribosome binding 
and mRNA translation in a cap independent manner. This allows two proteins to 
be translated from the same mRNA sequence, in this case β-catenin-FLAG and 
GFP. The β-catenin-FLAG sequence is transcribed before the GFP sequence, 
and therefore if incomplete transcription of β-catenin-FLAG occurs, no GFP 
transcription should occur, and subsequently no mRNA should be translated into 
GFP protein.  This allows GFP expression to be used as an indicator of β-catenin-
FLAG mRNA expression.  
The expression of β-catenin-FLAG mRNA, but not β-catenin-FLAG protein was 
not entirely unexpected given that β-catenin is a protein whose expression is 
chiefly regulated at the post-transcriptional level by the catenin destruction 
complex (1.3.1.1) as evidenced by the strong increase in protein expression 
following treatment with Bio.  
Further expression of β-catenin-FLAG was successful in HEK293T cells (Figure 
3.5D), this suggests that the FLAG-β-catenin protein can be expressed in other 
contexts. Given that HEK293T cells showed relatively good endogenous 
expression of β-catenin, it could be the case that overexpression was observed 
in this case because the destruction complex is less active in these cells.  
  
Chapter 3: Development of fractionation and immunoprecipitation techniques for 
analysis of leukaemia cell lines by MS 
 
Page | 97  
 
 
CHAPs was chosen for use in cytoplasmic/nuclear fractionation because it had 
been shown to maintain protein-protein interactions in other contexts, for 
example, maintenance of the raptor-mTOR complex in HEK293T cells and 
fibroblasts, when other detergents such as Triton-X-100 and NP-40 led to 
dissociation of this complex (Kim et al, 2002; Rosner & Hengstschläger, 2012). 
This was an important consideration for my experimental approach, whose 
success relied on identification of β-catenin interaction partners. 
Being a mild buffer, CHAPS is usually used to isolate cytoplasmic fractions, or at 
higher concentrations, whole cell lysates (Mancini et al, 2017; Rosner & 
Hengstschläger, 2008; Shaiken & Opekun, 2014). Since different detergents can 
influence the binding partners that are identified following immunoprecipitation 
and MS (Arachea et al, 2012), I wanted to use CHAPS in the nuclear fractionation 
buffer as well. To isolate nuclear fractions, freeze thawing of isolated nuclear 
pellets was used prior to lysis with CHAPS buffer. This technique has been used 
previously by another group (Rosner & Hengstschläger, 2008). Overall, this 
approach was designed to ensure that protein-protein interactions were 
maintained for the MS approach, however, it would have been more thorough to 
compare other detergents as well to determine if using them would have 
increased the efficiency of β-catenin immunoprecipitation. If this approach had 
been taken it would also be important to compare the levels of known binding 
partners following β-catenin immunoprecipitation using different detergent 
buffers, to ensure that protein-protein interactions were still maintained. 
 
The first decision made for the starting immunoprecipitation protocol was the type 
of beads to use; agarose, sepharose or magnetic. Each of these has their own 
advantages and disadvantages, including ease of use, surface area and cost. 
One important consideration was the amount of non-specific binding for each 
bead type, which can differ in cytoplasmic and nuclear cell fractions. In one study 
comparing non-specific protein binding to sepharose, agarose and magnetic 
beads in HeLa cytoplasmic and nuclear fractions, non-specific binding of nuclear 
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proteins was shown to be lowest using magnetic beads, and a similar amount of 
nuclear proteins bound to agarose and sepharose beads. In contrast, for 
cytoplasmic fractions the lowest amount of non-specific binding was observed 
using agarose beads, followed by sepharose and then magnetic beads (Trinkle-
Mulcahy et al, 2008). Since in this project cytoplasmic and nuclear proteins were 
being studied, the decision about which beads to use was based on other factors.  
Agarose beads were ultimately chosen because they are widely used and 
inexpensive compared to other beads. In this study, β-catenin 
immunoprecipitation using agarose beads was ineffective which led to different 
conditions being optimized to successfully immunoprecipitate β-catenin.  
 
One factor that could have caused the low immunoprecipitation efficiency was an 
insufficient concentration of antibody in the reaction. This is because if the 
antibody concentration is too low, not enough antibody binds to the agarose 
beads and there are less antibody-bead complexes for β-catenin to bind to. As 
such, the effect of using different antibody amounts in the immunoprecipitation 
was assessed. No significant differences in immunoprecipitation efficiency were 
observed by increasing the antibody concentration.  
Another factor that can lead to the low immunoprecipitation efficiency is the 
antibody used. This is because different antibodies have different binding 
efficiencies and the low efficiency of β-catenin binding could be due to a low 
binding efficiency. Additionally, β-catenin binding partners could be masking the 
antibody epitope and preventing the binding of the antibody to β-catenin. The 
antibody used for initial immunoprecipitations (from BD) was chosen because it 
was a monoclonal antibody, which have less variability batch-to-batch compared 
with polyclonal antibodies and are less likely to bind non-specifically to other 
proteins because they only bind to one specific epitope, however, this is not 
always the case and the specificity of antibodies varies greatly from antibody to 
antibody and from supplier to supplier (Gilda et al, 2015; Vanli et al, 2017). This 
was an important consideration for the consistency and reliability of the 
immunoprecipitation results because having the lowest possible amount of 
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background binding was important for the MS approach. One disadvantage of 
using monoclonal antibodies for immunoprecipitation, is that they tend to have a 
much lower overall binding affinity for their targets than polyclonal antibodies 
because they only bind to one epitope rather than multiple epitopes11, however, 
this is not always the case. In one study looking at the immunoprecipitation 
efficiencies of 11 antibodies for the estrogen receptor β (ERβ) in MCF-7 cells, a 
high degree of variability in immunoprecipitation efficiencies was observed, and 
this was not correlated with the antibodies being monoclonal or polyclonal 
(Weitsman et al, 2006). 
As such, a range of monoclonal and polyclonal antibodies were selected for 
optimization in this project. When selecting these antibodies, their IgG isotype 
was taken into consideration because different antibody isotypes have different 
binding affinities for protein G, which coated the agarose beads in my 
experiment12. Only IgG isotypes that bind to protein G with medium or high affinity 
were selected (mouse IgG1 and rabbit IgG) (Table 2.6).  
The antibody epitopes were also considered. Whilst many of the proteins that 
interact with β-catenin do so by binding to the armadillo repeats in the central part 
of the protein (Figure 1.6), other established binding partners interact with β-
catenin’s C terminus (e.g. the histone acetyltransferases CBP/p300 and TRRAP 
p400 and TIP60) and N terminus (e.g. the E3 ligase β-TrCP) (Valenta et al, 2012; 
Xu & Kimelman, 2007). As a result, I wanted to make sure that the ineffective 
immunoprecipitation was not due to binding partners masking the epitope for the 
BD antibody. When selecting antibodies for optimization, a selection of N terminal 
and C terminal binding antibodies were included. Comparisons of antibodies 
suggested that epitope screening was not a factor in IP efficiency of β-catenin in 
this study. 
                                            
11 http://www.abcam.com/protocols/a-comparison-between-polyclonal-and-monoclonal 
(accessed on 04/01/2018) 
12 https://www.neb.com/tools-and-resources/selection-charts/affinity-of-protein-ag-for-igg-types-
from-different-species (accessed on 04/01/2018) 
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The concentration of CHAPS in the buffer was another factor that was optimized 
to try and successfully immunoprecipitate β-catenin. Detergents can have 
different effects on proteins and protein interactions at different concentrations. 
For example, an experiment studying the effect of the NP-40 detergent on the 
recovery of alcohol dehydrogenase (ADH) in immunoprecipitation experiments 
determined that low levels of this detergent increased the efficiency of the 
immunoprecipitation compared to immunoprecipitations conducted with no 
detergent. This suggests that the detergent may change the conformation of the 
antibody and/or target protein in such a way that more effective target-antibody 
binding is observed. In contrast, higher levels of NP-40 decreased 
immunoprecipitation efficiency (Yang et al, 2009). The effect of detergent on 
antibody-antigen interactions is different for each detergent, with detergents like 
SDS destroying their interaction at relatively low levels (0.01%) and detergents 
like Triton-X-100 not having a profound effect on antibody-antigen binding up to 
concentrations of about 5% (Qualtiere et al, 1977) 
Given the differences in antibody-antigen binding affinities for each protein and 
antibody, the effect of detergents on the efficiency of immunoprecipitation is not 
always predictable. To determine if the concentration of CHAPS was influencing 
the efficiency of my immunoprecipitation, different concentrations of CHAPS 
(0.4% and 0.8%) were compared.  
In hindsight, this may not have been the best approach to take, as the effect of 
detergents on the efficiency of immunoprecipitations is not linear. In the study by 
Yang et al. 2009, the efficiency of immunoprecipitation decreased between 
0.02% and 0.1% NP-40, and then the efficiency remained relatively constant at 
higher concentrations. As a result, it would have been a better approach to use a 
wider range of CHAPS concentrations to determine if it was influencing the 
efficiency of β-catenin immunoprecipitation in my experiments. 
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Another component in the buffer that can lead to low immunoprecipitation 
efficiency is the salt level. Salts can impact protein stability and impact the 
efficiency of immunoprecipitation by disrupting antibody-target binding and/or 
antibody bead binding. For example, the salt ammonium sulfate was found to 
decrease protein stability of the proteins catalase and a-lactalbumin at ~1M 
concentration, ribonuclease A at ~1.5M and bovine serum albumin at ~ 2M. In 
contrast, the stability of myoglobin decreased only slightly at 2.5M (Dumetz et al, 
2007). This shows that different proteins are affected by the same salt, in this 
case ammonium sulfate, at different concentrations and determining the affect of 
salts on specific proteins is an important consideration when using a proteomics 
approach. 
Different studies have suggested that NaCl concentration does not have a 
significant effect on protein stability (Dumetz et al, 2007; Lindman et al, 2006). In 
one study, NaCl concentration only marginally impacted the stability of protein G. 
In this study, the Tm (temperature at the denaturation midpoint) was used to 
determine protein stability and only a very small decrease in the Tm was 
observed when comparing low salt concentration to 150mM. This suggests that 
there was a small decrease in protein stability, but this was not significant 
(Lindman et al, 2006). Similarly, in the study by Dumtez et al. 2007 the effect of 
a range of NaCl (0-4M) concentrations on the second osmotic virial coefficient 
(b2) values of seven proteins was measured using self-interaction 
chromatography. b2 values are a measure of non-ideal solution behaviour 
resulting from interactions between two solutes (in this case proteins). A positive 
b2 value indicates repulsion between the two solutes, whereas a negative b2 
value indicates attraction between the two solutes (Alford et al, 2008).  For each 
of the proteins, the b2 values remained constant at all NaCl concentrations, 
suggesting that NaCl does not impact protein stability in this context. In addition, 
150mM NaCl is a standard component of lysis buffers and immunoprecipitation 
buffers, and β-catenin and its binding partners have been co-immunoprecipitated 
successfully using 150mM containing buffer (Chen et al, 2012; Li et al, 2012; 
Palka-Hamblin et al, 2010).  
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Although this evidence suggests that NaCl does not impact the stability and 
interaction of proteins at the concentrations used in this study, the complexities 
of individual protein interactions in different contexts meant that I still wanted to 
rule this out as a factor leading to my low immunoprecipitation efficiency. In 
agreement with the literature outlined above, NaCl concentration did not affect β-
catenin immunoprecipitation in this project.  
Another factor that was considered was the effect of DTT on the efficiency of my 
immunoprecipitations. DTT targets disulphide bonds, which are important in 
maintaining protein structure and has been shown to impact the titration of IgM 
antibodies, however, DTT did not impact the titration of IgG antibodies under the 
same conditions (Okuno & Kondelis, 1978; Pirofsky & Rosner, 1974). Since I was 
using IgG antibodies in my study, this suggested that DTT may not be impacting 
the efficiency of my immunoprecipitations.  
A different study found that DTT does cleave IgG, but only at a concentration of 
2mM (Crivianu-Gaita et al, 2015). This is twice as high as the 1mM DTT used in 
my study. Despite this, DTT could not be ruled out as a factor that could be 
impacting the immunoprecipitation efficiency and was included in this analysis 
since it could potentially impact the structure of β-catenin, changing its 
confirmation and interfering with the binding of the antibody to its epitope.  
To summarize, conditions for β-catenin extraction were optimised using buffers 
known to favour protein-protein interactions.  Issues with IP efficiency led to the 
investigation of different variables affecting IP. An alternative protocol was 
adopted which used different beads, and this overcame the problems with poor 
IP efficiency. It was concluded that a defective batch of protein G beads was 
probably responsible for the poor immunoprecipitation efficiency. 
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4 Identification of candidate factors 
regulating the nuclear localization of β-
catenin by MS 
 
β-catenin is dysregulated in AML and its overexpression is associated with a poor 
prognosis (Chen et al, 2009; Simon et al, 2005; Xu et al, 2008; Ysebaert et al, 
2006).  Key to its role as a transcription factor is its localization to the nucleus. 
Although β-catenin nuclear localization factors have been identified in other 
contexts (Morgan et al, 2014), little is known about the factors regulating β-
catenin nuclear localization in AML. In this project an MS approach was 
conducted to identify candidate β-catenin nuclear localization factors in AML, 
using AML cell lines as a model system. In the previous chapter, β-catenin co-
immunoprecipitation was optimized in leukaemia lines. In this chapter, this 
protocol was subsequently used to co-immunoprecipitate β-catenin and its 
binding partners in nuclear and cytoplasmic fractions of leukaemia cell lines. 
These samples were sent for MS analysis at Bristol Proteomics Facility and 
analysed to produce a candidate list of potential β-catenin nuclear localization 
factors. The MS approach taken to identify candidate β-catenin nuclear 
localization factors is introduced in 2.6 and summarized in Figure 4.1.  Briefly, 
the presence/absence of β-catenin binding partners was compared in the nuclear 
and cytoplasmic fractions of translocator and non-translocator lines. Candidate 
β-catenin nuclear localization factors were identified based on the presence or 
absence of factors in each compartment, as shown in Table 4.1. These proteins 
were filtered and their potential role as regulators of β-catenin nuclear localization 
was validated. 
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• To use the optimized co-immunoprecipitation protocol to prepare protein 
samples for MS analysis; 
• To identify candidate β-catenin nuclear import and export factors in 
leukaemia cell lines.  
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Figure 4.1. Schematic of the experimental approach used to identify candidate β-catenin 
nuclear localization factors in leukaemia cell lines. 
This diagram is reproduced from 2.6 for convenience. It summarizes the steps taken to identify 
candidate β-catenin nuclear localization factors in leukaemia cell lines. 
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Table 4.1. Expected localization of β-catenin binding partners involved in its nuclear 
localization. 
The mechanism of β-catenin nuclear localization and expected localization of proteins involved 
in the process are highlighted below. Dark green (checked pattern) = presence, light green= 
possible presence and yellow (diagonal lined pattern) = absence. C= Cytoplasm and N= 
Nucleus. Note; data for the nuclear fractions of non-translocator cell lines is not available. 
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To identify candidate β-catenin nuclear localization factors, leukaemia cell lines 
were fractionated, followed by co-immunoprecipitation of β-catenin and its 
binding partners (2.6). Prior to β-catenin co-immunoprecipitation, cytosolic and 
nuclear fractions were immunoblotted with GAPDH and Histone H1 antibodies 
(2.5) to verify the purity/enrichment of the fractions. This was important because 
the identification of candidate β-catenin nuclear localization factors was 
dependent on the presence and absence of proteins in the cell compartments 
(Figure 4.1) and contamination between the fractions could confound the 
conclusions drawn from the MS analysis.  
Figure 4.2A outlines the purity of the cell fractions. The blot was probed with both 
GAPDH and Histone H1 antibodies, with the expectation that the different 
molecular weights of these proteins would clearly discriminate the signal from 
each antibody. In the cytoplasmic fractions of all the lines, a band was visible at 
approximately 37kDa, corresponding to the expected weight of GADPH. 
Additionally, there was a cluster of weak bands in the nuclear fractions at the 
same molecular weight. This was likely due to unexpected signal from the histone 
H1 antibody at a high molecular weight rather than GAPDH signal. 
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Figure 4.2. Co-immunoprecipitation of β-catenin in leukaemia cell lines for MS analysis. 
(A) Inputs for each cell line and fraction were immunoblotted with GAPDH and Histone H1 to 
determine the purity of the fractions prior to co-immunoprecipitation (2.5). (B) Western blotting 
of samples following co-immunoprecipitation with β-catenin antibody in translocator lines. The 
higher than expected banding pattern observed in the HEL nuclear fractions is due to slower 
sample migration on one side of the gel. (C) Western blotting of samples following co-
immunoprecipitation with β-catenin antibody in non-translocator lines. An IgG control co-
immunoprecipitation was also analysed for each cell line to allow removal of background 
binding proteins (non-specific binding). Abbreviations; β-cat=β-catenin, C= cytosolic fraction, N= 
nuclear fraction, IB= immunoblot, Ab= antibody, MW= molecular weight, kDa= kilodalton. 
Marker= MagicMark XP (Thermo Fisher).  
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In the nuclear fractions, two bands were visible just below the 20kDa marker, 
corresponding to Histone H1. As expected it was absent in the cytoplasmic 
fractions, except for HEL cells, where there was a small amount of nuclear 
contamination. Since the level of β-catenin in the nucleus of these cell lines is 
minimal compared to the amount in the cytoplasm (Figure 1.7), this was unlikely 
to impact the MS results. Therefore, these samples were considered ‘pure’ 
enough to be used for subsequent co-immunoprecipitation and MS analysis.  
 
Co-immunoprecipitation of β-catenin and its binding partners was conducted 
following the method optimized in Chapter 3 (2.6). Prior to sending the samples 
for MS, non-specific binding of β-catenin to IgG was assessed. IgG control and 
β-catenin co-immunoprecipitations were immunoblotted with β-catenin antibody 
(Figure 4.2B&C). There was only very faint β-catenin signal in the IgG lanes of 
some of the samples. This suggested that non-specific binding of β-catenin to 
IgG was unlikely to be an issue and I could confidently remove background 
binding partners from the analysis of MS data without removing β-catenin binding 
partners.  
In contrast, β-catenin signal was detected in all the β-catenin co-
immunoprecipitation samples. This confirmed that β-catenin co-
immunoprecipitation was successful, and the samples could be analysed using 
MS at Bristol Proteomics Facility. In Bristol, the samples were analysed by 
tandem MS using an LTQ- Orbitrap Velos mass spectrometer (2.6.6). 
 
Details of the methodology used for MS are outlined in (2.6.6). Briefly, samples 
were electrophoresed on an SDS-PAGE gel and each lane was cut into three 
equal slices. Each slice was subject to in gel tryptic digestion and fractionated 
prior to MS. The raw data files were processed using Proteome Discoverer 
software (Thermo Scientific) and false discovery rates (FDR) of 1% and 5% were 
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used to produce two MsExcel files of identified peptides (2.6.6) (Appendix 4 - see 
the attached CD disk).  
These data were filtered to remove proteins that non-specifically bound to IgG 
(Figure 4.3A). Peptides present in all IgG lanes were filtered out. This removed 
proteins from the list that were only non-specific IgG binding proteins. 
The next step was to take each cell line at a time and remove background binding 
proteins specific to that cell line. To do this Excel filtering was used on the Area 
columns for IgG and β-catenin co-immunoprecipitation. The IgG column was 
filtered based on “Equals 0” and the co-immunoprecipitation column was filtered 
based on “Does Not Equal 0”. Next, proteins with a peptide score of less than 3 
were removed by filtering the Peptide column based on “Greater than 2”. 
The remaining proteins were used to identify candidate nuclear β-catenin 
localization factors. 
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Figure 4.3. Schematic of the data analysis approach used to identify candidate β-catenin 
nuclear localization factors. 
This is an overview of the analysis strategy discussed in the text.  Data received from Bristol 
Proteomics Facility was analysed following the steps above. (A) Removal of non-specific 
binding partners (or background proteins). (B) Identification of candidate factors regulating the 
nuclear localization of β-catenin.  
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To identify candidate β-catenin exporters, β-catenin binding partners from 
translocator and non-translocator cytoplasmic fractions were compared. This 
approach was based on the expected localization of nuclear export proteins in 
the cytoplasm and nucleus of non-translocator lines, outlined in Table 4.1. 
Briefly, proteins present in the cytoplasmic fraction of non-translocator cell lines 
and absent in the cytoplasmic fraction of translocator cell lines were identified as 
potential β-catenin exporters. This approach was based on the presumption that 
the presence of β-catenin exporters in leukaemia cell lines is sufficient for nuclear 
β-catenin export. Comparisons of peptides between different cell lines and cell 
compartments were conducted using an online Venn diagram creator13. This 
produced Venn diagrams comparing peptide presence based on their accession 
numbers.   
Firstly, peptides present in the cytoplasmic fraction of all non-translocator cell 
lines were identified (Figure 4.4A). 52 proteins from NOMO-1 cells, 22 proteins 
from U937 cells and 15 proteins from THP-1 cells were compared. Out of these, 
3 proteins were common to all non-translocator lines; α-catenin 1, α-catenin 2, 
and APC. This represents 6% of NOMO-1 cytoplasmic proteins, 14% of U937 
cytoplasmic proteins and 20% of THP-1 cytoplasmic proteins. 
Next, peptides present in the cytoplasmic fraction of both translocator lines were 
identified (Figure 4.4B). 45 peptides from K562 cells and 142 peptides from HEL 
cells were compared. Out of these, 24 peptides were present in both translocator 
cell lines. This represents 53% of K562 cytoplasmic proteins and 17% of HEL 
cytoplasmic proteins. 
Finally, the three non-translocator cytoplasmic proteins and the 24 translocator 
cytoplasmic proteins were compared (Figure 4.4C). No peptides were present in 
the cytoplasm of non-translocator lines and absent in the cytoplasm of 
translocator lines. This means that no candidate β-catenin nuclear export factors 
were identified in this project.  
                                            
13 http://bioinformatics.psb.ugent.be/webtools/Venn/ (accessed on 04/01/2018) 
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Figure 4.4. Identification of candidate nuclear β-catenin exporter proteins following 
removal of background binding partners. 
(A) Venn diagrams were created to compare proteins found in the cytoplasm of non-translocator 
cell lines. (B) Venn diagrams were created to compare proteins found in the cytoplasm of 
translocator cell lines. (C) The 3 proteins identified in the cytoplasm of all non-translocator cell 
lines and the 24 proteins identified in the cytoplasm of all translocator cell lines were compared. 
Abbreviation; IP= immunoprecipitation 
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To identify candidate β-catenin importers and nuclear retention factors, nuclear 
β-catenin binding partners were compared. This approach was based on the 
expected localization of nuclear importers to the nucleus of translocator cell lines 
only (Table 4.1). Owing to the absence of β-catenin in the nuclear fraction of non-
translocator lines, peptides present in the nucleus of translocator and non-
translocator cell lines could not be compared. Instead, peptides present in the β-
catenin co-immunoprecipitations of both translocator nuclear fractions were 
viewed as potential candidates. To investigate if the candidates were potential 
cytoplasmic-nuclear shuttling proteins (rather than retention factors) the 
localization of these peptides in the cytoplasm of translocator lines was 
compared. It would be expected that candidate cytoplasmic-nuclear shuttling 
proteins would be predominantly present in the cytoplasmic co-
immunoprecipitations, whereas nuclear retention factors would be predominately 
in the nucleus (Table 4.1). Comparisons of peptides between different cell lines 
and cell compartments were conducted using an online Venn diagram creator14. 
This produced Venn diagrams comparing peptide presence based on their 
accession numbers.   
Firstly, peptides present in the nuclear fraction of both translocator cell lines were 
identified (Figure 4.5A). 107 proteins from HEL (Table 4.2) cells and 53 proteins 
from K562 cells (Table 4.3)  were compared. Out of these, 27 proteins were 
present in both translocator cell lines (Table 4.4) and were identified as potential 
candidate β-catenin nuclear localization factors. 
Next, to identify which of these factors were potential cytoplasmic-nuclear 
shuttling proteins, these 27 proteins were compared to those present in the 
cytoplasmic fractions of translocator cell lines (Figure 4.5B). 7 peptides were 
present in the cytoplasmic and nuclear fractions of both cell lines and were 
potential cytoplasmic-nuclear shuttling factors. 11 peptides were present in the 
nucleus of both translocator cell lines and the cytoplasm of HEL cells only. Due 
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to the presence of nuclear contamination in the cytoplasmic fraction of HEL 
(Figure 4.2), for further analysis these proteins were taken as candidate nuclear 
retention factors, along with the 8 peptides present in the nucleus of both 
translocator cell lines only.  
In summary, 27 candidate β-catenin nuclear localization factors were identified, 
of which 7 were highlighted as potential cytoplasmic-nuclear shuttling proteins 
and 19 factors were identified as potential nuclear retention factors. 
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Figure 4.5. Identification of candidate nuclear β-catenin importers and retention factors, 
following removal of background binding partners. 
(A) Venn diagram comparing proteins found in the nucleus of translocator lines. (B) The 27 
proteins identified in (A) were compared to proteins present in the cytoplasm of translocator 
lines. The discrepancies in the total number of translocator nuclear proteins (27 in (A) and 26 in 
(B) are due to the removal of the α-catenin 2 protein from the list prior to analysis. This was 
done due to its detection in the cytoplasm of non-translocator cell lines in earlier analysis. 
Abbreviation; IP= immunoprecipitation..  
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Table 4.2. β-catenin binding partners in the HEL nuclear fraction prior analysis. 
A total of 107 proteins were present in the nuclear β-catenin IP and absent from the nuclear IgG 
control sample in HEL cells. These proteins are listed below and were used for the comparisons 
made in Figure 4.5. Proteins with HUGO gene names of N/A could not be found in the HUGO 
database based on their accession number or protein name. 
Accession 
number 
HUGO gene name 
(symbol)15 
Protein name 
P07437 Tubulin beta class I (TUBB) Tubulin beta chain  
P68371 Tubulin beta 4B class IVb 
(TUBB4B) 
Tubulin beta-4B chain 
P84095 Ras homolog family member 
G (RHOG) 
Rho-related GTP-binding protein RhoG 
Q59H57 N/A Fusion (Involved in t(12;16) in malignant 
liposarcoma) isoform a variant (Fragment) 
Q9BTQ7 N/A Similar to ribosomal protein L23 (Fragment) 
B2R6L0 N/A cDNA, FLJ93005, highly similar to Homo 
sapiens tubulin, beta polypeptide (TUBB), Mrna 
B3KQ75 N/A cDNA FLJ33018 fis, clone THYMU1000459, 
highly similar to Homo sapiens transcription 
factor 7 (T-cell specific, HMG-box) (TCF7), 
transcript variant 5, mRNA 
H0Y2W2 ATPase family, AAA domain 
containing 3A (ATAD3A) 
ATPase family AAA domain-containing protein 
3A (Fragment) 
Q9UJU2 Lymphoid enhancer binding 
factor 1 (LEF1) 
Lymphoid enhancer-binding factor 1 
Q2TAM6 Runt related transcription 
factor 1 (RUNX1) 
RUNX1 protein (Fragment) 
P42167 Thymopoietin (TMPO) Lamina-associated polypeptide 2, isoforms 
beta/gamma OS 
F5GXX5 Defender against cell death 1 
(DAD1) 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit DAD1 
Q96T67 ATPase family, AAA domain 
containing 3B (ATAD3B) 
TOB3 
E2GH18 Transcription factor 7 like 2 
(TCF7L2) 
T-cell factor-4 variant C 
P05141 Solute carrier family 25 
member 5 (SLC25A5) 
ADP/ATP translocase 2 
P12236 Solute carrier family 25 
member 6 (SLC25A6) 
ADP/ATP translocase 3 
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Accession 
number 
HUGO gene name 
(symbol)15 
Protein name 
O75955 Flotillin 1 (FLOT1) Flotillin-1 
P36402 Transcription factor 7 (TCF7) Transcription factor 7 
P25705 ATP synthase F1 subunit 
alpha (ATP5F1A) 
ATP synthase subunit alpha, mitochondrial 
O95167 NADH:ubiquinone 
oxidoreductase subunit A3 
(NDUFA3) 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 3 
B7Z597 N/A cDNA FLJ54373, highly similar to 60 kDa heat 
shock protein, mitochondrial 
O00161 Synaptosome associated 
protein 23 (SNAP23) 
Synaptosomal-associated protein 23 
B4E2V5  N/A cDNA FLJ52062, highly similar to Erythrocyte 
band 7 integral membrane protein 
P42166 Thymopoietin (TMPO) Lamina-associated polypeptide 2, isoform 
alpha 
C6ZRK5 Transcription factor 7 like 2 
(TCF7L2) 
TCF7L2 isoform pFC8A_TCF7L2_ex1-11-13-
14 
A0A0D9SGH8  Transcription factor 7 like 2 
(TCF7L2) 
Transcription factor 7-like 2 
O95298 NADH:ubiquinone 
oxidoreductase subunit C2 
(NDUFC2) 
NADH dehydrogenase [ubiquinone] 1 subunit 
C2 
Q8N3E6 N/A Putative uncharacterized protein 
DKFZp761L1023 (Fragment) 
Q9P0J0 NADH:ubiquinone 
oxidoreductase subunit A13 
(NDUFA13) 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 13 
B4DLA6 N/A cDNA FLJ54365, highly similar to DNA 
replication licensing factor MCM4 
B4DQY2 N/A cDNA FLJ59388, highly similar to Mitochondrial 
inner membrane protein 
Q96PK6 RNA binding motif protein 14 
(RBM14) 
RNA-binding protein 14 
A0A0C4DGS1 Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 
non-catalytic subunit 
(DDOST) 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit 
B4DKE6 N/A cDNA FLJ60629, highly similar to Replication 
factor C subunit 3 
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Accession 
number 
HUGO gene name 
(symbol)15 
Protein name 
Q5T2N8 ATPase family, AAA domain 
containing 3C (ATAD3C) 
ATPase family AAA domain-containing protein 
3C 
P17483 Homeobox B4 (HOXB4) Homeobox protein Hox-B4 
B4DDX2 N/A cDNA FLJ54590, highly similar to KH domain-
containing, RNA-binding, signaltransduction-
associated protein 1 
A0A0D9SFB3 DEAD-box helicase 3, X-
linked (DDX3X) 
ATP-dependent RNA helicase DDX3X 
P62140 Protein phosphatase 1 
catalytic subunit beta 
(PPP1CB) 
Serine/threonine-protein phosphatase PP1-
beta catalytic subunit 
Q14145 Kelch like ECH associated 
protein 1 (KEAP1) 
Kelch-like ECH-associated protein 1 
P17482 Homeobox B9 (HoxB9) Homeobox protein Hox-B9 
P20700 Lamin B1 (LMNB1) Lamin-B1 
P35249 Replication factor C subunit 4 
(RFC4) 
Replication factor C subunit 4 
B9A062 Methylenetetrahydrofolate 
dehydrogenase (NADP+ 
dependent) 2, 
methenyltetrahydrofolate 
cyclohydrolase (MTHFD2) 
Bifunctional methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase, mitochondrial 
P22695 Ubiquinol-cytochrome c 
reductase core protein 2 
(UQCRC2) 
Cytochrome b-c1 complex subunit 2, 
mitochondrial 
P35453 Homeobox D13 (HOXD13) Homeobox protein Hox-D13 
P78527 Protein kinase, DNA-
activated, catalytic 
polypeptide (PRKDC) 
DNA-dependent protein kinase catalytic subunit 
E9PQ56 Poly(U) binding splicing factor 
60 (PUF60) 
Poly(U)-binding-splicing factor PUF60 
(Fragment) 
P40939 Hydroxyacyl-CoA 
dehydrogenase trifunctional 
multienzyme complex subunit 
alpha (HADHA) 
Trifunctional enzyme subunit alpha, 
mitochondrial 
H3BQZ7 N/A HCG2044799 
A5PLK7 Regulator of chromosome 
condensation 2 (RCC2) 
RCC2 protein (Fragment) 
B4DU18 N/A cDNA FLJ51093, highly similar to Cadherin-5 
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Accession 
number 
HUGO gene name 
(symbol)15 
Protein name 
B2R8R5 N/A cDNA, FLJ94025, highly similar to Homo 
sapiens tripartite motif-containing 28 (TRIM28), 
mRNA 
Q9Y285 Phenylalanyl-tRNA 
synthetase alpha subunit 
(FARSA) 
Phenylalanine--tRNA ligase alpha subunit 
Q86YV0 Ras protein activator like 3 
(RASAL3) 
RAS protein activator like-3 
B7Z8L8 N/A cDNA FLJ50339, highly similar to A-kinase 
anchor protein 8 
B4DP70 N/A cDNA FLJ51017, highly similar to ATP-
dependent RNA helicase DDX1 (EC 3.6.1.-) 
(Fragment) 
O43707 Actinin alpha 4 (ACTN4) Alpha-actinin-4 
P24468 Nuclear receptor subfamily 2 
group F member 2 (NR2F2) 
COUP transcription factor 2 
B7WNQ9 GATA binding protein 1 
(GATA1) 
Erythroid transcription factor 
O15169 Axin 1 (AXIN1) Axin-1 
P43246 MutS homolog 2 (MSH2) DNA mismatch repair protein Msh2 
B3KUJ5 N/A Histone deacetylase 
B7Z9V0 N/A cDNA, FLJ78964, highly similar to Coronin-1C 
Q13422 IKAROS family zinc finger 1 
(IKZF1) 
DNA-binding protein Ikaros 
Q7Z518 N/A NADH dehydrogenase 
B4DGI9 Transcription factor 12 
(TCF12) 
Transcription factor 12 (Fragment) 
B4E0S6 N/A cDNA FLJ55635, highly similar to pre-mRNA-
splicing factorATP-dependent RNA helicase 
DHX15 (EC 3.6.1.-) 
B0I1T2 Myosin IG (MYO1G) Unconventional myosin-Ig 
Q13547 Histone deacetylase 1 
(HDAC1) 
Histone deacetylase 1 
B4DUD5 N/A cDNA FLJ58787, highly similar to Cleavage 
stimulation factor 64 kDa subunit 
Q08211 DExH-box helicase 9 (DHX9) ATP-dependent RNA helicase A 
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Accession 
number 
HUGO gene name 
(symbol)15 
Protein name 
B4DJ81 NADH:ubiquinone 
oxidoreductase core subunit 
S1 (NDUFS1) 
NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial 
Q5JTC6 APC membrane recruitment 
protein 1 (AMER1) 
APC membrane recruitment protein 1 
H3BT57 Promyelocytic leukemia 
(PML) 
Protein PML 
V9P4H4 N/A Magi1d 
D3DV75 Adenosine deaminase, RNA-
specific (ADAR) 
Adenosine deaminase, RNA-specific, isoform 
CRA_b 
B2RBM8  N/A cDNA, FLJ95596, highly similar to Homo 
sapiens activity-dependent neuroprotector 
(ADNP), mRNA 
B0AZS5 N/A Kinesin-like protein 
O75475 PC4 and SFRS1 interacting 
protein 1 (PSIP1) 
PC4 and SFRS1-interacting protein 
B3KM90 N/A cDNA FLJ10529 fis, clone NT2RP2000965, 
highly similar to Targeting protein for Xklp2 
B7Z2Z1 N/A cDNA FLJ59523, highly similar to Scaffold 
attachment factor B 
Q92878 RAD50 double strand break 
repair protein (RAD50) 
DNA repair protein RAD50 
Q92621 Nucleoporin 205 (NUP205) Nuclear pore complex protein Nup205 
Q4FD37 Zinc finger protein 148 
(ZNF148) 
ZBP-89 delta-Nter isoform 
B0AZQ4 N/A Structural maintenance of chromosomes 
protein 
O75326 Semaphorin 7A (John Milton 
Hagen blood group) 
(SEMA7A) 
Semaphorin-7A 
Q9Y2X9 Zinc finger protein 281 
(ZNF281) 
Zinc finger protein 281 
P98175 RNA binding motif protein 10 
(RBM10) 
RNA-binding protein 10 
Q14151 Scaffold attachment factor B2 
(SAFB2) 
Scaffold attachment factor B2 
O00308 WW domain containing E3 
ubiquitin protein ligase 2 
(WWP2) 
NEDD4-like E3 ubiquitin-protein ligase WWP2 
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Accession 
number 
HUGO gene name 
(symbol)15 
Protein name 
A0A0G2JMS7 Scribbled planar cell polarity 
protein (SCRIB) 
Protein scribble homolog 
B4DF22 N/A cDNA FLJ55615, highly similar to SWI/SNF-
related matrix-associatedactin-dependent 
regulator of chromatin subfamily C member 2 
P35580 
 
Myosin heavy chain 10 
(MYH10) 
Myosin-10 
Q9UBW7 Zinc finger MYM-type 
containing 2 (ZMYM2) 
Zinc finger MYM-type protein 2 
O14776 Transcription elongation 
regulator 1 (TCERG1) 
Transcription elongation regulator 1 
Q15149 Plectin (PLEC) Plectin 
A0A024QZW7 Nucleoporin 153 (NUP153) Nucleoporin 153kDa, isoform CRA_a 
O75533 Splicing factor 3b subunit 1 
(SF3B1) 
Splicing factor 3B subunit 1 
X5D2J9 General transcription factor Iii 
(GTF2I) 
General transcription factor IIi isoform D 
(Fragment) 
Q9C0D5 Tetratricopeptide repeat, 
ankyrin repeat and coiled-coil 
containing 1 (TANC1) 
Protein TANC1 
G8JLG1 Structural maintenance of 
chromosomes 1A (SMC1A) 
Structural maintenance of chromosomes 
protein 
D3DR32 Kinesin family member 20B 
(KIF20B) 
Kinesin-like protein 
P49792 RAN binding protein 2 
(RANBP2) 
E3 SUMO-protein ligase RanBP2 
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Table 4.3. β-catenin binding partners in the K562 nuclear fraction prior to analysis. 
A total of 53 proteins were present in the nuclear β-catenin IP and absent from the nuclear IgG 
control sample in K562 cells. These proteins are listed below and were used for the 
comparisons made in Figure 4.5. Proteins with HUGO gene names of N/A could not be found in 
the HUGO database based on their accession number or protein name. 
Accession 
number 
HUGO gene name 
(symbol)16 
Protein name 
P62249 Ribosomal protein S16 
(RPS16) 
40S ribosomal protein S16 
P39019 Ribosomal protein S19 
(RPS19) 
40S ribosomal protein S19 
P19474 Tripartite motif containing 21 
(TRIM21) 
E3 ubiquitin-protein ligase TRIM21 
B7Z4V2 N/A cDNA FLJ51907, highly similar to Stress-70 
protein, mitochondrial 
Q59H57 N/A Fusion (Involved in t(12;16) in malignant 
liposarcoma) isoform a variant (Fragment) 
P35232 Prohibitin (PHB) Prohibitin 
P50402 Emerin (EMD) Emerin 
F5GY37 Prohibitin 2 (PHB2) Prohibitin-2 
Q01196 Runt related transcription 
factor 1 (RUNX1) 
Runt-related transcription factor 1 
B3KQ75 N/A cDNA FLJ33018 fis, clone THYMU1000459, 
highly similar to Homo sapiens transcription 
factor 7 (T-cell specific, HMG-box) (TCF7), 
transcript variant 5, mRNA 
H0Y2W2 ATPase family, AAA domain 
containing 3A (ATAD3A) 
ATPase family AAA domain-containing 
protein 3A (Fragment) 
Q9UJU2 Lymphoid enhancer binding 
factor 1 (LEF1) 
Lymphoid enhancer-binding factor 1 
Q2TAM6 Runt related transcription 
factor 1 (RUNX1) 
RUNX1 protein (Fragment) 
Q96T67 ATPase family, AAA domain 
containing 3B (ATAD3B) 
TOB3 
E2GH18 Transcription factor 7 like 2 
(TCF7L2) 
T-cell factor-4 variant C 
P12236 Solute carrier family 25 
member 6 (SLC25A6) 
ADP/ATP translocase 3 
P36402 Transcription factor 7 (TCF7) Transcription factor 7 
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Accession 
number 
HUGO gene name 
(symbol)16 
Protein name 
Q96AG4 Leucine rich repeat containing 
59 (LRRC59) 
Leucine-rich repeat-containing protein 59 
B7Z597  N/A cDNA FLJ54373, highly similar to 60 kDa 
heat shock protein, mitochondrial 
Q92841 DEAD-box helicase 17 
(DDX17) 
Probable ATP-dependent RNA helicase 
DDX17 
Q9UPN1 Protein phosphatase 1 
catalytic subunit gamma 
(PPP1CC) 
Serine/threonine-protein phosphatase 
(Fragment) 
Q4ZG57 Minichromosome 
maintenance complex 
component 6 (MCM6) 
Putative uncharacterized protein MCM6 
(Fragment) 
C6ZRK5 Transcription factor 7 like 2 
(TCF7L2) 
TCF7L2 isoform pFC8A_TCF7L2_ex1-11-13-
14 
A0A0D9SGH8 Transcription factor 7 like 2 
(TCF7L2) 
Transcription factor 7-like 2 
M0QXS5 Heterogeneous nuclear 
ribonucleoprotein L 
(HNRNPL) 
Heterogeneous nuclear ribonucleoprotein L 
(Fragment) 
B4DN41 N/A cDNA FLJ53366, highly similar to Probable 
ATP-dependent RNA helicase DDX5 (EC 
3.6.1.-) 
Q96BA7 N/A HNRPU protein 
Q8N3E6 N/A Putative uncharacterized protein 
DKFZp761L1023 (Fragment) 
P55084 Hydroxyacyl-CoA 
dehydrogenase trifunctional 
multienzyme complex subunit 
beta (HADHB) 
Trifunctional enzyme subunit beta, 
mitochondrial 
B2R659 N/A cDNA, FLJ92803, highly similar to Homo 
sapiens hydroxysteroid (17-beta) 
dehydrogenase 4 (HSD17B4), mRNA 
B4DLA6 N/A cDNA FLJ54365, highly similar to DNA 
replication licensing factor MCM4 
B4DQY2 N/A cDNA FLJ59388, highly similar to 
Mitochondrial inner membrane protein 
M0QZM1 Heterogeneous nuclear 
ribonucleoprotein M 
(HNRNPM) 
Heterogeneous nuclear ribonucleoprotein M 
(Fragment) 
Q96PK6 RNA binding motif protein 14 
(RBM14) 
RNA-binding protein 14 
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Accession 
number 
HUGO gene name 
(symbol)16 
Protein name 
A0A024QZP7 Cyclin dependent kinase 1 
(CDK1) 
Cell division cycle 2, G1 to S and G2 to M, 
isoform CRA_a 
Q5T2N8 ATPase family, AAA domain 
containing 3C (ATAD3C) 
ATPase family AAA domain-containing 
protein 3C 
P42357 Histidine ammonia-lyase 
(HAL) 
Histidine ammonia-lyase 
B4DDX2 N/A cDNA FLJ54590, highly similar to KH domain-
containing, RNA-binding, signaltransduction-
associated protein 1 
P62140 Protein phosphatase 1 
catalytic subunit beta 
(PPP1CB) 
Serine/threonine-protein phosphatase PP1-
beta catalytic subunit 
A0A087WTP3 KH-type splicing regulatory 
protein (KHSRP) 
Far upstream element-binding protein 2 
P35249 Replication factor C subunit 4 
(RFC4) 
Replication factor C subunit 4 
B4E0E1 N/A cDNA FLJ53442, highly similar to Poly (ADP-
ribose) polymerase 1 (EC 2.4.2.30) 
P78527 Protein kinase, DNA-
activated, catalytic 
polypeptide (PRKDC) 
DNA-dependent protein kinase catalytic 
subunit 
Q8NBX0 Saccharopine dehydrogenase 
(putative) (SCCPDH) 
Saccharopine dehydrogenase-like 
oxidoreductase 
Q6NUK7 LYN proto-oncogene, Src 
family tyrosine kinase (LYN) 
Non-specific protein-tyrosine kinase 
(Fragment) 
O15169 Axin 1 (AXIN1) Axin-1 
A0A024R5M9 Nuclear mitotic apparatus 
protein 1 (NUMA1) 
Nuclear mitotic apparatus protein 1, isoform 
CRA_a 
P23490 Loricrin (LOR) Loricrin 
Q92621 Nucleoporin 205 (NUP205) Nuclear pore complex protein Nup205 
O00308 WW domain containing E3 
ubiquitin protein ligase 2 
(WWP2) 
NEDD4-like E3 ubiquitin-protein ligase WWP2 
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Following the identification of potential candidates, these data were further 
refined by removing proteins based on certain criteria, as outlined in Table 4.4. 
Two proteins were removed as they were suspected to be present because of 
mitochondrial contamination, rather than nuclear proteins. These were the well 
characterized mitochondrial proteins ATPase family AAA domain-containing 
protein 3C and ADP/ATP translocase 3. Six candidates were removed because 
they were only evident at the transcript level (cDNA) or had only been 
experimentally verified at a transcript level17 and three proteins were removed 
because they were present in non-translocator cytoplasmic fractions. 
Next, proteins present in more than two IgG co-immunoprecipitates were 
removed from the candidate list. Their presence in the IgG samples suggests 
they bind to IgG non-specifically (rather than being a specific β-catenin binding 
partner). Proteins present in more than two IgG samples were chosen as the cut-
off point resulting in the removal of three candidates.  
The remaining proteins were organised into a final candidate list (Table 4.5) 
consisting of 12 proteins. It is important to point out that some of these candidate 
factors (DNA-dependent protein kinase, TCF7 and TCF7L2 (TCF-4)) were 
detected in the cytoplasmic fraction of one of the non-translocator cell lines with 
a peptide score of >2, however they were included in the candidate list for specific 
reasons, as outlined in Table 4.6. Briefly, DNA-dependent protein kinase was 
included in the list because in the cell line in which it was detected, it was also 
detected in the IgG lane.  TCF7L2 and TCF7 were included in the list because of 
their identification as candidate nuclear localization factors in other contexts 
(4.4.2). 
Candidate proteins with commercially available antibodies and of functional 
relevance (had already been identified as potential β-catenin nuclear localization 
factors; Table 1.10) were chosen for validation. Due to time constraints, not all 
the proteins could be validated. 
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Table 4.4. Filtering of candidate β-catenin nuclear localization factors. 
Proteins were filtered out based on the following properties: green; present in non-translocator 
(NT) cytoplasmic IPs, grey; probable mitochondrial contamination, peach; only evident at 
transcript level, blue; present in >2 IgG samples. The reason that only 24 proteins are included 
in this list (rather than the 27 identified in Figure 4.5) is because α-catenin 1, α-catenin 2 and 
APC were removed, owing to their presence in the cytoplasm of non-translocator cell fractions 
as well. Proteins with HUGO gene names of N/A could not be found in the HUGO database 
based on their accession number or protein name. 
Accession 
number 
HUGO gene name 
(symbol)18 Candidate protein 
name 
 
Potential 
Mechanism 
O00308 
WW domain 
containing E3 
ubiquitin protein 
ligase 2 (WWP2) 
NEDD4-like E3 
ubiquitin-protein 
ligase WWP2 
Nuclear retention 
B4DDX2 
N/A cDNA FLJ54590, 
highly similar to KH 
domain-containing, 
RNA-binding, 
signaltransduction-
associated protein 1 
Nuclear retention 
P35249 
Replication factor C 
subunit 4 (RFC4) 
Replication factor C 
subunit 4 
Nuclear retention 
O15169 Axin1 (AXIN1) Axin-1 Nuclear retention 
P36402 
Transcription factor 7 
(TCF7) 
Transcription factor 7 
Nuclear retention 
A0A0D9SGH8 
Transcription factor 7 
like 2 (TCF7L2) 
Transcription factor 7-
like 2 
Nuclear retention 
Q92621 
Nucleoporin 205 
(NUP205) 
Nuclear pore complex 
protein Nup205 
Nuclear retention 
B3KQ75 
N/A cDNA FLJ33018 fis, 
clone 
THYMU1000459, 
highly similar to 
Homo sapiens 
transcription factor 7 
(T-cell specific, HMG-
box) (TCF7), 
transcript variant 5, 
mRNA 
Nuclear retention 
Q96T67 
ATPase family, AAA 
domain containing 3B 
(ATAD3B) 
TOB3 
Cytoplasmic/nuclear 
shuttling 
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Accession 
number 
HUGO gene name 
(symbol)18 Candidate protein 
name 
 
Potential 
Mechanism 
H0Y2W2 
ATPase family, AAA 
domain containing 3A 
(ATAD3A) 
ATPase family AAA 
domain-containing 
protein 3A 
Cytoplasmic/nuclear 
shuttling 
Q59H57 
N/A Fusion (Involved in 
t(12;16) in malignant 
liposarcoma) isoform 
a variant 
Cytoplasmic/nuclear 
shuttling 
Q9UJU2 
Lymphoid enhancer 
binding factor 1 
(LEF1) 
Lymphoid enhancer-
binding factor 1 
Cytoplasmic/nuclear 
shuttling 
Q2TAM6 
Runt related 
transcription factor 1 
(RUNX1) 
RUNX1 protein 
Cytoplasmic/nuclear 
shuttling 
P78527 
Protein kinase, DNA-
activated, catalytic 
polypeptide (PRKDC) 
DNA-dependent 
protein kinase 
catalytic subunit 
Cytoplasmic/nuclear 
shuttling 
Q96PK6 
RNA binding motif 
protein 14 (RBM14) 
RNA-binding protein 
14 
Cytoplasmic/nuclear 
shuttling 
Q5T2N8 
ATPase family, AAA 
domain containing 3C 
(ATAD3C) 
ATPase family AAA 
domain-containing 
protein 3C 
Nuclear retention  
Q8N3E6 
N/A Putative 
uncharacterized 
protein 
DKFZp761L1023 
Nuclear retention  
B4DQY2 
N/A cDNA FLJ59388, 
highly similar to 
Mitochondrial inner 
membrane protein 
Nuclear retention  
P62140 
Protein phosphatase 
1 catalytic subunit 
beta (PPP1CB) 
Serine/threonine-
protein phosphatase 
PP1-beta catalytic 
subunit 
Nuclear retention 
B7Z597 
N/A cDNA FLJ54373, 
highly similar to 60 
kDa heat shock 
protein, mitochondrial 
Nuclear retention  
B4DLA6 
N/A cDNA FLJ54365, 
highly similar to DNA 
replication licensing 
factor MCM4 
Nuclear retention  
E2GH18 
Transcription factor 7 
like 2 (TCF7L2) 
T-cell factor-4 variant 
C 
Nuclear retention  
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Accession 
number 
HUGO gene name 
(symbol)18 Candidate protein 
name 
 
Potential 
Mechanism 
C6ZRK5 
Transcription factor 7 
like 2 (TCF7L2) 
TCF7L2 isoform 
pFC8A_TCF7L2_ex1-
11-13-14 
Nuclear retention  
P12236 
Solute carrier family 
25 member 6 
(SLC25A6) 
ADP/ATP translocase 
3 
Nuclear retention  
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Table 4.5. Final candidate list. 
Following filtering of candidate nuclear localization factors (4.3.5) a final candidate list was 
produced. 
Accession 
number 
HUGO gene 
name (symbol)19 
Candidate 
protein name 
Role 
Potential 
mechanism 
O15169 
 
Axin1 (AXIN1) Axin-1 
Part of the 
Canonical Wnt 
Pathway catenin 
degradation 
complex. 
Nuclear 
retention 
P36402 
Transcription factor 
7 (TCF7) 
Transcription 
factor 7 
Canonical Wnt 
Pathway 
component that is 
a co-activator of 
Wnt target genes. 
Nuclear 
retention 
A0A0D9SGH8 
Transcription factor 
7 like 2 (TCF7L2) 
Transcription 
factor 7-like 2 
(TCF-4) 
 
Nuclear 
retention 
P78527 
Protein kinase, 
DNA-activated, 
catalytic 
polypeptide 
(PRKDC) 
DNA-dependent 
protein kinase 
catalytic subunit 
Ser/thr kinase 
involved in 
sensing DNA 
damage 
Nuclear 
retention  
Q96PK6 
RNA binding motif 
protein 14 
(RBM14) 
RNA-binding 
protein 14 
Ribonucleoprotein. 
General nuclear 
co-activator. 
Nuclear 
retention  
P62140 
Protein 
phosphatase 1 
catalytic subunit 
beta (PPP1CB) 
Serine/threonine-
protein 
phosphatase 
PP1-beta 
catalytic subunit 
 
Nuclear 
retention  
Q2TAM6 
 
Runt related 
transcription factor 
1 (RUNX1) 
RUNX1 protein 
Transcription 
factor involved in 
regulating 
haematopoiesis. 
Aberrations in 
RUNX1 are 
involved in 
leukaemia. 
Nuclear 
retention 
Q9UJU2 
Lymphoid 
enhancer binding 
factor 1 (LEF1) 
Lymphoid 
enhancer-
binding factor 1 
Canonical Wnt 
Pathway 
component that is 
a co-activator of 
Wnt target genes. 
 
Cytoplasmic-
nuclear 
shuttling 
                                            
19 https://www.genenames.org/ (accessed on 26/03/2018) 
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Table 4.6 Reasons for keeping specific proteins in the candidate list 
Candidate name Reason 
DNA-dependent protein 
kinase 
The non-translocator cell line in which this protein was detected 
also contained it in the IgG control lane, so this could be due to 
non-specific binding in this cell line meaning that it could be falsely 
excluded by this criterion. Therefore, this protein was kept in the 
candidate list 
TCF7 
This has relevance to β-catenin mediated transcription and 
possibly to β-catenin nuclear localization in other contexts 
(4.4.2.2). Although this protein was detected in the cytoplasm of 
one of the non-translocator cell lines, the lack of data for the 
nuclear fractions of non-translocator cell lines meant that this 
factor could not be completely ruled out as a candidate β-catenin 
nuclear localization factor in this context. 
TCF7L2 (TCF-4) This was kept in the candidate list for the same reasons as TCF7. 
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Following the establishment of a final candidate list, their expression and 
subcellular localization needed validating to verify their potential role as β-catenin 
nuclear localization factors. To do this, leukaemia cell lines were fractionated and 
western blotting was used to verify that the localization of candidate proteins was 
consistent with the MS results (Chapter 0). Axin-1, TCF7, LEF-1 and RUNX1 
were all chosen for analysis based on the criteria above (4.3.5). The reasons for 
selecting these factors and not others for western blotting is discussed further in 
4.4.  
Axin-1 could not be verified as no signal was detected following western blotting 
(data not shown). Figure 4.6 shows the results of the western blots for the other 
candidate factors. Firstly, translocator and non-translocator cell lines were 
immunoblotted with TCF7 antibody (Table 2.5). Three bands were visible in the 
nuclear fraction of K562 cells at approximately 43-51kDa, corresponding to the 
expected band for full length TCF7. This was not visible in HEL cells or non-
translocator cell lines. This contrasted with the MS results, in which TCF7 was 
distributed in the nucleus of both translocator cell lines. This may be because the 
peptide count for HEL cells was lower than K562 cells and/or because of 
differences in sensitivity between the two techniques. This suggests that TCF7 
could be a potential candidate regulating the nuclear localization of β-catenin 
(based on the MS results) but the levels on TCF7 in HEL cells were undetectable 
by western blot and hence TCF7 could not be validated. 
Next, leukaemia cell lines were immunoblotted with LEF-1 and RUNX1 
antibodies. In both translocator cell line nuclear fractions, bands were visible at 
~50kDa upon blotting with both antibodies, corresponding to the expected bands 
for LEF-1 and RUNX1. A weak signal was observed in the nuclear fractions of 
non-translocator cell lines when blotted with RUNX1 antibody. This may correlate 
with β-catenin localization in these cells, as although they are classed as non-
translocator cell lines, a low level of β-catenin does localize to the nucleus in 
these cells (Appendix 1). No LEF-1 signal was detected in the nucleus of non-
translocator cell lines. The localization of LEF-1 and RUNX1 in these cell lines 
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corresponds to the expected localization of a potential β-catenin nuclear import 
factor (Table 4.1), suggesting LEF-1 and RUNX1 could be potential candidates.  
To summarize, Axin-1 could not be verified as a potential β-catenin nuclear 
localization factor. The localization of TCF7 was inconsistent with the results of 
the MS analysis and could not be fully verified as a potential β-catenin nuclear 
localization factor. The localization of LEF-1 and RUNX1 was consistent with the 
MS results (absent in the cytoplasm of all cell lines, present in the nucleus of 
translocator cell lines and absent in the nucleus of non-translocator cell lines) and 
corresponded to that of potential nuclear β-catenin localization factors.  
 
 
 
 
 
 
 
  
Figure 4.6. Validation of candidate factors by Western blotting in leukaemia cell lines. 
Western blots of translocator (left) and non-translocator (right) cells following 
cytoplasmic/nuclear fractionation. Antibodies for the candidate β-catenin nuclear localization 
factors TCF7, LEF-1 and RUNX1 were used (Table 2.5). Abbreviations; C= cytoplasmic fraction 
N= nuclear fraction, IB= immunoblot, Ab= antibody, MW= molecular weight, kDa= kilodalton. 
Marker= MagicMark XP (Thermo Fisher). 
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Nuclear localization of β-catenin is fundamental for its role as a transcription 
factor. Despite this, little is known about the mechanisms regulating this process 
in AML; previous work has shown AML blasts and cell lines are highly variable in 
their ability to translocate β-catenin from the cytosol to the nucleus (Morgan et al, 
2014). The aim of the experiments presented in this chapter was to analyse the 
data generated from the MS approach outlined in (Figure 4.1) to identify 
candidate β-catenin nuclear localization factors in AML. This section discusses 
aspects of the experimental techniques used, as well as the factors that were 
identified as candidate β-catenin nuclear localization factors in AML. 
 
 
One concern regarding the MS experiment was the quality of the samples, 
particularly with regards to the presence of proteins in the IgG control samples. 
Each of the samples had a high number of proteins in the IgG control lane. To 
calculate the extent of the problem, the number of proteins detected in the IgG 
lane for each sample was calculated as a percentage of the total number of 
proteins in each sample. The percentage of proteins detected in the IgG lanes 
was 72.5% in the K562 cytoplasmic fraction, 53.7% in the HEL cytoplasmic 
fraction, 76.2% in the THP-1 cytoplasmic fraction, 71.9% in the NOMO-1 
cytoplasmic fraction, 85.5% in the U937 cytoplasmic fraction, 79.5% in the K562 
nuclear fraction and 73.8% in the HEL nuclear fraction. Unfortunately, this high 
degree of IgG protein binding could not be detected prior to running the MS 
analysis, although steps were taken throughout the sample preparation to reduce 
the amount of background binding (Chapter 3). Briefly, a monoclonal antibody 
was used in the immunoprecipitation, a preclearing step was used to remove 
proteins that bound to IgG control antibody/beads from the cell fractions, the bead 
complex was washed thoroughly, and a fresh tube was used for elution (Moser 
et al, 2009). Benzonase was included in the nuclear buffer to break down DNA 
and prevent the sticking of DNA and DNA bound proteins to the beads in nuclear 
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fractions (Benedik & Strych, 1998; Liao et al, 2007). In addition, gloves were 
always worn and the workspace was kept as clean as possible whilst the samples 
were prepared to limit the amount of keratin contamination (Hodge et al, 2013). 
Finally, Sypro staining was used to detect bands present in the IgG control and 
immunoprecipitation samples (data not shown) (Chevalier, 2010). The Sypro 
stain did not detect the large number of bands that were observed in the MS of 
IgG samples.  
Perhaps the detergent used in this experiment was the reason so many 
background binding proteins were present. To maintain protein-protein 
interactions between β-catenin and its binding partners, a mild detergent, 
CHAPS, was used for cytoplasmic/nuclear fractionation and in the 
immunoprecipitation buffer. As a trade-off for maintaining β-catenin interaction 
partner binding, it could also have made the immunoprecipitation washes less 
effective, with less disruption of non-specific weakly bound proteins (Huang & 
Kim, 2013). 
 
Following on from the previous section, another troubling issue was the presence 
of β-catenin in the IgG control lanes of each sample, with peptide scores in the 
range of 1-5. This may be due to some of the reasons outlined in the section 
above, and was problematic for data analysis. It was necessary to remove 
proteins present in the IgG lanes as part of the data analysis approach (Figure 
4.3). As a result, additional candidate factors may have been removed as part of 
the filtering process, if they were present in the IgG samples because of their co-
localization with β-catenin. This could not be avoided, however, because it was 
necessary to remove the proteins in the IgG samples to remove background 
binding proteins. It is likely that the results of this experiment have been 
particularly biased towards proteins that bind strongly to β-catenin and that are 
expressed at higher levels, with proteins that bind more weakly and/or have a 
lower expression being missed.  
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Eight candidate β-catenin nuclear localization factors were identified (Table 4.5) 
in this project using β-catenin immunoprecipitation and MS analysis of β-catenin 
interaction partners.  Each of these candidates are discussed in more detail 
below. 
 
Axin-1 is a component of the canonical Wnt pathway catenin degradation 
complex that has a well-established role in regulating the stability of cytoplasmic 
β-catenin (1.3.1.1) and mutations in Axin-1 have been observed in solid tumours 
(Mazzoni & Fearon, 2014). 
In this project, Axin-1 was identified as a candidate β-catenin nuclear retention 
factor. This contrasts with other studies in which Axin-1 has been identified as a 
β-catenin nuclear export factor. In HEK293 cells, overexpression of Axin-1 
promoted a shift in β-catenin from the nucleus to the cytoplasm (Cong & Varmus, 
2004). In this study, nuclear import and nuclear export signals (NLS and NES) 
were identified in Axin-1, and the results of this study suggested that Axin-1 
functions as a nuclear-cytoplasmic β-catenin shuttling protein. In another study, 
Axin-1 expression in HEK293T cells promoted the cytoplasmic localization of β-
catenin, however, the proposed mechanism was by cytoplasmic retention. This 
was because expressing Axin-1 did not increase the speed of β-catenin transport 
across the nuclear membrane (Krieghoff et al, 2006).  
Since Axin-1 has been identified as a β-catenin nuclear export protein, the 
observation that Axin-1 may be a β-catenin nuclear localization factor in 
leukaemia cell lines was unexpected, but given the lack of data for the nuclear 
fractions of non-translocator cells and the fact that Axin-1 localization could not 
be validated by western blotting, the most that can be stated is that Axin-1 is a 
nuclear β-catenin binding partner in the translocator cell lines studied. Further 
studies would be necessary to determine if it acts as a nuclear β-catenin 
localization factor in this context. 
Chapter 4: Identification of candidate factors regulating the nuclear localization 
of β-catenin by MS 
 
Page | 137  
 
The reasons for the ineffective detection of Axin-1 by western blots could be 
because of its size and/or low protein expression levels. Axin-1 is a large protein 
with a molecular weight of 110kDa. Larger proteins can sometimes be difficult to 
detect by western blotting because they transfer less efficiently from the SDS-
PAGE gel to the membrane. If Axin-1 protein levels are also low in these cells, 
this could explain why it was difficult to detect it by western blotting. Axin-1 mRNA 
levels in these cell lines are not low20, however, it could be that protein levels do 
not correlate with mRNA levels in these cells. In other studies, the success of 
Axin-1 detection by western blotting is variable depending on the context. While 
Axin-1 can be detected easily in some contexts, for example, platelets and breast 
cancer cells (MDA-MB-231 and MCF-7 cells), in others e.g. HEK293T cells, 
although detection was successful, only a very faint band was observed using the 
same antibody (Arnold et al, 2009; Bao et al, 2012; Steele et al, 2009). If more 
time had been available, I would have attempted to detect Axin-1 by 
immunoprecipitation in my cells.  
 
TCF7 (also known as TCF-1) is a member of the TCF family of transcription 
factors with well-established roles in regulating β-catenin mediated transcription 
(1.3), and it has recently been shown to promote the self-renewal and survival of 
LSCs, maintaining the LSC in the bone marrow and propagating disease (Yu et 
al, 2016).  
In this study, TCF7 was identified by MS as a candidate β-catenin nuclear 
retention protein, which agrees with the observations made by Molenaar, 1996. 
Injection of the Xenopus TCF7 homologue (XTcf-3) into Xenopus embryos led to 
translocation of β-catenin from the cytoplasm and plasma membrane to the 
nucleus (Molenaar et al, 1996). 
The results of western blotting of translocator and non-translocator cell line 
fractions with TCF7 antibody (Figure 4.6) contrasted with the results of the MS 
analysis. In the western blots, TCF7 was only detected in the nucleus of K562 
cells, whereas using MS it was detected in the nucleus of both translocator cells. 
                                            
20 https://www.proteinatlas.org/ENSG00000103126-AXIN1/cell (accessed on 04/01/2018) 
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As mentioned previously, this could be due to the differences in sensitivity of the 
two techniques, but could also be due to differences in the level of TCF7 in these 
cell lines.  The levels of TCF7 mRNA expression are low in K562 cells, but not 
detected in HEL cells21. This could indicate that protein levels might also be very 
low in HEL cells, which would explain the results of the western blot. Due to the 
inconsistencies between the MS and western blotting, no further analysis of this 
protein was conducted.  
 
TCF7L2 (also known as TCF-4) is a member of the TCF family of transcription 
factors with well-established roles in regulating β-catenin mediated transcription 
(1.3). TCF7L2 is also dysregulated in AML; microarray analysis of AML blasts 
from 223 patients identified TCF7L2 as the most significantly dysregulated Wnt 
factor in this patient cohort, with overexpression of TCF7L2 mRNA being 
observed in 78% of samples (Daud, 2014).  
In this project, TCF7L2 was identified as a potential β-catenin nuclear retention 
factor in leukaemia cell lines. This agrees with other studies that have identified 
TCF7L2 as a β-catenin nuclear localization factor. Expression of TCF7L2 in MCF-
7 (breast cancer) cells with low levels of TCF proteins led to the nuclear 
localization of β-catenin (Jamieson et al, 2016). In another study, overexpression 
of TCF7L2 in HEK293T cells localized β-catenin to the nucleus, and the authors 
proposed that it was acting as a nuclear retention factor. This was based on the 
observation that TCF7L2 overexpression slowed down β-catenin transport across 
the nuclear membrane, rather than speeding it up (Krieghoff et al, 2006).  
Another study looking at the correlation of nuclear β-catenin and nuclear TCF7L2 
in lung cancer brain metastases, suggests that TCF7L2 does not regulate the 
nuclear localization of β-catenin (Bleckmann et al, 2013). In this study, TCF7L2 
was detected in the nucleus of 100% of the samples used, whereas nuclear β-
catenin was only detected in 36% of samples. It is difficult to draw conclusions 
from this observation because no functional analysis was conducted (e.g. 
knockdown or overexpression studies). It could be that specific post translational 
                                            
21 https://www.proteinatlas.org/ENSG00000081059-TCF7/cell (accessed on 04/01/2018) 
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modifications and/or interaction partners are necessary for TCF7L2 mediated 
nuclear localization of β-catenin, and the factors responsible for this are not 
present in this context. Alternatively, TCF7L2 may regulate β-catenin nuclear 
localization, but another factor may be present that more efficiently exports β-
catenin out of the nucleus in the cells in which nuclear β-catenin was not detected. 
Although TCF7L2 was identified as a candidate nuclear β-catenin localization 
factor by my MS approach, it was not validated by western blotting because 
previous studies in our laboratory have found that the localization of TCF7L2 and 
β-catenin does not correlate in these lines, suggesting that it might not regulate 
β-catenin nuclear localization in this context (Appendix 2). 
 
DNA dependent protein kinase (DNA-PK) is a serine/threonine protein kinase that 
plays a role in DNA repair, mitosis, chromatin remodelling and telomere 
maintenance (Smith & Jackson, 1999). In this project, DNA-PK was identified as 
a candidate β-catenin nuclear retention factor. Interestingly, a previous study 
using LEF-1 immunoprecipitation and MS analysis in adenocarcinoma cell lines 
(SW480 and HT29) identified DNA-PK as a candidate LEF-1 interaction partner. 
Co-immunoprecipitation and immunohistochemistry were used to validate the 
binding of LEF-1 and DNA-PK and colocalization of LEF-1 and DNA-PK in the 
nucleus of these cells (Shimomura et al, 2013). It is possible that although we 
have proposed DNA-PK as a β-catenin interaction partner in this project, it may 
in fact bind indirectly via LEF-1. If this is the case, it could be that DNA-PKs 
localization in the nucleus of translocator lines does not mediate the nuclear 
localization of β-catenin, but is due to its co-localization with LEF-1 (see below).  
An interesting hypothesis is that DNA-PK could regulate LEF-1 mediated β-
catenin nuclear localization. Since LEF-1 has also been identified as a candidate 
nuclear β-catenin localization factor and DNA-PK has been implicated in the 
regulation of nuclear import of other proteins by phosphorylation of residues close 
to their NLS (Xiao et al, 1997), perhaps DNA-PK could regulate the nuclear 
localization of β-catenin by interacting with LEF-1, phosphorylating its NLS and 
promoting LEF-1 mediated β-catenin nuclear localization. This might explain the 
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inefficient nuclear localization of LEF-1 in non-translocator cell lines in which LEF-
1 was overexpressed (Chapter 5). 
This protein was not chosen as a factor for western blotting to validate its 
localization, since most of the other factors identified were established β-catenin 
binding partners and had already been implicated in the nuclear localization of β-
catenin in other contexts and/or had been implicated in AML. As such they were 
favoured for further analysis and due to the time constraints of the project not all 
the factors could be analysed.  
Given the lack of data for the nuclear fractions of non-translocator cells and the 
fact that DNA-PK localization was not validated by western blotting, the most that 
can be stated is that DNA-PK is a nuclear β-catenin binding partner in the 
translocator cell lines studied. Further studies would be necessary to determine 
if it acts as a nuclear β-catenin localization factor in this context. 
 
RNA-binding protein 14, also known as co-activator activator (CoAA) is a general 
nuclear transcriptional regulator. In this study it was identified as a candidate β-
catenin nuclear retention factor. To my knowledge, it has not been identified 
previously as a β-catenin interaction partner. Interestingly, RNA-binding protein 
14 has been demonstrated to bind to the runt domain of RUNX proteins (4.4.2.7) 
(Li et al, 2009), which could suggest that it binds indirectly to β-catenin via its 
interaction with RUNX1.  
This protein was not chosen as a factor for western blotting to validate its 
localization in leukaemia cell lines, since most of the other factors identified were 
established β-catenin binding partners and had already been implicated in the 
nuclear localization of β-catenin in other contexts and/or had been implicated in 
AML. As such they were favoured for further analysis and due to the time 
constraints of the project not all the factors could be analysed.  
Given the lack of data for the nuclear fractions of non-translocator cells and the 
fact that RNA-binding protein 14 localization was not validated by western 
blotting, the most that can be stated is that RNA-binding protein 14 interacts in a 
complex with β-catenin in the nucleus of the translocator cell lines studied.  
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Protein phosphatase 1-beta (PP1-β) is a global serine/threonine phosphatase 
that performs varied roles, for example, in glycogen metabolism, cell-cycle 
progression and protein synthesis (Korrodi-Gregório et al, 2014; Rebelo et al, 
2015). PP1 is involved in the regulation of canonical Wnt signalling by its 
interaction with and dephosphorylation of Axin, leading to less effective 
destruction of β-catenin by the catenin destruction complex, and subsequent 
stabilization of β-catenin (Kim et al, 2013; Luo et al, 2007).  
In this project PP1-β was identified as a candidate β-catenin nuclear retention 
factor. To my knowledge, PP1 has not been identified as a direct binding partner 
of β-catenin, so it could be that PP1 binds indirectly via its association with Axin-
1, which was also identified as a candidate β-catenin nuclear retention factor. 
Similarly, another protein phosphatase family member, PP2A, also binds β-
catenin indirectly via other catenin destruction complex components e.g. Axin 
(Hsu et al, 1999; Stamos & Weis, 2013). Again, to my knowledge PP1 has not 
been implicated as a direct regulator of β-catenin mediated localization, except 
because of stabilization of β-catenin following dephosphorylation of Axin (Kim et 
al, 2013; Luo et al, 2007). This does not apply in a haematopoietic context, in 
which stabilization of β-catenin does not normally lead to its nuclear localization 
(Morgan et al, 2014). 
Owing to the uncertainty about the regulation of β-catenin nuclear localization by 
PP1, it was not chosen for validation by western blotting. 
 
Runt-related transcription factor 1 (RUNX1) is an important haematopoietic 
transcription factor and is commonly dysregulated in AML (1.2.2); either fused 
with other genes through chromosomal translocations or mutated. In this project, 
RUNX1 was identified as a candidate β-catenin nuclear retention factor in 
leukaemia lines. To my knowledge, RUNX1 has not been identified as a β-catenin 
interaction partner, but it has been identified as a LEF-1 interaction partner 
(Kahler & Westendorf, 2003), suggesting that RUNX1 may indirectly interact with 
β-catenin via LEF-1 in the nucleus of leukaemia cell lines.  
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RUNX1 was one of the two proteins whose localization was verified by western 
blotting (Figure 4.6), being present in the nucleus of translocator cell lines and 
absent in non-translocator cell . This corresponded to the localization of LEF-1, 
and together these two proteins were the only two factors identified by the MS 
approach that were validated as potential nuclear β-catenin localization factors. 
Due to time constraints, RUNX1 was not included in further functional analysis, 
as LEF-1 was favoured based on its more established role as a candidate β-
catenin nuclear localization factor in other contexts.  
 
LEF-1 is a member of the TCF family of transcription factors with well-established 
roles in regulating β-catenin mediated transcription (1.3). It is frequently 
dysregulated in AML and its overexpression has clinical significance, with LEF-1 
overexpression being associated with a favourable prognosis (Fu et al, 2014; 
Metzeler et al, 2012). In this project, LEF-1 was identified as a candidate nuclear 
localization factor. LEF-1 has been shown to regulate the nuclear localization of 
β-catenin in other contexts, including, SW480, NIH-3T3 and MDCK cell lines and 
mouse embryos (Henderson et al, 2002; Huber et al, 1996; Jamieson et al, 2016; 
Jamieson et al, 2011; Simcha et al, 1998). In SW480 colon cancer cells, 
immunohistochemistry was used to detect the localization of β-catenin in cells i) 
transfected with APC and ii) co-transfected with APC and LEF-1. Whilst 
transfection of cells with APC reduced nuclear β-catenin levels, co-transfection 
of cells with APC and LEF-1 prevented APC mediated export of β-catenin 
(Henderson et al, 2002), suggesting that LEF-1 regulates the nuclear localization 
of β-catenin in these cells. LEF-1 has also been implicated as a β-catenin nuclear 
localization factor following GSK3β inhibition in NIH-3T3 and SW480 cells 
(Jamieson et al, 2011). In another study, nuclear injection of LEF-1 cDNA into 
blastomeres of murine two-cell stage embryos, led to co-localization of β-catenin 
and LEF-1 in the nucleus. In blastomeres without injection of LEF-1 cDNA, this 
localization was not observed (Huber et al, 1996). Another study, in which 
immunohistochemistry was used to detect the localization of β-catenin in LEF-1 
overexpressing canine MDCK cells, also suggests that LEF-1 acts as a β-catenin 
nuclear localization factor (Simcha et al, 1998). 
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In summary, MS analysis identified eight potential candidate nuclear localization 
factors. Out of these, factors were primarily chosen for further analysis due to 
their identification as candidate β-catenin nuclear localization factors in other 
contexts. This contrasts with the project aim outlined in 1.4, to identify novel 
candidate β-catenin nuclear localization factors, however, given the tight time 
constraints towards the end of this project, this represented the approach most 
likely to identify β-catenin nuclear localization factors in AML. Since these factors 
had not yet been identified as candidates in this context, this approach still had 
potential to discover novel findings in AML. Out of the eight candidates, two of 
the chosen factors, were successfully validated by western blotting (LEF-1 and 
RUNX1). Again, due to the time constraints of the project, only one of these 
factors could be examined further, and LEF-1 was chosen for further analysis, 
based on its well-established role in canonical Wnt signalling, and its identification 
as a candidate β-catenin nuclear localization factor in other contexts.  
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5 The role of LEF-1 in regulating the nuclear 
localization of β-catenin and its functional 
relevance in leukaemia  
 
Chapter 4 identified candidate factors involved in regulating the nuclear 
localization of β-catenin. Further analysis of these proteins is necessary to 
validate their role in this process and their functional relevance in leukaemia. Due 
to time constraints, analysis of every candidate is outside the scope of this 
project. Instead, LEF-1 was chosen for further analysis due to its established role 
in regulating the Wnt pathway. Upon Wnt activation, LEF-1 (a TCF family 
member) binds in a complex with active β-catenin and regulates transcription of 
β-catenin target genes (1.3.1.2). Additionally, LEF-1 has been implicated in the 
nuclear localization of β-catenin in different contexts by cytosolic-nuclear shuttling 
and/or nuclear retention (Behrens et al, 1996; Henderson et al, 2002; Huber et 
al, 1996; Jamieson et al, 2016; Jamieson et al, 2011). LEF-1 has also been 
implicated in AML pathogenesis. Transplantation of bone marrow cells 
overexpressing LEF-1 into mice leads to the development of AML, and LEF-1 
was also identified as one of the Wnt pathway components regulating AML by 
AML associated fusion proteins (Müller-Tidow et al, 2004; Petropoulos et al, 
2008). LEF-1 also has clinical relevance in AML, with LEF-1 overexpression 
being associated with a favourable prognosis (Fu et al, 2014; Metzeler et al, 
2012). Together, these factors make LEF-1 a good candidate for further analysis.  
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• To establish whether LEF-1 regulates the nuclear localization of β-catenin 
in leukaemia cell lines. 
• To examine the effects of modulating LEF-1 on β-catenin mediated 
transcription. 
• To determine whether LEF-1 mediated β-catenin nuclear localization is 
important in regulating key cancer processes in leukaemia cell lines 
including; proliferation, viability, migration, survival and differentiation. 
 
 
LEF-1 has been implicated in the regulation of β-catenin nuclear localization in 
different contexts via cytoplasmic-nuclear shuttling or retention of β-catenin in the 
nucleus. To examine whether LEF-1 regulates the nuclear localization of β-
catenin in leukaemia, lentiviral constructs were used to knockdown and 
overexpress full length LEF-1 in pBARV reporter lines (2.3). Cell lines were 
induced with the GSK3β inhibitor BIO (Meijer et al, 2003) to stabilize β-catenin, 
fractionated and western blotted (Chapter 0). 
 
To study the role of LEF-1 in translocator cell lines (K562 and HEL) an shRNA 
LEF-1 construct was used to knockdown LEF-1 in these cell lines.  To choose a 
suitable shRNA construct, that effectively knocked down LEF-1 and did not have 
adverse effects on the cells, the knockdown efficiencies of five different LEF-1 
shRNA constructs (Table 2.3) were tested in K562 cells. Cells were grown, 
transduced with LEF-1 shRNA and fractionated into nuclear and cytoplasmic 
fractions. A control shRNA vector (harbouring a sequence to a non-human gene) 
was included for comparison (Table 2.3). Due to the exclusive localization of LEF-
1 in the nucleus of K562 cells, only nuclear fractions were analysed by western 
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blotting. Each of the LEF-1 shRNA constructs reduced expression of LEF-1 
(Figure 5.1A). None of the constructs had adverse consequences for the cells 
with all of them coming through puro selection equivalently to shRNA control 
lines. The percentage of LEF-1 knockdown for each of the LEF-1 shRNA 
constructs was calculated. These were; ~82% for shRNATRCN0000020163, 
~62% for shRNATRCN0000413476, ~90% for shRNATRCN0000418104, ~83% 
for shRNATRCN0000428178 and ~95% for shRNATRCN0000428355. The most 
effective LEF-1 shRNA construct (shRNATRCN0000428355) was chosen for use 
in further analysis in K562 and HEL cells. A control shRNA vector was included 
in all experiments (Figure 5.1B). Knockdown efficiency using the chosen LEF-1 
shRNA was 78% in K562 cells and 76% in HEL cells (Figure 5.2A). 
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Figure 5.1. LEF-1 shRNA vectors. 
(A) Western blot of the five LEF-1 shRNA vectors tested in K562 cells and immunoblotted with 
LEF-1 antibody (Table 2.5). A control shRNA vector was included for comparison. (B) shRNA 
control vector map. Abbreviations; IB= immunoblot, Ab= antibody, MW= molecular weight. 
Marker= MagicMark XP (Thermo Fisher). 
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To study the role of LEF-1 in non-translocator cell lines (THP-1 and U937), cells 
were lentivirally transduced with a LEF-1 overexpression vector, pLV-
EGFP:T2A:Puro-EF1A>hLEF1. The cells were grown, transduced and 
fractionated into cytosolic and nuclear fractions (Chapter 0). A control vector was 
included in all experiments (pLV-EGFP-T2A-Puro-EF1A). To determine if the 
overexpression of LEF-1 in non-translocator cell lines was successful, control and 
LEF-1 transduced cells nuclear and cytosolic fractions were immunoblotted for 
LEF-1 (2.5). BIO was used to stabilize β-catenin prior to fractionation.  
In U937 cells a band was seen in the cytoplasmic fraction at ~45kDa, 
corresponding to full length LEF-1. There were additional bands at lower 
molecular weights, suggesting LEF-1 degradation in the cytoplasmic fraction of 
U937 cells. LEF-1 was not observed in the nucleus of U937 cells (Figure 5.2B). 
The lack of LEF-1 banding in the nuclear fraction could be due to a strong 
regulatory mechanism preventing its translocation to the nucleus. Additionally, 
incubation with BIO led to stabilization of LEF-1 in the cytoplasmic fraction of 
U937 cells.  
In THP-1 cells, no bands were observed in the cytoplasmic or nuclear fractions 
following incubation with LEF-1 antibody. In contrast, in THP-1 cells induced with 
BIO, bands were observed in the nuclear fraction. (Figure 5.2B). These bands 
were lower than those expected for full length LEF-1 suggesting that following 
BIO induction, LEF-1 translocates to the nucleus of THP-1 cells and is 
subsequently degraded. This reaffirms the observations made in U937 cells and 
suggests that LEF-1 could be regulated by degradation in non-translocator cell 
lines. The banding observed in THP-1 cells is suggestive of a mechanism by 
which LEF-1 enters the nucleus but is subsequently degraded. 
To summarize, LEF-1 overexpression was observed in both non-translocator 
lines following induction with BIO. This suggests that regulation of LEF-1 protein 
levels in non-translocator cell lines is complex, involving transcriptional 
regulation, post transcriptional regulation by BIO and regulation by subcellular 
localization, as observed in U937 cells.  
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Figure 5.2. The effect of LEF-1 on the nuclear localization β-catenin in leukaemia cell 
lines. 
Western blotting of cytoplasmic/nuclear fractions in (A) translocator cell lines lentivirally 
transduced with LEF-1 shRNA or corresponding shRNA control and (B) non-translocator cell 
lines lentivirally transduced with a LEF-1 overexpression vector and corresponding control 
(Table 2.3). In the lanes without BIO induction, the β-catenin lanes appear empty due to the 
relative exposure (BIO gives a very strong signal). MW markers were not visible on re-probed 
blots, but the relative migration of detected bands was consistent with the indicated proteins. 
Abbreviations; C= cytoplasmic fraction, N= nuclear fraction, KD= knockdown, KI= knock in, IB= 
immunoblot, MW= molecular weight, Ab= antibody, kDa= kilodalton. Marker= MagicMark XP 
(Thermo Fisher). BIO was added to stabilize β-catenin. GAPDH and Histone H1 antibodies 
were used as loading and fractionation efficiency controls. 
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To examine the role of LEF-1 in regulating nuclear localization of β-catenin, LEF-
1 knockdown and overexpression cell lines were fractionated and western blotted 
with β-catenin antibody (2.5). shRNA and overexpression control lines were 
included and BIO was added to stabilize β-catenin, thereby increasing the 
amount of β-catenin available for nuclear translocation. 
In translocator cell lines (K562 and HEL) induced with BIO, knockdown of LEF-1 
reduced the level of nuclear β-catenin (Figure 5.2A) by 52% in K562 cells and 
60% in HEL cells. This suggests that LEF-1 promotes the nuclear localization of 
β-catenin in these cell lines, and reducing the amount of LEF-1 lowers the amount 
of nuclear β-catenin. 
In non-translocator cell lines (U937 and THP-1) the overexpression of LEF-1 and 
associated changes in β-catenin localization were more complicated (Figure 
5.2B). In THP-1 cells, overexpression of LEF-1 resulted in a weak β-catenin 
signal in the nucleus of induced cells (+BIO) not observed in the induced control 
line. This is consistent with the weak nuclear expression of LEF-1 in this line and 
suggests that LEF-1 may play a role in regulating the nuclear localization of β-
catenin in THP-1 cells. In contrast, in the U937 line, no β-catenin signal was 
observed in the nuclear fraction of LEF-1 overexpressing cells. Given the 
absence of LEF-1 in the nucleus of LEF-1 overexpressing U937 cells this was 
expected. 
In conclusion, LEF-1 knockdown and overexpression studies suggest LEF-1 
plays a role in regulating the nuclear localization of β-catenin, however, the 
contrasting results in THP-1 and U937 cells suggest the presence of multiple 
mechanisms to exclude LEF-1 (and correspondingly, β-catenin) from the nucleus. 
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Following the confirmation that LEF-1 regulates the nuclear localization of β-
catenin in leukaemia cell lines the next step was to examine whether subsequent 
changes in β-catenin mediated transcription occurred.  Flow cytometry was used 
to measure β-catenin mediated transcription (visualised by Venus GFP reporter 
(2.4). 
 
To study β-catenin mediated transcription, BIO was used to stabilize β-catenin 
and induce β-catenin mediated nuclear translocation and subsequent 
transcription in leukaemia cell lines.  
In translocator cell lines induction of Wnt signalling by BIO resulted in an increase 
in reporter activity representing an increase in β-catenin mediated transcription 
(Figure 5.3A). In K562 control cells, adding BIO resulted in ~40% of cells 
expressing a level of reporter activity above the defined threshold value. 
Knockdown of LEF-1 reduced this to only 10% of cells. The threshold value is 
defined by the background reporter readout (from uninduced cells) hence the 
percentage induction represents the proportion of cells exhibiting higher reporter 
activity than that observed in uninduced cells. In HEL control cells, adding BIO 
resulted in ~52% of cells expressing a level of reporter activity above the defined 
threshold value.  Knockdown of LEF-1 reduced this to only 2% of cells. These 
decreases in reporter activity in translocator cell lines are indicative of decreased 
β-catenin mediated transcription upon knockdown of LEF-1. 
In LEF-1 overexpressing cell lines the study of β-catenin mediated transcription 
was complicated by the presence of GFP in the LEF-1 overexpression vector 
which interfered with the readout of the Venus reporter. The effect of GFP in the 
overexpression vector on the reporter readout can be observed in Figure 5.4A. 
This is based on the transduction of cell lines with the control LEF-1 
overexpression vector (expressing the background GFP). Any additional reporter 
activity was taken as a readout of β-catenin mediated transcription. In non-
translocator cell lines treatment with BIO did not result in reporter readout above 
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the defined threshold value (Figure 5.4B&C). This is because β-catenin does not 
translocate to the nucleus in these lines and is not able to regulate the reporter 
gene.  Small increases observed in these parental lines are likely due to the 
fluorescence of BIO itself. 
In THP-1 cells LEF-1 overexpression resulted in an increase in reporter readout 
following BIO induction (Figure 5.4B). In THP-1 control cells, adding BIO resulted 
in ~5% of cells expressing a level of reporter activity above the defined threshold 
value.  Overexpression of LEF-1 increased this to 42% of cells. This suggests 
that there may be an increase in β-catenin mediated transcription resulting from 
overexpression of LEF-1 in this cell line. Together with the western blot data 
(Figure 5.2B) this supports the hypothesis that LEF-1 promotes nuclear 
localization of β-catenin and subsequent transcriptional activation in THP-1 cells. 
In U937 cells, LEF-1 overexpression and BIO induction only resulted in 5% of 
cells expressing reporter activity above the defined threshold value (Figure 
5.4B). This is supported by the western blot data (Figure 5.2B) which suggests 
LEF-1 (and β-catenin) does not translocate to the nucleus of U937 cells and 
subsequently cannot regulate β-catenin mediated transcription. 
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Figure 5.3.  The effect of LEF-1 on β-catenin mediated transcription in translocator cell 
lines. 
Top: Flow cytometric analysis of translocator lines expressing the pBARV reporter to measure 
β-catenin mediated transcription in cells transduced with LEF-1 shRNA or shRNA control (Table 
2.3). Wnt signalling was induced with (A) BIO and (B) Wnt3a. Bottom: Bar charts representing 
the percent of cells expressing reporter activity above the defined threshold value (relative to 
uninduced) with addition of (A) BIO and (B) Wnt3a.  
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Figure 5.4. β-catenin mediated transcription in non-translocator cell lines in response to 
LEF-1 overexpression. 
(A) Flow cytometric analysis of GFP expression in parental and control infected cells. (B) Flow 
Analysis of β-catenin mediated transcription in pBARV lines in non-translocator cell lines -/+ BIO 
and Wnt3a. Abbreviation; KI= knock-in (LEF-1 overexpression). 
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In addition to using BIO, Wnt3a was included as another agonist to stimulate Wnt 
signalling and study β-catenin mediated transcription. Wnt3a is a canonical Wnt 
pathway component and was included in the analysis because it represents a 
more biologically relevant system than the artificial GSK3β inhibitor BIO. Ideally 
Wnt3a would have been used to study the effect of LEF-1 on β-catenin mediated 
localization via western blotting (5.3.1), however, the amount of Wnt3a required 
for western blot analysis made this prohibitively expensive. 
In translocator cell lines (K562 and HEL) induced with Wnt3a, knockdown of LEF-
1 resulted in a decrease in reporter activity. In K562 control cells, adding Wnt3a 
resulted in ~9.6% of cells expressing a level of reporter activity above the defined 
threshold value.  Knockdown of LEF-1 decreased this to 1% of cells. In HEL 
control cells, adding Wnt3a resulted in 22% of cells expressing a level of reporter 
activity above the defined threshold value.  Knockdown of LEF-1 decreased this 
to 1% of cells. These reporter readouts suggest there was a reduction in β-catenin 
mediated transcription following LEF-1 knockdown (Figure 5.3B). This supports 
the data observed in BIO induced cells that LEF-1 regulates β-catenin mediated 
transcription (5.3.2.1).  
In non-translocator cell lines (THP-1 and U937) induced with Wnt3a, β-catenin 
mediated transcription reporter readout followed the same pattern as with BIO 
induction (5.3.2.1). In THP-1 LEF-1 overexpressing cells, adding Wnt3a resulted 
in ~19% of cells expressing a level of reporter activity above the defined threshold 
value (Figure 5.4C). In U937 LEF-1 overexpressing cells no change in reporter 
readout was observed with Wnt3a induction (Figure 5.4C). Again, this can be 
explained by the absence of overexpressed LEF-1 in the nucleus of U937 cells 
(Figure 5.2B). 
In conclusion, knockdown of LEF-1 in translocator cell lines decreased β-catenin 
mediated transcription in cells induced with BIO and Wnt3a. In addition, induction 
of LEF-1 overexpressing THP-1 cells resulted in an increase in reporter activity 
corresponding to an increase in β-catenin mediated transcription. In U937 cells 
this was not the case, owing to the absence of LEF-1 in the nucleus. Together 
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with the western blot results (Figure 5.2A & B) this data suggests that LEF-1 
regulates both the nuclear localization of β-catenin and subsequent β-catenin-
mediated transcription. 
Ideally repeating this experiment with another LEF-1 vector (without GFP) would 
be necessary to negate possible confusion with GFP present in the 
overexpression vector and strengthen these observations.  
 
Wnt signalling regulates the cell cycle and proliferation in many contexts. To 
establish whether LEF-1 regulates proliferation of leukaemia cell lines, a 
proliferation assay was used to study cell lines with LEF-1 knockdown and 
overexpression (2.4.3). Briefly, cells were grown in different concentrations of 
serum to identify any differences in growth rate and serum dependence and 
counted over a 3-day period using flow cytometry (Figure 5.5, Figure 5.6 & 
Figure 5.7). Proliferation was measured as a fold change from seeding density. 
 
In K562 cells (Figure 5.5A) on days 1-2 the overall trend was that LEF-1 
knockdown led to a decreased proliferation rate, particularly at lower serum 
concentrations. On day 1 there was a significant difference in the proliferation 
rate between control (~1-fold increase) and LEF-1 knockdown (no change) at 
0.3% serum. Similarly, at 3% serum there was a significant difference between 
control (~1.5-fold increase) and LEF-1 knockdown (~1-fold increase). On day 2 
at 0.3% serum there was a significant difference between control (~4-fold 
increase) and LEF-1 knockdown (~2-fold increase). At 3% serum, there was a 
significant difference between control (~4.5-fold increase) and LEF-1 knockdown 
(~3-fold increase).   
On day 3 the differences in proliferation rate did not follow the trend. At serum 
concentrations 0.1%, 0.3% and 3% there was no difference in proliferation rate 
between control and LEF-1 cells.  
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In HEL cells (Figure 5.5B) on day 1 there was no difference in the proliferation 
of control and LEF-1 knockdown cell lines at all serum concentrations. On days 
2-3 the general trend was decreased proliferation in LEF-1 knockdown cells 
compared to control. On day 2 at 0.3% serum there was a significant difference 
between control (~3-fold increase) and LEF-1 knockdown (~2-fold increase). At 
3% serum, there was a significant difference between control (~5-fold increase) 
and LEF-1 knockdown (~2.5-fold increase).  
On day 3 there was a significant difference in proliferation between control (~5.5-
fold increase) and LEF-1 knockdown (~2-fold increase) at 0.3% serum. At 3% 
serum, there was a significant difference between control (~6.5-fold increase) and 
LEF-1 knockdown (~3.5-fold increase) cells. At 10% serum, there was a 
significant difference between control (~6.5-fold increase) and LEF-1 knockdown 
(~4-fold increase) cells. This experiment suggests that LEF-1 may regulate 
proliferation in HEL cells as knocking down LEF-1 resulted in reduced 
proliferation.  
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Figure 5.5. Effect of LEF-1 knockdown on proliferation of translocator cells. 
Flow cytometric analysis of cell proliferation in control shRNA and LEF-1 shRNA K562 and HEL 
cells, on day 1 (top), day 2 (middle) and day 3 (bottom). Each data point corresponds to the 
average cell count from two replicates. The assay was repeated twice, but the second 
experiment failed. * p=<0.05, ** p=<0.01 (two sample T test. n=2). The starting density of cells 
was 0.8x105/ml for K562 control, 1x105/ml for K562 LEF-1 KD, 0.8x105/ml for HEL control and 
1x105/ml for HEL LEF-1 KD.  
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In both repeat experiments LEF-1 overexpression did not impact the proliferation 
of THP-1 cells. As with the translocator cell lines, there was a general trend for 
increased proliferation with increasing serum concentration up to 10% (normal 
growth conditions). In the first experiment (Figure 5.6A), on days 1-2 there were 
some small significant differences between control and LEF-1 transduced cells 
at certain serum concentrations (Day 1; 3 % serum. Day 2; 0.1% serum and 3% 
serum). This data does not provide enough evidence to support the hypothesis 
that LEF-1 regulates proliferation in THP-1 cells due to the lack of any trend and 
the very small differences observed. 
In the second experiment (Figure 5.6B) there was no difference in proliferation 
between control and LEF-1 overexpressing cells on any days or serum 
concentrations. Given the issues observed in the second set of repeats for HEL 
and K562 cells (data not shown), there may be issues with this set of results for 
THP-1 cells as well.  
To conclude, both repeat experiments suggest that LEF-1 does not play a role in 
regulating the proliferation of THP-1 cells as there were no differences in fold 
change between control and LEF-1 overexpressing cells. 
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Figure 5.6. Effect of overexpression on proliferation of THP-1 cells. 
Flow cytometric analysis of cell proliferation in control and LEF-1 overexpressing THP-1 cells on 
day 1 (top), day 2 (middle) and day 3 (bottom). Each data point corresponds to the average cell 
count from two replicates. The assay was repeated twice(A&B). * p=<0.05 (Two sample T test. 
n=2). The starting densities of cells in (A) were 2.7x105/ml for THP-1 control and 2.9x105/ml for 
THP-1 LEF-1 KI. The starting densities of cells in (B) were 2.5x105/ml for THP-1 control and 
THP-1 LEF-1 KI. 
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Figure 5.7. Effect of overexpression on proliferation of U937 cells. 
Flow cytometric analysis of cell proliferation in control and LEF-1 overexpressing U937 cells. 
Each data point corresponds to the average cell count from two replicates. The assay was 
repeated twice(A&B). The starting densities of cells in (A) were 1.4x105/ml for U937 control and 
1.3x105/ml for U937 LEF-1 KI. The starting densities of cells in (B) were 1.1x105/ml for U937 
control and U937 LEF-1 KI. 
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In U937 cells the effect of serum concentration was the same as the other cell 
lines with increasing proliferation up to serum concentration of 10%. In both 
repeat experiments LEF-1 overexpression did not impact the proliferation of U937 
cells (Figure 5.7A &B). There are no significant differences between control and 
LEF-1 overexpressing cells on any day or at any serum concentration.  
To conclude, LEF-1 does not impact the proliferation of U937 cells. Taken 
together with the results observed in THP-1 cells this suggests that LEF-1 does 
not regulate the proliferation of non-translocator cells.  
 
Migration plays an important role in cancer progression and β-catenin has been 
implicated in the regulation of migration in different contexts including epithelial 
cells, solid tumours, and macrophages (Amini-Nik et al, 2014; Müller et al, 2002; 
Yang et al, 2017). To determine if overexpression or knockdown of LEF-1 impacts 
the migration capabilities of leukaemia cell lines a migration assay was used 
(2.4.4). Briefly, a trans-well assay was set up in which cells were loaded into the 
upper chamber and a chemoattractant (SDF-1) was added to the lower chamber. 
Flow cytometry was used to measure the number of cells that migrated from the 
upper to lower chamber.  Figure 5.8 shows the percentage of cells that migrated 
through to the bottom chamber for each cell line and condition. To validate the 
assay CD34+ cells from human cord blood were included as a positive control. 
The migration of each cell line was also measured without the addition of SDF-1 
to provide an indication of background migration. If LEF-1 regulates the migration 
of leukaemia cell lines, we would expect to see a reduction in the migration of 
cells in translocator cell lines with LEF-1 KD and an increase in migration of cells 
in non-translocator cell lines with overexpression of LEF-1.   
In both translocator cell lines (HEL and K562) LEF-1 knockdown had no effect on 
the migration of cells from the upper chamber to the lower chamber in this trans-
well assay. The lack of response to SDF-1 in these cells prior to LEF-1 
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knockdown means that the effect of LEF-1 knockdown on migration could not be 
scored. 
Both non-translocator cell lines responded to SDF-1 in this assay, with migration 
of cells into the lower chamber, despite undetectable LEF-1. This suggests that 
LEF-1 expression is not required for the migratory response. Overexpression of 
LEF-1 in non-translocator cell lines gave conflicting results. In the THP-1 cell line 
a reduction in migration was observed with overexpression of LEF-1 whereas in 
the U937 cells the opposite was observed. The contrasting results could be due 
to experimental error or due to mechanistic differences in each of the cell lines. 
The conflicting results do suggest the absence of a global mechanism regulating 
LEF-1 mediated changes in migration, with cell line specific mediators likely to be 
involved. 
Given the lack of consistent effects of LEF-1 overexpression on migration in non-
translocator cell lines and the lack of response in translocator cell lines, further 
studies on migration were not pursued and the experiment was not repeated.  
  
Chapter 5: The role of LEF-1 in regulating the nuclear localization of β-catenin 
and its functional relevance in leukaemia 
 
Page | 164  
 
 
Figure 5.8.  Effect of LEF-1 on the migration of leukaemia cell lines. 
Migration data for leukaemia cell lines transduced with control, LEF-1 shRNA (KD) or LEF-1 
overexpression vectors (KI) (Table 2.3). SDF-1 was used as a chemoattractant in the lower well 
to stimulate migration across the cell permeable membrane. Data is presented as a percentage 
of total cells that migrated through the membrane. CD34 cells were included as a positive 
control. Cells were counted using flow cytometry (2.4). 
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Another hallmark of leukaemia is the ability of cancer cells to resist apoptosis. To 
establish whether changes in LEF-1 levels have an impact on cell survival in 
leukaemia cell lines a viability assay was used (2.4.3). Control and LEF-1 
overexpression/knockdown cell lines were stained with 7-AAD and cells were 
analysed by flow cytometry to measure viability (2.4). 7-AAD is a cell viability stain 
that works by binding to the DNA of non-viable cells. In viable cells the stain 
cannot readily cross the intact cell membrane. As with the proliferation assays 
(5.3.3 & 5.3.4) the viability assay was conducted under a range of serum 
concentrations (0.1%, 0.3%, 3% and 10%) to determine if LEF-1 regulates 
apoptosis under conditions of stress (low serum concentration). 
 
In K562 cells (Figure 5.9) there was a general trend of decreased survival with 
decreasing serum concentrations on all 3 days. Knockdown of LEF-1 did not 
impact cell survival in K562 cells. The only significant difference in cell viability 
between control and LEF-1 knockdown lines was on day 1 at 3% serum. Cell 
viability was ~63% in control cells and ~70% in LEF-1 knockdown cells. Given 
the lack of significant differences between control and LEF-1 knockdown cells at 
any other data point, this is likely to be an anomaly. This data suggests that LEF-
1 does not regulate cell survival in K562 cells, however, ideally this data would 
be repeated with a Wnt agonist such as Wnt3a. 
In HEL cells (Figure 5.9) there was a trend of decreased survival with decreasing 
serum concentrations. There appeared to be an additional small negative effect 
on survival with knockdown of LEF-1. There were only significant differences 
between control and knockdown cells at the lower serum concentrations on days 
1 and 3. On Day 1 there was a significant difference in cell viability of ~7% at 
0.3% serum. On Day 2 there were significant differences in cell viability of ~7% 
at 0.1% serum and ~4% at 0.3% serum. This data suggests that LEF-1 could play 
a role in regulating the survival of HEL cells at low serum concentrations, 
however, owing to the very small differences observed, repeat experiments would 
be necessary to strengthen this hypothesis. 
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Taken together, the results of the viability assays in translocator cell lines (K562 
and HEL) provide evidence that LEF-1 may regulate cell survival to some extent 
in HEL cells but that this is not the case in K562 cells. This suggests that if LEF-
1 does regulate the survival of HEL cells, this is not a global mechanism in 
leukaemia cell lines.  
 
In THP-1 cells, cell viability decreased slightly with decreasing serum 
concentrations (Figure 5.10). Cell viability remained constant between 60-75% 
for all 3 days in both control and LEF-1 overexpressing cells. There were no 
significant differences in cell viability between the control and LEF-1 knockdown 
cells. 
Similarly, in U937 cells, cell viability decreased with decreasing serum 
concentrations (Figure 5.10). Viability remained constant for the 3 days and there 
were no significant differences in cell viability between control and LEF-1 
overexpressing cells. 
The results of the viability assays in non-translocator cells suggest that 
overexpressing LEF-1 does not impact cell survival in these cell lines, however, 
as discussed in 5.4.5.1, overexpression of LEF-1 was not effective in these cell 
lines making it difficult to draw conclusions from this data. 
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Figure 5.9. Effects of LEF-1 knockdown on survival in translocator lines. 
Flow cytometric analysis of cell viability in translocator cell lines. Viability was calculated as a 
percentage of total cells. Each data point represents the average of two replicate experiments.  
* p=<0.05, ** p=<0.01 (Two sample T test. n=2). The starting cell densities were 1.1x105/ml for 
K562 control, 1.2x105/ml for K562 LEF-1 KD, 1.2x105/ml for HEL control and 1.2x105/ml for HEL 
LEF-1 KD. 
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Figure 5.10. Effects of LEF-1 overexpression on survival in non-translocator lines. 
Flow cytometric analysis of cell viability in non- translocator cell lines. Viability was calculated as 
a percentage of total cells. Each data point represents the average of two replicate experiments. 
The starting cell densities for THP-1 control and THP-1 LEF-1 KI were 2.5x105/ml. The starting 
cell densities for U937 control and U937 LEF-1 KI were 1.1x105/ml. 
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Wnt signalling is involved in regulating the differentiation of cells in different 
contexts, including dendritic cells, embryonic stem cells and HSCs (Davidson et 
al, 2012; Famili et al, 2016; Xu et al, 2016). One of the characteristics of 
leukaemia is a block in normal differentiation and an accumulation of immature 
blasts. To examine the potential role of LEF-1 in changing the morphology and/or 
differentiation of leukaemia cell lines, flow cytometry was used to analyse the 
scatter profiles of control and LEF-1 overexpressing/knockdown lines (2.4). In 
three of the cell lines (K562, HEL and U937) there was no difference in the scatter 
profiles of control or LEF-1 knockdown/overexpression cell lines (Figure 5.11A 
& B). In the non-translocator cell line THP-1 there was a difference in the scatter 
profile of LEF-1 overexpressing cells compared to control cells (Figure 5.11A). 
In LEF-1 overexpressing cells there was an increase in forward scatter in 11.4% 
of cells. This increased to 18.2% and 32.5% in Wnt3a and BIO induced cells. This 
shift in forward scatter suggests these cells are larger than the control cells. The 
side scatter profiles of the THP-1 control and LEF-1 overexpressing cells were 
the same. This indicates that LEF-1 does not impact the granularity of the cells. 
This data suggests that LEF-1 impacts the morphology of THP-1 cells but due to 
time constraints this was only repeated once and further experiments would be 
necessary to determine if this is a significant change and whether it is indicative 
of differences in differentiation. 
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Figure 5.11. Forward scatter analysis of leukaemia cell lines following knockdown and 
overexpression of LEF-1. 
Flow cytometric measurement of cell size using forward scatter profiles in (A) non-translocator 
cells lines transduced with control or LEF-1 overexpression vectors and (B) translocator cell 
lines transduced with control or LEF-1 shRNA vectors. BIO and Wnt3a were used to induce Wnt 
signalling. 
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LEF-1 is frequently dysregulated in AML and its overexpression has clinical 
significance, with LEF-1 overexpression being associated with a favourable 
prognosis (Fu et al, 2014; Metzeler et al, 2012). It has been shown to regulate 
the nuclear localization of β-catenin in different contexts, including, SW480, NIH-
3T3, MDCK cell lines and mouse embryos (Henderson et al, 2002; Huber et al, 
1996; Jamieson et al, 2016; Jamieson et al, 2011; Simcha et al, 1998), and has 
a well-established role in regulating β-catenin mediated transcription as a 
member of the TCF family of proteins (1.3.1.2). The aim of the experiments 
presented in this chapter was to establish whether LEF-1 regulates β-catenin 
nuclear localization in leukaemia cell lines, and to assess the functional relevance 
of any findings. In this chapter, LEF-1 was knocked down in translocator cell lines 
and overexpressed in non-translocator cell lines. This was an attempt to “convert” 
translocator cells into non-translocator cells and vice versa. One thing that was 
not considered when conducting these experiments was overexpressing LEF-1 
in translocator cell lines. This may have identified LEF-1 as a factor that regulates 
the nuclear localization of β-catenin in translocator cell lines without addition of 
BIO. This would be more functionally relevant than the artificial induction of β-
catenin nuclear localization with BIO and is something that would be interesting 
to look at in future work.  
This section discusses aspects of the experimental techniques used in this 
chapter, as well as the conclusions made about the role of LEF-1 in mediating β-
catenin nuclear localization, β-catenin mediated transcription, proliferation, cell 
survival and cell migration.  
 
Little is known about the factors that regulate β-catenin nuclear localization in 
AML, and this study aimed to identify factors that regulate this process. In this 
chapter, the candidate β-catenin nuclear localization factor LEF-1 was studied. 
LEF-1 was identified as a candidate nuclear localization factor by MS in Chapter 
4 and western blotting results (Figure 5.2) support this data, suggesting that LEF-
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1 regulates the nuclear localization of β-catenin in leukaemia cell lines. This 
agrees with observations in other contexts, as discussed in 4.4.2.8. 
Although LEF-1 has been shown to regulate β-catenin nuclear levels, it does not 
appear to be essential for β-catenin nuclear localization. In one study, binding of 
LEF-1 to β-catenin was disrupted in Cos-1 cells by mutating β-catenin. In these 
cells, nuclear localization of β-catenin was still observed, suggesting that, at least 
in this context, LEF-1 is not essential for its nuclear localization (Prieve & 
Waterman, 1999). It is difficult to say whether my results agree with this 
observation, because although knockdown of LEF-1 was 77-78% efficient in 
translocator lines, some LEF-1 was still detectable in the nuclei of these cells and 
so could have been sufficient to localize β-catenin to the nucleus. Recent data 
shows a strong correlation between nuclear LEF-1 and nuclear β-catenin levels 
in AML. In 23 AML patients (mainly paediatric) the relative percent nuclear 
translocation of LEF-1 and β-catenin strongly correlates (and is highly significant). 
This supports LEF1 as a key translocation partner in AML (Morgan unpublished; 
2017). 
In summary, LEF-1 has been shown to regulate the nuclear localization of β-
catenin in different contexts. Most research into LEF-1 mediated β-catenin 
nuclear localization in cancer has focused on solid tumours (Table 1.10) and little 
is known about the factors that regulate β-catenin nuclear localization in 
leukaemia. This study has identified LEF-1 as a regulator of β-catenin nuclear 
localization in leukaemia cells. It would be interesting to determine if LEF-1 
knockdown also impacts the levels of nuclear β-catenin in AML blasts with 
abnormal nuclear β-catenin localization, which occurs in ~50% of AML patients 
(Xu et al, 2008). This would be particularly interesting given the recent data in 
support of LEF-1 as a key regulator of β-catenin nuclear localization in AML 
patients (Morgan unpublished; 2017).  
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As a central Wnt signalling pathway component, LEF-1 has a well-established 
role in regulating β-catenin (TCF/LEF) mediated transcription (1.3.1.2). In a 
haematopoietic context, normal CD34+ cells overexpressing LEF-1 have 
increased activation of Wnt target gene expression, including cyclin D1, c-myc 
and survivin (Skokowa et al, 2006).  
LEF-1 is not essential for Wnt target gene transcription. Wnt target genes are 
regulated by other redundant factors, such as its close family member TCF-1. In 
one study, LEF-1, TCF-1 and LEF-1/TCF-1 knock outs were conducted in mice 
and the effects of these knockouts on the differentiation of thymocytes was 
observed. Only the double knock out of LEF-1 and TCF-1 affected the 
transcription of the target genes RAG-1, TCRα and TCRβ, leading to a complete 
block in T cell differentiation (Okamura et al, 1998). This suggests that 
knockdown of LEF-1 alone is not sufficient to impact target gene expression in 
this context. Additionally, β-catenin redundant factors, such as γ-catenin, can 
regulate TCF/LEF mediated transcription. In a study by our laboratory, 
overexpression of γ-catenin led to increased TCF/LEF mediated transcription. 
This increase was dampened by β-catenin knockdown, but was not reversed 
(Morgan et al, 2013).  
Due to the existence of these redundant factors, it was important to verify that the 
reduction in nuclear β-catenin levels observed in LEF-1 knockdown cells led to a 
decrease in TCF/LEF mediated transcription. The results in Figure 5.3 show that 
knockdown of LEF-1 in translocator cell lines was accompanied by a reduction in 
TCF/LEF mediated transcription. This suggests that LEF-1 regulates β-catenin 
mediated transcription in myeloid leukaemia cell lines, which is consistent with 
the results observed in CD34+ cells (Skokowa et al, 2006). Since β-catenin 
mediated transcription was not completely abolished by LEF-1 knockdown in 
K562 and HEL cells, this suggests that in agreement with the findings made in 
thymocytes (Okamura et al, 1998), LEF-1 redundant factors are likely to regulate 
β-catenin mediated transcription in myeloid leukaemia cells. 
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One of the hallmarks of AML is uncontrolled proliferation leading to the 
accumulation of blast cells. The Wnt pathway effector β-catenin and TCF factors 
have well established roles in regulating proliferation by upregulating gene 
expression of target genes such as cyclinD1 and c-myc (He et al, 1998; Shtutman 
et al, 1999). In normal haematopoiesis LEF-1 has been shown to regulate 
proliferation. Knockdown of LEF-1 in murine pre-B cells led to reduced 
proliferation (Reya et al, 2000), although the effects of LEF-1 knockdown on β-
catenin mediated transcription were not established, so LEF-1 may have been 
acting in a β-catenin independent manner in this study. Knockdown of LEF-1 in 
normal CD34+ cells led to a 50% reduction in proliferation, measured using BrDU 
staining (Skokowa et al, 2006). Interestingly, in the same assay knockdown of β-
catenin did not impact the proliferation of CD34+ cells, suggesting that in this 
context LEF-1 was acting in a β-catenin independent manner. 
Dysregulation of LEF-1/β-catenin mediated proliferation is associated with 
cancer. In one study, elevated levels of β-catenin in colon cancer cells and its 
binding to LEF-1 led to activation of the cyclinD1 gene and uncontrolled entry into 
the cell cycle (Shtutman et al, 1999). Similarly, in acute lymphoblastic leukaemia 
(ALL), LEF-1 is associated with increased cyclinD1 and c-myc mRNA levels and 
increased proliferation of ALL cells (Guo et al, 2015).  
This project used a proliferation assay (2.4.3) to determine if LEF-1 mediated 
nuclear localization of β-catenin and β-catenin mediated transcription affected 
proliferation in LEF-1 knockdown translocator cell lines. The results in Figure 5.5 
suggest that knockdown of LEF-1, and subsequent reduction in β-catenin nuclear 
localization and β-catenin mediated transcription, may lead to a reduction in 
proliferation. This agrees with another study in which the proliferation of 
leukaemia cell lines was measured following expression of dominant negative β-
catenin (Chung et al, 2002). In this study, proliferation of a subset of leukaemia 
cell lines was regulated by β-catenin (Jurkat, HUT-102 and K562), but 
proliferation of HL-60 cells was not. In another study, knockdown of β-catenin in 
HL-60 cells and AML blasts decreased their proliferation in vitro (Siapati et al, 
2011).  
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To conclude, my results suggest that LEF-1/β-catenin may regulate the 
proliferation of leukaemia cell lines and may play a role in regulating proliferation 
in AML, and this agrees with other studies looking at the role of β-catenin in 
regulating proliferation in haematopoietic and leukemic contexts. Owing to the 
failure of a repeat assay, however, this conclusion is only based on one 
experiment in two cell lines. It would be interesting to repeat this experiment on 
other translocator cell lines and on β-catenin translocating AML blasts to 
determine if knockdown of LEF-1 impacts the proliferation of these cells.  
 
Another hallmark of leukaemogenesis is evasion of apoptosis, which contributes 
to the accumulation of blast cells. The canonical Wnt pathway has a well-
established role in regulating survival by upregulating gene expression of target 
genes such as survivin (Zhang et al, 2001). In a haematopoietic context, normal 
CD34+ progenitor cells overexpressing β-catenin have reduced apoptosis, 
suggesting that β-catenin regulates cell survival in these cells (Simon et al, 2005). 
In addition, knockdown of LEF-1 has a pro apoptotic effect on CD34+ cells 
(Skokowa et al, 2006). 
The results in Figure 5.9 show that knockdown of LEF-1 did not significantly 
impact the survival of translocator cell lines, although there was a small reduction 
in survival of HEL cells with LEF-1 knockdown, which concurs with the 
observation that in HEL cells there was a greater reduction in proliferation. This 
contrasts with experiments in chronic lymphocytic leukaemia in which knockdown 
of LEF-1 by siRNA and inhibition of LEF-1/β-catenin binding by small molecule 
inhibitors led to increased apoptosis of these blasts (Gandhirajan et al, 2010; 
Gutierrez et al, 2010), suggesting that canonical Wnt signalling regulates cell 
survival in these cells. This suggests that there are differences in the regulation 
of LEF-1 mediated Wnt signalling in myeloid and lymphoid leukaemia. It could 
also be the case that the low level of β-catenin/LEF-1 that was detectable in the 
nucleus of knockdown cells (Figure 5.2) in this project was enough to maintain 
cell survival, or that redundant factors such as γ-catenin and TCF-1 are sufficient 
to regulate Wnt target genes that mediate cell survival.  
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Another process that contributes to leukaemogenesis is cell migration. β-catenin 
mediated signalling has been shown to regulate cell migration in different 
contexts including in epithelial cells and solid tumours (Müller et al, 2002; Yang 
et al, 2017). Macrophage specific deletion of β-catenin leads to impaired 
migration and cell adhesion (Amini-Nik et al, 2014). 
Despite the regulation of migration by Wnt signalling in other contexts, the results 
in Figure 5.8 do not show any differences in cell migration following knockdown 
of LEF-1 and the subsequent reduction in nuclear β-catenin and β-catenin 
mediated transcription in translocator cell lines. This may suggest that LEF-1/β-
catenin does not regulate cell migration in AML, or alternatively, the lack of 
migration observed in my assay could be because these cell lines do not respond 
to SDF-1. The lack of response to SDF-1 in the translocator lines without LEF-1 
knockdown meant that the migration endpoint for LEF-1 knockdown cells could 
not be measured. This meant that only the data for LEF-1 overexpression in non-
translocator cell lines could be used. The lack of response in translocator cell 
lines could be due to the fact they lack the receptor for SDF-1 (the 
chemoattractant used in the migration assay). The receptor for SDF-1, CXCR4, 
is expressed in low levels in HEL cells and is almost undetectable in K562 cells22. 
Both THP-1 and U937 cells have a comparatively higher expression of CXCR4 
which could explain why more of these cells migrated in my assay. It would be 
interesting to express CXCR4 in K562/HEL cells with i) endogenous LEF-1 and 
ii) knockdown of LEF-1 and repeat this assay to determine if this is the case.  
 
 
One factor that limited the conclusions that could be drawn from the analysis of 
LEF-1 in this project was that overexpression of LEF-1 was ineffective in non-
translocator cell lines. In other studies, successful overexpression of LEF-1 was 
achieved in murine HSCs and normal human CD34+ cells (Petropoulos et al, 
2008; Skokowa et al, 2006). This suggests that despite the unsuccessful 
                                            
22 https://www.proteinatlas.org/ENSG00000121966-CXCR4/cell (accessed on 04/01/2018) 
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overexpression of LEF-1 in this project, it can be overexpressed in a 
haematopoietic context. Perhaps LEF-1 overexpression is tolerated in HSCs and 
early progenitor cells but not in myeloid cells. Indeed, in normal mouse myeloid 
cells, the expression of LEF-1 mRNA is low23, suggesting that LEF-1 levels are 
tightly controlled in these cells. In one study, RT-PCR was used to measure LEF-
1 mRNA levels in different murine bone marrow fractions (Sakhinia et al, 2006). 
In this study, LEF-1 expression was highest in Lin- cells, suggesting that LEF-1 
expression is associated with HSCs and early progenitors in normal 
haematopoiesis. LEF-1 was not detected in the Lin+ cell fraction. Next, they 
analysed single cell BM precursors to determine the levels of LEF-1 mRNA 
expression in more differentiated haematopoietic precursors. LEF-1 was 
undetectable in these more differentiated cells, except for mast cell and B cell 
precursors. This suggests that LEF-1 is primarily expressed in HSCs and early 
progenitors, whereas in more differentiated haematopoietic cells LEF-1 
expression is maintained at low levels. This could explain why other studies have 
managed to overexpress LEF-1 in HSCs and CD34+ cells yet I was unsuccessful 
in overexpressing LEF-1 in the non-translocator cells used in this study. It could 
be that the non-translocator cells have retained mechanisms that maintain low 
LEF-1 levels in normal myeloid cells. The presence of bands in western blots of 
non-translocator cells at lower molecular weights than would be expected for 
LEF-1 (Figure 5.2B), suggests that this mechanism could be degradation. 
Although LEF-1 overexpression was unsuccessful in this study, it is observed in 
AML, is associated with leukaemogenesis (Petropoulos et al, 2008), and has 
clinical significance for patient prognosis and survival (Fu et al, 2014; Metzeler et 
al, 2012). 
Due to the ineffective overexpression of LEF-1 in this study, the conclusions 
based on LEF-1 overexpression are not discussed further.  
                                            
23 http://servers.binf.ku.dk/bloodspot/?gene=Lef1&dataset=mouse_nl_rna_seq (accessed on 
04/01/2018) 
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The predicted weight of full length LEF-1 is 45kDa, yet in translocator cell lines, 
western blotting detected a cluster of bands at ~55kDa, suggesting that 
endogenous LEF-1 is larger in these cells than expected. It is unlikely that these 
bands are due to non-specific binding of the antibody to another factor, because 
bands between 50-60kDa are regularly observed in other contexts using different 
LEF-1 antibodies (Jamieson et al, 2016; Lambertini et al, 2009; Warsito et al, 
2012; Wu et al, 2014)  
It could be that post-translational modifications are contributing to the 10kDa 
larger size of LEF-1 than is predicted based purely on its amino acid sequence. 
One potential candidate for modification of LEF-1, that could account for a 10kDa 
increase in molecular weight is the SUMO protein (Hilgarth & Sarge, 2005). 
SUMOylation of LEF-1 has been observed in other contexts, and has been 
implicated in regulating its localization to nuclear bodies, repressing β-catenin 
mediated transcriptional activity (Sachdev et al, 2001). Other post translational 
modifications may also be responsible for the detection of bands at larger 
molecular weights. It would be interesting to determine which post translational 
modifications of LEF-1, including SUMOylation, occur in translocator cells. 
In summary, LEF-1 knockdown studies suggested that LEF-1 regulates the 
nuclear localization of β-catenin and β-catenin nuclear localization in myeloid 
leukaemia cell lines, however, due to the experimental limitations outlined above, 
it was difficult to draw conclusions as to the effects of this on proliferation, survival 
and migration of these cells.  
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6 General Discussion 
 
β-catenin is the principle canonical Wnt pathway effector that regulates the 
transcription of genes involved in key cellular processes, including proliferation 
and cell survival. Canonical Wnt signalling has been identified as one of the most 
commonly dysregulated signalling pathways in AML and β-catenin 
overexpression is associated with a poor prognosis (Daud, 2014; Majeti et al, 
2009a). Nuclear localization of β-catenin is key to its role as a transcription factor, 
and although multiple β-catenin nuclear localization factors have been identified 
in other contexts, this process is not well understood in AML (Morgan et al, 2014). 
In this study, cytoplasmic/nuclear fractionation and immunoprecipitation of β-
catenin was optimized in leukaemia cell lines, and candidate β-catenin nuclear 
localization factors were identified by immunoprecipitation and MS analysis. 
Initially, in Chapter 3, cytoplasmic/nuclear fractionation and β-catenin 
immunoprecipitation was optimized in K562 cells. Immunoprecipitation with 
agarose G beads was unsuccessful despite testing of various factors that could 
be impacting the immunoprecipitation efficiency. Alternatively, a different 
immunoprecipitation approach was tested, using protein G Dynabeads. This was 
successfully used to immunoprecipitate β-catenin in the leukaemia cell lines 
tested and to generate ample material for MS analysis. Although this was 
sufficient for my analysis, it might be useful to improve the immunoprecipitation 
efficiency further if this was to be repeated on patient material, which would be 
more limiting than the cell lines used in this study. Additionally, when optimizing 
the fractionation of cell lines and immunoprecipitation of β-catenin, it may have 
been better to focus on different detergent conditions and analyse their effects on 
co-immunoprecipitation efficiency prior to MS analysis, for example by 
determining their effects on interactions between β-catenin and known binding 
partners. Comparing more than one immunoprecipitation protocol earlier in the 
optimization steps could also have saved more time trying to optimize 
immunoprecipitation using agarose beads. This may have allowed more time for 
thorough functional analysis of LEF-1 in Chapter 5. 
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In Chapter 4, data analysis of MS results from β-catenin immunoprecipitations 
was conducted. Peptides present in the cytoplasmic and nuclear fractions of 
translocator and non-translocator cell lines were compared. This identified eight 
β-catenin interaction partners as potential candidate β-catenin nuclear 
localization factors. Western blotting of these factors validated RUNX1 and LEF-
1 as candidates for further analysis. Due to time constraints and technical 
difficulties, not all the candidates could be validated by western blotting (4.4) and 
of the validated factors, LEF-1 was favoured for further analysis over RUNX1, 
owing to its well established role in canonical Wnt signalling (1.3.1.2) and its 
identification as a candidate β-catenin nuclear localization factor in other contexts 
(Henderson et al, 2002; Huber et al, 1996; Jamieson et al, 2016; Jamieson et al, 
2011; Simcha et al, 1998). There is some evidence to suggest that RUNX1 is 
involved in the regulation of canonical Wnt signalling in other contexts. For 
example, in estrogen receptor positive breast cancer cells, RUNX1 binds to Axin1 
and prevents estrogen receptor mediated Axin1 suppression (Chimge et al, 
2016). RUNX1 loss in these cells leads to stabilization of β-catenin, suggesting 
that RUNX1 is a negative regulator of canonical Wnt signalling in this context. 
RUNX1 also plays a role in regulating Wnt signalling in AML as part of AML 
associated fusion proteins. In one study, expression of RUNX1-ETO in K562 cells  
led to a 12 fold increase in  catenin/TCF mediated transcription, measured using 
a TOPFLASH reporter (Yeh et al, 2009). In a separate study, expression of 
RUNX1-ETO in U937 cells led to increased γ-catenin mRNA expression, 
increased γ-catenin and β-catenin protein levels and association of γ-catenin with 
the promoter region of the Wnt target gene c-myc (Müller-Tidow et al, 2004). 
Taking these data into account, it would be interesting to further establish the role 
of RUNX1 in regulating β-catenin nuclear localization. 
In Chapter 5, functional analysis of LEF-1 mediated β-catenin nuclear localization 
was conducted. Knockdown and overexpression studies showed that LEF-1 can 
regulate the nuclear localization of β-catenin and subsequent β-catenin mediated 
transcription in leukaemia cell lines. This did not have significant effects on 
proliferation, survival or migration of leukaemia cells, though, this analysis was in 
part hindered by ineffective LEF-1 overexpression in non-translocator cell lines 
(5.4.5.1). 
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The details of the techniques used in this project are discussed in 3.4, 4.4 and 
5.4. This section discusses the general approach taken to identify candidate β-
catenin nuclear localization factors and its limitations.  
One of the main limitations of the MS approach used in this project is that it was 
based on identifying proteins that were either present or absent in each cell 
fraction, rather than the relative levels of proteins. This does not consider the 
possibility that the level of certain β-catenin interaction partners may determine 
their effects on β-catenin nuclear localization. Initially, a quantitative proteomics 
approach was considered for analysis of β-catenin interaction partners in this 
study, but given the number of samples required this was not feasible. In the 
original experimental design two translocator lines and two non-translocator lines 
were going to be used, which would result in a total of six samples (cytoplasmic 
and nuclear translocator cell line fractions and cytoplasmic non-translocator cell 
line fractions). In addition to this, IgG samples for each would need to be included, 
bringing the total number of samples to 12. This was too many samples for use 
in quantitative SILAC or ITRAQ based MS (the two most commonly used 
quantitative approaches).  
One way that a quantitative approach could still have been used for analysis was 
if I reduced the number of samples used, for example, by only comparing one 
translocator cell line and one non-translocator cell line. The decision was made 
to include more cell lines and use a non-quantitative approach rather than use a 
quantitative approach with only two cell lines. This was because it made it easier 
to identify candidate β-catenin nuclear localization factors that play a global role 
in leukaemia, rather than cell line specific factors which could have less relevance 
for AML. 
Another experimental technique that was not included in this project was co-
immunoprecipitation of candidate factors and β-catenin. Ideally, following 
identification of candidate factors, rather than just western blotting of the samples 
sent for MS, a repeat β-catenin immunoprecipitation for each cell 
line/compartment would have been conducted and then western blotting using 
candidate factor antibodies. In addition, immunoprecipitation of candidate factors 
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would have been conducted followed by western blotting with β-catenin antibody. 
This would give more confidence in the identification of candidate factors as β-
catenin interaction partners, particularly for factors that have not been identified 
as candidate β-catenin interaction partners previously (4.4). The reason this was 
not done was because this was not considered a priority in this case, as LEF-1 
was already a known β-catenin interacting protein. 
 
In this project I found that LEF-1 mediates the nuclear localization of β-catenin in 
leukaemia cell lines. LEF-1 has previously been identified as a β-catenin nuclear 
localization factor in other contexts and its expression has been associated with 
AML (Fu et al, 2014; Metzeler et al, 2012; Müller-Tidow et al, 2004; Petropoulos 
et al, 2008). It would be interesting to determine if LEF-1 expression correlates 
with nuclear β-catenin in AML blasts, which would indicate that LEF-1 may be 
regulating nuclear localization of β-catenin in AML patients. In addition, if there 
was a correlation between LEF-1 expression and β-catenin nuclear localization, 
it would be interesting to determine if this is also associated with specific 
molecular abnormalities in AML. It may be particularly interesting to look at MLL 
abnormalities in cell lines and AML blasts, given the proposed role that β-catenin 
has in the establishment of LSCs in MLL AML (Yeung et al, 2010). Many of the 
cell lines used in the study of AML have MLL abnormalities, which seem to confer 
immortalisation, making them useful for in vitro culture (Drexler et al, 2004). It 
would be interesting to determine if there are certain MLL abnormalities that 
correlate with LEF-1 expression and β-catenin nuclear localization in these lines. 
There is evidence to suggest that β-catenin nuclear localization and LEF-1 
expression do not always correlate in AML. For example, certain molecular 
abnormalities such as FLT3-ITD have been shown to promote the nuclear 
localization of β-catenin and increase β-catenin mediated transcription. In 
contrast, FLT3-ITD has been associated with low LEF-1 expression, suggesting 
that this factor does not impact LEF-1 mediated β-catenin nuclear localization 
(Kajiguchi et al, 2007; Metzeler et al, 2012; Tickenbrock et al, 2005). This 
suggests that there are additional mechanisms regulating the nuclear localization 
of β-catenin in AML.  
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It would be interesting to  get a more complete picture of the factors regulating 
the nuclear localization of β-catenin by i) validating more of the identified 
candidate factors (Table 4.5) by western blotting, ii) perform functional analysis 
of these factors to determine their role in regulating β-catenin nuclear localization 
and β-catenin mediated transcription as well as any consequence for 
proliferation, cell survival and migration in leukaemia cell lines and iii) determine 
if these factors also colocalize in primary AML. RUNX1 would be an interesting 
one to start with given its role as a haematopoietic transcription factor and its 
frequent dysregulation in AML (1.2.2). 
This project focused on in vitro studies of leukaemia cell lines, which is limited as 
a model system. As discussed in 1.1.2, external factors in the niche are important 
in regulating cell signalling. In vitro studies are biased, with only selected agonists 
being used. Although this can make it easier to study a very specific mechanism, 
it oversimplifies complex signalling networks and can result in conclusions that 
are not functionally relevant in vivo. It would be important to study the role of LEF-
1 and other candidate factors in vivo to determine their effects on β-catenin 
nuclear localization, β-catenin mediated transcription and leukemogenesis. 
It would also be interesting to repeat the immunoprecipitation and MS analysis 
using different fractionation/immunoprecipitation buffers to potentially identify 
more candidate β-catenin nuclear localization factors. The buffers used to isolate 
proteins and their binding partners can have a big impact on the interaction 
partners that are identified. Some buffers can interrupt the binding of certain 
proteins, and based on some of the issues encountered in this project (3.4 and 
4.4), repeating this experiment with different buffers could identify other candidate 
β-catenin binding partners that were missing from the analysis using CHAPS 
buffer.  
It would also be useful to determine if LEF-1 and other candidate nuclear β-
catenin localization factors regulate the nuclear localization of γ-catenin. γ-
catenin was not identified as a β-catenin binding factor in these cells, but it has 
been previously identified as a factor regulating the nuclear localization of β-
catenin (Morgan et al, 2013). It would be interesting to see if there is a common 
mechanism regulating the nuclear localization of both catenins in leukaemia.  
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Finally, one of the main limiting factors in performing functional analysis of LEF-
1 and β-catenin in this project was that these are not independent variables. It 
may be worthwhile to focus further studies on establishing the role of β-catenin 
itself outside its role in MLL AML. It’s role in non MLL AML is still controversial 
(1.3.3), and knockdown or the use of β-catenin inhibitors may not be sufficient to 
establish this if only small amounts of β-catenin are required for its function, as 
has been suggested by (Luis et al, 2011). The role of β-catenin in AML could be 
reinvestigated using new technology such as CRISPR gene editing (Czarnek & 
Bereta, 2016) to see if AML blasts can survive a double knockout of β-catenin.   
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Appendices 
 
 
 
  
β-catenin translocation status of cell lines used in this study. 
Western blotting of cell lines used in this study. Cells were fractionated using CHAPS 
buffer (2.6.2) and western blotted using β-catenin antibody (BD) (2.5). Abbreviations; IB= 
immunoblot, Ab= antibody, MW= molecular weight, kDa= kilodaltons, C= cytoplasm, N= 
nuclear. Marker= MagicMark XP (Thermo Fisher). 
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Distribution of TCF7L2 in myeloid cell lines. 
TCF7L2 is present in both translocator and non-translocator cell lines. This figure was 
created by Dr. Sara Daud. 
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Method: Whole cell lysis using Triton buffer 
To extract whole cell lysates, cell pellets were thawed on ice in the presence of 
1µL DNase (1mg/mL) for 5 min, tapping the tube regularly. 50 µL of Triton buffer 
(0.25µM sucrose, 10mM HEPES-KOH (pH 7.2), 1mM magnesium acetate, 
0.5mM EDTA, 0.5mM EGTA, 10mM BME, 1mM sodium orthovanadate, PIC, v/v 
1% Triton X-100) was added to the cells and the tube was incubated on ice for 
30 min with occasional vortexing. The tubes were centrifuged at 3000 x g for 5 
min at 4 °C. The supernatant (cell lysate) was aspirated into a clean 1.5mL 
Eppendorf tube, snap frozen in liquid nitrogen and stored at -80 °C. 
To view the raw mass spectrometry data generated in this project, please see the 
attached CD disk. 
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The following sequencing data is for the pHIV-EGFP FLAG-β-catenin vector.  
Primers used: 
- pHIVFor - this is the forward primer for the pHIV-EGFP vector. This was 
bought from Sigma. 
- pHIVRev - this is the reverse primer for the pHIV-EGFP vector. This was 
bought from Sigma. 
- b-catP1(TTCCAGACACGCTATCATGC) - A β-catenin primer designed 
using Primer3. 
- b-catP2 (TGCAGTTCGCCTTCACTATG) - A β-catenin primer designed 
using Primer3. 
These primers combined gave full coverage of the β-catenin-FLAG insert. 
The sequencing data was compared to the predicted sequence of the pHIV-
EGFP-β-catenin-FLAG vector (predicted-vector-full). 
During the first sequencing run using the b-catP1 primer, an extra T was detected. 
In a repeat sequencing run the extra T was not detected, suggesting that there 
may have been a sequencing error in the first run. 
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START codon 
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Extra T 
No Extra T in repeat run 
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FLAG tag 
STOP codon 
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